-

Ref. No.: F.02(353)/RMSCL/PROCUREMENT/DRUG/NIB-10/2022/ 1236 Dated:-30.04.2022

RAJASTHAN MEDICAL SERVICES CORPORATION LTD.

(A Govt. of Rajasthan Undertaking)
Gandhi Block, Swasthya Bhawan, Tilak Marg, Jaipur – 302005, India
Tel No: 0141-2228066, 2228064, E-mail: rmsc@nic.in, edprmsc@nic.in

E-BID FOR RATE CONTRACT CUM SUPPLY AND EMPANELMENT OF DRUGS AND MEDICINES

(Rate Contract for the period ending on 30.06.2024)

!! सर्वे सन्तु निरामयाः!!

LAST DATE OF SUBMISSION OF ONLINE BIDS	**30.05.2022 & 06.00 PM**
DATE AND TIME OF OPENING OF ONLINE TECHNICAL BIDS	**31.05.2022 & 11.00 AM**

RAJASTHAN MEDICAL SERVICES CORPORATION LTD.
(A Govt. of Rajasthan Undertaking)
Gandhi Block, Swasthya Bhawan, Tilak Marg, Jaipur – 302005, India
Phone No: 0141-2228066, 2228064 Website: www.rmsc.health.rajasthan.gov.in
CIN:U24232RJ2011SGC035067 E-mail : edprmsc@nic.in

Ref. No.: F.02(353)/RMSCL/PROCUREMENT/DRUG/NIB-10/2022/ 1236 Dated:-30.04.2022

Notice Inviting E-Bid

E-bids are invited upto 06:00 PM of 30.05.2022 for E-BID FOR RATE CONTRACT CUM SUPPLY AND EMPANELMENT OF DRUGS AND MEDICINES. Details of NIB may be seen in the Bidding Documents at our office or at the website of State Public procurement Portal http://sppp.raj.nic.in (UBN– ----------) www.dipronline.org, http://eproc.rajasthan.gov.in. http://rmsc.health.rajasthan.gov.in and may be downloaded from there.

Note:- If any amendment is carried out in the tender specifications and terms & conditions following pre-bid meeting, the same will be uploaded on the Departmental website http://rmsc.health.rajasthan.gov.in/, sppp.raj.nic.in and https://eproc.rajasthan.gov.in. In case any inconvenience is felt, please contact on telephone number i.e. 0141- 2228064

Executive Director (Procurement)
RMSCL

-

RAJASTHAN MEDICAL SERVICES CORPORATION LTD. RAJASTHAN

E-BID FOR RATE CONTRACT CUM SUPPLY AND EMPANELMENT OF DRUGS AND MEDICINES

(Rate Contract for the period ending on 30.06.2024)

Bid Reference	:	F.02(353)/RMSCL/PROCUREMENT/DRUG/NIB-10/2022/ 1236 Dated:-30.04.2022
Date and time for downloading bid document	:	02.05.2022 **from 6.00 PM**
Pre Bid	:	09.05.2022 **AT 02:30 PM**
Last date and time of submission of online bids and e-deposit	:	30.05.2022 **at 6.00 PM**
Date and time of opening of Online technical bids	:	31.05.2022 **at 11.00 AM**
Tender Cost	**:**	**1057 Cr.**
Cost of the Bid Document	:	**Rs. 2000/-**
Cost of the Bid Document For MSME Unit of Rajasthan	:	**Rs. 1000/-**
RISL Processing Fees	:	**Rs. 1000/-**
Empanelment Fee (If applying for Empanelment also)	:	**Rs. 5000/-**

INDEX

GENERAL INSTRUCTIONS FOR BIDDERS

The bidders are instructed to read the complete bid document carefully. The following points may be noted so that mistakes/lapses/shortcomings during Bid submission can be avoided.

1. It is expected from all bidders that they will ensure that documents to be used in bid set will be given to a reliable person only, and that only a fully reliable person shall be authorized for DSC. So that the confidentiality of your bid/ rates can be maintained upto bid opening & that your documents are not put to any misuse.
2. It is advisable for bidder to authorize only those persons for RMSCL tender who are employed in your company on salary basis.
3. The turnover should be as per bid conditions. Do not submit Bid if the turnover of the firm is less.
4. Quote only for the products for which Product Permission meets the Bid specifications. Do not quote if it differs with regard to any parameter.
5. Quote rate in BOQ for the packing unit exactly given in annexure VIII. For example :-
    - If the packing unit is given for 10x10 tablets / capsule, the rate should be quoted for 10x10 tablets / capsule, and not for 1 tablet / capsule or 10 tablets/ capsule.
    - If the packing unit is given for 10x10x1 tablets / capsule, the rate should be quoted for 10x10x1 tablets / capsule, and not for 1 tablet / capsule or 10 tablets/ capsule.
    - If the packing unit is given for 10x14 tablets / capsule, the rate should be quoted for 10x14 tablets / capsule, and not for 1 tablet / capsule or 10 tablets/ capsule.
    - If the packing unit is given for 2 ml ampoule (25 ampoules), the rate should be for 25 ampoules and not for 1 ampoule or 10 ampoules etc.
    - If the packing unit is given for 2 ml ampoule (10 ampoules), the rate should be for 10 ampoules and not for 1 ampoule etc.

6. Highlight the quoted items in the documents like Product Permission and Market Standing Certificate, and also mark the item code no. at appropriate place in the documents.

7. The uploaded product permission and other documents should be clearly legible. Date of issue of the documents should be clearly legible.

8. Upload the Bids on the e-portal well in advance so that failure in uploading can be avoided and no desired document remains un-uploaded.

9. In case there is any suggestion regarding Bid conditions/specifications/shelf life, strength, packing/turn over etc. The suggestions should be submitted/sent/E – Mailed one/two days earlier from the date of pre bid meeting so that the representation of the bidders may be well processed and decision could be taken well in time. **After pre bid meeting date no representation/ suggestions will be entertained.**

10. If there is any query regarding terms and conditions in Bid document, you may contact :-

Sh. Rajesh Kumar Gupta, Senior Manager (Proc)

Ph.0141-2228064, Mob. No. 93140-78838

Sh. Deepak Sharma, Senior Manager (Drug)

Ph.0141-2228064, Mob. No. 88752-98700

-

RAJASTHAN MEDICAL SERVICES CORPORATION LTD. RAJASTHAN

Rajasthan Medical Services Corporation Ltd., (hereinafter referred to as Bids Inviting Authority unless the context otherwise requires) invites **E-BID FOR RATE CONTRACT CUM SUPPLY AND EMPANELMENT OF DRUGS AND MEDICINES**.

1. **LAST DATE FOR RECEIPT OF BIDS, BID DOCUMENT FEES, BID SECURITY DEPOSIT, RISL PROCESSING FEES AND EMPANELMENT FEES**

(a) E-Bid in two separate bids (Technical bid & Price Bid)] will be received till **30.05.2022 at 6.00 PM** by the Rajasthan Medical Services Corporation Ltd, for the E-BID FOR RATE CONTRACT CUM SUPPLY AND EMPANELMENT OF DRUGS AND MEDICINES. (**Rate Contract for the period ending on 30.06.2024**)

(b) The bid should be valid for a Period of 120 days from the date of opening of Technical Bid and prior to the expiration of the bid validity the Bid Inviting Authority may request the Bidders to extend the bid validity period for an additional specified period of time. The Bidder may refuse extension of bid validity, and in such a case its Bid security deposit shall not be forfeited.

(c) Bid form fee Rs. 2000.00 (Rs. 1000.00 for MSME Units of Rajasthan) for downloading from the website.

(d) Bid Security Deposit as applicable in Bid condition no. 8.

(e) Processing fee of Rs.1000.00 of R.I.S.L.

These fees are to be paid through three separate prescribed challans (***format enclosed in Annexure- I)*** in any branch of the Punjab National Bank Account no. 2246002100024414 & IFSC Code no. PUNB0224600 throughout country upto **30.05.2022** or through D.D. / bankers cheque in favour of M.D. RMSCL (Bid document fees and Bid security)/ M.D. RISL (Bid processing fees) physically in the office of RMSCL on **30.05.2022** upto **6.00 PM.** Alternatively, bidder may also deposit Bid document fees, Bid security and RISL processing fees by way of e-deposit, through Internet Banking by accessing RMSCL website http://www.rmsc.health.rajasthan.gov.in clicking e-deposit icon

following the laid down steps; Rs.25 plus applicable service tax will be the per transaction charge to be debited in respective depositor's account after successful e-deposit. Supplier should enclose the generated receipt. The bidders shall submit/upload scanned copy of all the challans/DD/ e – deposit generated receipt in Technical Bid**.** Bids will be opened only after ensuring receipt of Bid document fees along with processing fees and Bid Security Deposit. In the absence of Bid document fees and processing fees and Bid Security Deposit the Bids will be rejected and will not be opened.

Note:- (I) While the Bid uploading it would be asked on e procurement website about Bid Security, whether it is Rs. 2.00 lacs or Rs. 5.00 lacs , the bidder may mention any option for the purpose of Bid uploading but has to submit required Bid Security as specified in clause no 8.

Note:- (II) There is no option of online payment of tender fee, processing fee, bid security etc. on e-procurement portal.

Click on offline mode (either DD or BC) on e procurement portal for the purpose of bid uploading only.

(f) Those who wish to apply for Empanelment as supplier for Drugs and Medicines are required to deposit separately an Empanelment Fee of Rs 5000 (Five Thousand rupees only) in the form of DD (in favour of MD, RMSCL)/challan/e-deposit before due time and date of bid submission. Please see clause 20 and Annexure-XI in this regard.

2. ELIGIBILITY CRITERIA

(a) Bidder should be a manufacturer having valid manufacturing licence/loan licence or direct importer holding valid import licence. Distributors/ Suppliers / Agents are not eligible to participate in the Bids.

(b) Average Annual turnover (for drugs and medicines including Surgical and sutures Business) in the last three financial years 2017-18, 2018-19 & 2019-20 or 2018-19, 2019-20 & 2020-21 should not be less than Rs. 20 Crores.

For MSME units of Rajasthan, the average annual turnover in the last three financial years 2017-18, 2018-19 & 2019-20 or 2018-19, 2019-20 & 2020-21 should not be less than Rs. 2 Crore.

For drug items falling in the category of Disinfectants & Antiseptics, Eye preparations and Ear drops etc bidder's firms average annual turnover of last three financial years should not be less than Rs. 2 Crore

Explanatory Note:-

1) The merger / amalgamation / transfer of business / transfer of assets etc. of a firm affect the bid condition relating to 'Turnover' in preceding years. The eligibility of a bidder in this regard shall be ascertained on the basis of a certificate issued by a competent authority regarding amalgamation / transfer of business / transfer of assets.

(c) Bidder should have at least 3 years market standing as a manufacturer for the items quoted in the bid, on the date of bid opening. In the case of imported products, the product should have minimum 3 years standing in the market. The importer should have at least 3 year standing as manufacturer/ importer of drugs in general. Imported drugs shall be accepted in brand name also. **The period of Market Standing will be reckoned from the date of issue of Product Permission.**

Explanatory note:-

"In case of imported products, market standing for the product in international market would be considered for establishing eligibility regarding this particular clause of the bidding document. Also if a bidder is manufacturing a product abroad at various locations/countries and participating in the bid quoting a product being manufactured at a particular place, market standing of the product manufactured at other then particular place would be considered."

(d) Bidder should have permission to manufacture the item /drug quoted as per specification given in the Bid from the competent authority. Product permission of *brands* shall be accepted in the Bid submitted, but the Bidder has to submit the product permission in generic names at the time of signing of the agreement/before supply.

(e) **Bid should not be submitted for the product/products for which the concern/company stands blacklisted /banned/debarred on the date of bid submission either by Bid inviting Authority or Govt. of Rajasthan or its departments on any ground. The Bid should not be submitted for those products also for which the concern/company stands blacklisted/banned/debarred on the date of bid submission by any other State/Central Govt. or it's any agencies (central Drugs procurement agencies) on the ground of conviction by court of law or the products being found Not of Standard Quality. (NoSQ)**

(f) **The concern/company/firm which stands blacklisted/banned/debarred on any ground either by Bid Inviting Authority (RMSCL) or Govt. of Rajasthan or its departments on the date of bid submission, shall not be eligible to participate in the Bid. The concern/company/firm which stands blacklisted/banned/debarred on the ground of conviction by court of law or the products being found Not of Standard Quality (NoSQ) by any other State /Central Government or it's any agencies (central Drugs procurement agencies) shall also not be eligible to participate in the Bid. For Specific cases regarding other quality issues the purchase committee of RMSCL may decide the case on merit basis.**

(g) If any product/products of a company/firm have been declared as not of standard quality, as per Drugs & Cosmetics Act during last 2 years anywhere, such concern/company/firm shall not be eligible to participate in Bid for such product/products. If any company/firm is found to have any such product quoted in the Bid, the product shall be blacklisted for 2 years and a penalty equivalent to Bid Security Deposit shall also be levied. [Penalty should be minimum and maximum as per bid security given in clause 8] In such situation, the bid will be considered further only if the amount of penalty is deposited before the completion of technical evaluation.

(h) The concern/firm/company whose product has been declared as of spurious or adulterated quality and any criminal case is filed and pending in any court shall not be eligible to participate for that particular product, in the Bid. Similarly convicted firm/company shall also not be eligible to participate in the Bid.

(i) If a company has two or more separate manufacturing units at different sites/states, the company will be allowed to submit only one Bid for all units but necessary document regarding separate manufacturing units will be submitted as a separate set with the same Bid. But a bidder will be allowed to submit only one offer for one product..

3. PRICE PREFERENCE AND PURCHASE PREFERENCE

(1) Price preference is not applicable as GST has been made effective from 01.07.2017 in place of VAT.

(2) Purchase preference shall be given to MSME's unit of Rajasthan as per notification of Finance (GF&AR Division) Department, Government of Rajasthan notification S.O.165 dated 19.11.2015).

4. GENERAL CONDITIONS

i. At any time prior to the date of submission of Bid, Bid Inviting Authority may, for any reason, whether on his own initiatives or in response to a clarification requested by a prospective Bidder, modify the condition in Bid documents by way of amendment. In order to provide reasonable time to take the amendment into account in preparing their bid, Bid Inviting Authority can at his discretion, extend the date and time for submission of Bids.

ii. Interested eligible Bidders may obtain further information in this regard from the office of the Bid Inviting Authority, i.e RMSCL.

iii. In case any document submitted by the bidder or his authorized representative is found to be forged, false or fabricated, the bid will be rejected and Bid Security/Performance Security will be forfeited. Bidders or their representative may also be blacklisted/banned/debarred. Report with police station can also be filed.

5. TECHNICAL BID

The Bidder should furnish the following in technical bid:-

(a) Bidders are allowed the option to quote for anyone item or more items as mentioned in bid (list of medicines proposed to be purchased at Annexure-VIII). The amount of Bid Security Deposit will be Rs. 20,000/- per item of drug quoted subject to minimum of Rs.2.00 lacs and maximum of Rs. 5.00

lacs.

(b) The bidders shall submit/upload scanned copy of all the challans, D.D./ BC/ e-deposit generated receipt annexed with Technical Bid in proof of deposition / submission of Bid document fees, RISL processing fee and Bid security. The required Bid Security Deposit / Bid document fees/ RISL fee may be in form of physical D.D./ BC and should be in favour of M.D. RMSCL (bid document fees and Bid Security Deposit), MD, RISL (bid processing fees).

(c) Those who wish to apply for Empanelment as supplier for Drugs and Medicines are required to deposit separately an Empanelment Fee of Rs 5000 (Five Thousand rupees only) in the form of DD /challan/e-deposit in favour of MD, RMSCL before due time and date of bid submission.

(d) Documentary evidence for the constitution of the company/Firm such as Memorandum and Articles of Association, Partnership Deed etc. with details of the Name, Address, Telephone Number, Fax Number, e-mail address of the firm and of the Managing Director/Partners/Proprietor.

(e) The Bidder should furnish attested copy of the valid Licence for the product duly approved by the Licensing authority for each and every product quoted as per specification in the Bid. The licence must have been duly renewed/ valid up to date and the items quoted shall be clearly highlighted (Bid item codes marked against each item) in the licence.

(f) Attested photocopy of the valid import licence in Form 10 with Form 41 (as per Rule 122A of Drugs and Cosmetics Act), if the product is imported. The licence must have been renewed /valid up to date. A copy of a valid licence for the sale of Drugs imported by the firms issued by the licensing authority shall be enclosed.

(g) The instruments such as power of attorney, resolution of board etc., authorizing an officer of the Bidder should be enclosed.

(h) Authorization/nominating a responsible person of the Bidder to transact the business with the Bid Inviting Authority with photograph and signature in Annexure VII.

(i) Bidder should have at least 3 years market standing as a manufacturer for the items quoted in the bid.

For imported items, the quoted item should have 3 years market standing, for which bills of entry, sale invoices, etc should be submitted in token of proof. The importing firm should have 3 years standing as importer / manufacturer of medicines in general. The importer firm may submit Bills of entry, etc of same or other Surgical /Drugs to establish the market standing of the firm. The bidder shall submit valid import licence for direct import of the quoted item.

(j) Market Standing Certificate issued by the Licensing Authority / competent authorities as a Manufacturer for the product for last 3 years (Certificate should be enclosed with list of items) should be enclosed. Items quoted should be highlighted in the market standing certificate. The Market Standing Certificate should not have been issued by competent authority more than 2 years old as on the last date of bid submission. The bidder shall submit valid import licence for import of the quoted item.

(k) Non-conviction Certificate issued by the Drugs Controller of the State. It should be recent and not more than one year old.

(l) WHO-GMP (WHO - Good manufacturing practices Certificate) Certificate issued by the Licensing Authority. The WHO-GMP certificate must not be older than one year from the due date of Bid submission in the case where validity is not mentioned in the certificate. The WHO-GMP certificate of all the manufacturing plants, of which products have been quoted, should be submitted. The Bidder shall also furnish an undertaking in the format given in Annexure-VII point no.8 declaring that the Bidder complies with the requirements of WHO-GMP.

The Importer should produce WHO- GMP / COPP of the manufacturing firm or a certificate which is at par with WHO-GMP issued by exporting countries like US- FDA approval, etc. In the case of imported drugs, labels and product literature of all quoted products must be submitted.

The Firm will continue to hold WHO-GMP Certificate for the product during entire rate contract period of the product. If WHO-GMP certificate expires, it

is firm's responsibility to inform RMSCL about the same and not to accept any further purchase order till re-issue /renewal of WHO-GMP certificate. During the period of non validity of WHO-GMP certificate of the firm the rate contract will deemed to be suspended. If the firm fails to inform RMSCL about the expiry of WHO-GMP certificate and accept purchase order of RMSCL and later on it comes to the knowledge of RMSCL, in this situation firm shall be liable for a panel action.

(m) Annual turnover statement for 3 years i.e., 2017-18, 2018-19 & 2019-20 or 2018-19, 2019-20 & 2020-21 in the format given in Annexure-III should be certified by the practicing Chartered Accountant.

(n) Copies of the Balance Sheet and Profit and Loss Account for three years i.e. 2017-18, 2018-19 & 2019-20 or 2018-19, 2019-20 & 2020-21 duly certified by the practicing Chartered Accountant will have to be submitted with bid.

(o) GST return 01.09.2021 to 31.12.2021

(p) Details of GST registration. The industries situated in GST free zones will produce the copy of appropriate notification. Bidders have to submit GSTIN number and state where GSTIN registered for every quoted items for which supply will be made. (Annexure VII at point no 3)

(q) Undertaking (as in Annexure-VII) for embossment of logo on labels as per conditions specified at Clause 14 herein.

(r) Undertaking that the manufacturer has not been blacklisted, the product never been declared as not of standard quality during last two years, it's manufacturing capacity and other details required on a format mentioned at Annexure-VII.

(s) Details of technical personnel employed in the manufacture and testing of drugs (Employee Name, Qualification, and Experience) as enclosed in license.

(t) List of items quoted to be shown in the Annexure-VII point number 6

(u) A Checklist (Annexure-V) for the list of documents enclosed with their page number. The documents should be serially arranged as per Annexure-V.

Every bidder will also be required to submit details of product permission of the quoted item and the desired market standing, in Annexure- VI

(v) An undertaking that the bidder complies with all the terms, conditions, amendments (if any) of bid document to be submitted in Annexure-VII point no.11.

(w) A declaration under Section 7 of Rajasthan Transparency in Public Procurement Act, 2012 in Annexure-VII point no. 13

(x) All copies submitted should be self attested.

(y) An undertaking in Annexure-XI that the bidder whishes to get empanelled as supplier for the quoted items and has submitted the necessary fee for the same. (This is only for those who apply for empanelment also).

(z) A copy of PAN issued by Income Tax Department.

Note:- 1. Clarification regarding submission of documents

It is found that some of the documents are sometimes not valid on the exact date of bid opening; the firm has submitted slightly older documents in the bid as it has not been able to get the new/renewed certificate issued from the concerned department till bid submission. Documents such as Non conviction certificate, WHO-GMP certificate & MSC etc. shall be accepted if they have been issued after bid submission but submitted to Tendering authority when asked to do so in the form of clarification/short fall document submission. But such documents shall be considered only if it is proved that the competence as certified by the competent authority regarding the required documents existed with the bidder on the date of submission of bid.

6. PRICE BID –

The price bid will also be known as financial document and every bidder will be required to submit its price in excel format attached to the bid document (BOQ). BOQ template must not be modified/ replaced by the bidder and the same should be uploaded after filling the relevant columns, else the bidder is liable to be rejected for this bid. Bidders are allowed to enter the bidder name and values only. The bidder should quote rate for the mentioned packing unit only.

7. **OPENING OF TECHNICAL AND FINANCIAL EVALUATION**

The Bid will be scrutinized by Bid evaluation committee and inspection of manufacturing unit for compliance of WHO-GMP may be carried out by technical committee. Price Bid (BOQ) of the Bidder found eligible on satisfying the criteria for technical evaluation and inspection, will only be opened.

8. **BID SECURITY**

The Bid Security shall be @ Rs. 20,000/- for each item of Drugs & Medicines quoted subject to minimum of Rs. 2.00 lacs and maximum of Rs. 5.00 Lacs. In case Bid Security submitted by the bidder is at the minimum or more but number of quoted items is more than the Bid Security submitted, the quoted items by the bidder will be counted in sequence up to the Bid Security deposited. However without minimum Bid Security the offer will not be considered at all., Bid Security will not be taken from undertakings, corporation of GoI & GoR. Further, Bid Security will be taken @ Rs. 5,000/- per item of Drugs & Medicines quoted subject to minimum of Rs. 50,000/- and maximum of Rs. 1.25 Lacs, from MSME Units of Rajasthan. They will furnish copy duly attested by gazetted officer of the registration of MSME units of Rajasthan issued by the Director of Industries in respect of the stores for which they are registered. Duly attested copy of Acknowledgement of EM-II issued by DIC with an affidavit worth Rs.100 as per Annexure-II under preference to Industries of Rajasthan rules 1995 in respect of stores for which they are registered. (Annexure-II(B)). In case Bid Security submitted by the bidder is at the minimum or more but number of quoted items is more than the Bid Security submitted, the quoted items by the bidder will be counted in sequence up to the number matching the Bid Security deposited. However without minimum Bid Security the offer will not be considered at all.

The Bid Security shall be paid through separate prescribed challans (format enclosed in Annexure-I) in any branch of the Punjab National Bank Account no. 2246002100024414 (IFSC Code no. PUNB0224600) throughout country upto 30.05.2022 or through D.D. / bankers cheque in favour of M.D. RMSCL physically in the office of RMSCL on or before 30.05.2022 upto 6.00 PM. Bid security Deposit in any other form will not be accepted. Alternatively bidder may also deposit Bid document fees, Bid security and RISL processing

fees by way of e-deposit, through Internet Banking by accessing RMSCL website http://www.rmsc.health.rajasthan.gov.in clicking e-deposit icon following the laid down steps; Rs.25 plus applicable service tax will be the per transaction charge to be debited in respective depositor's account after successful e-deposit. Supplier should enclose the generated receipt.

The Bids submitted without sufficient Bid Security will be summarily rejected. The Bid Security will be forfeited, if the Bidder withdraws its Bid after last time & date fixed for receiving bids or in the case of a successful Bidder, if the Bidder fails within specified time to sign the contract agreement or fails to furnish the performance security.

9. OTHER CONDITIONS

1. The orders will be placed by the Managing Director or any officer designated, Rajasthan Medical Services Corporation Ltd, (hereinafter referred to as Ordering Authority).
2. **The details of the required drugs, medicines, etc., are shown in Annexure-VIII. The quantity mentioned is only the tentative requirement and may increase or decrease as per the decision of Ordering Authority. The rates quoted should not vary with the quantum of the order or the destination. The commitment quantity for an item submitted by the bidder (in Annexure VII) shall be taken into account. The whole commitment quantity to be supplied during contract period should not be less than estimated bid quantity. As well, the monthly commitment quantity should not be less than 5 % of the whole commitment qty. A bidder having manufacturing capacity less than commitment quantity (either monthly or for whole contract period) may be technically disqualified.**
3. e- Bid has been called for in the generic names of drugs. The Bidders should quote the rates for the generic products. The composition and strength of each product should be as per details given in Annexure-VIII. Any variation, if found, will result in rejection of the Bid. The products should conform to the specified standards IP/BP/USP. In case the product is not included in the said compendium, the supplier, upon award of the contract, must provide the reference standards and testing protocols for quality control testing.
4. Rates (inclusive of **all expenses / charges but exclusive of GST)** should be quoted for each of the required drugs, medicines etc., separately on door delivery

basis according to the unit ordered. Bid for the supply of drugs, medicines, etc. with conditions like “AT CURRENT MARKET RATES” shall not be accepted. Handling, clearing, transport charges etc., will not be paid. The delivery should be made as stipulated in the purchase order placed with successful Bidders. No quantity or cash discount should be offered.

5.

a) To ensure sustained supply without any interruption, the Bid Inviting Authority reserves the right to fix more than one supplier to supply the requirement among the qualified Bidders

b) Orders will be placed periodically during rate contract period based on the RMSCL's requirement to the firms approved for rate contract as per above clause no. 3 . After the conclusion of Price Bid opening, the lowest offer of the Bidder, if required will be considered for negotiations, and rate arrived after negotiations will be L-1 rate and L-1 supplier for an item of drugs/medicines for which the Bid has been invited.

c) The Bidder who has been declared as L-1 supplier for certain item or items of drugs/medicines shall execute necessary agreement for the supply of the Bided quantity of such drugs/medicines as specified in the Bid document on depositing the required amount as performance security and on execution of the agreement, such Bidder is eligible for the placement of purchase orders. Moreover, purchase order can be placed after the issue of letter of acceptance, pending the execution of agreement and issuance of rate contract for an item.

d) RMSCL will inform the L1 rate to the Bidders who qualified for Price Bid opening, through RMSCL web site or e-mail; willing bidders may inform in writing their consent to match with the L-1 rate for the item of the Drugs/Medicines quoted by them and the Bidders who agree to match L1 rate, will be considered as Matched L1.

e) The Bidder, who agrees to match L-1 rate shall furnish the breakup detail (Rate, GST etc.) of price (L-1 rate).

f) The supplier upon receipt of the purchase order finds that the purchase orders exceeds the production capacity declared in the Bid documents and the delay would occur in executing the order, shall inform to the RMSCL immediately without loss of time and the purchase order shall be returned within 7 days from the date of the order, failing which the supplier is stopped from disputing the imposition of liquidated damages, fine for the delayed supply.

g) If the L1 supplier has failed to supply /intimated RMSCL about his inability/delay in supply as per the purchase order, the required Drugs/ Medicines within the stipulated time or as the case may be, RMSCL may also place purchase orders with the L1 Rate Matched Bidder for purchase of the Drugs/Medicines, provided such rate matched Bidders shall execute necessary agreement indicating the production capacity as specified in the Bid document on depositing the required amount. Such Bidder is eligible for the placement of purchase orders for the item or items of Drugs/Medicines quoted by them.

h) Subject to Para **(g)** above, while RMSCL has chosen to place purchase orders with Matched L1 supplier and there are more than one such matched L1 suppliers, then the purchase orders for the requirement of Drugs/Medicines will be placed with L-2 first on matched rates of L-1 and in case L-2 does not have the required capacity than L-3 would be considered on matched L-1 rates and the same order would be followed in case of L-3, L-4 etc.

i) The matched L1 supplier, on placement of purchase orders, will be deemed as L-1 rate supplier for the purpose of the Bid and all provisions of the Bid document applicable to L-1 rate Bidder will apply mutatis mutandis to the matched L1 supplier.

j) If the purchase order quantity is very less (which do not make even a normal small batch size; order quantity is less than 1 lac Tab/Cap, or less than 10,000 injections/ bottles/ tubes), the supply may be allowed in brand name to ensure uninterrupted sustained supply. However, the label should possess the required logogram, and the price should not appear on the label.

6. The rates quoted and accepted will be binding on the Bidder during validity period of the bid and any increase in the price (except increase in **GST rate** or any other statutory taxes) will not be entertained.
7. No Bidder shall be allowed to claim revision or modification of bid after opening of bid. If any bidder withdraws or modifies its bid after opening of bid the bid security taken from the bidder shall be forfeited. Representation to make correction in the Bid documents on the ground of Clerical error, typographical error, etc., committed by the Bidders in the Bids shall not be entertained after submission of the Bids. Conditions such as "SUBJECT TO AVAILABILITY" "SUPPLIES WILL BE MADE AS AND WHEN SUPPLIES ARE RECEIVED" etc., will not be entertained under any circumstances and the Bids of those who have given such conditions shall be treated as incomplete and accordingly the Bid will be rejected.
8. The rates should be quoted only for the composition stated in the Bid.
9. Supplies should be made directly by the bidder and not through any other agency.
10. The Bidder shall allow inspection of the factory at any time by a team of Experts/Officials of the Bid Inviting Authority and or of the Govt. of Rajasthan. The Bidder shall extend all facilities to the team to enable to inspect the manufacturing process, quality control measures adopted etc., in the manufacture of the items quoted. If a Company/Firm does not allow for any such inspection, its Bid / contract may be rejected.

10. ACCEPTANCE OF BID

1. The Bid evaluation committee formed by Managing Director, Rajasthan Medical Services Corporation Ltd. will evaluate the Bid with reference to various criteria.
2. Bid Inviting Authority reserves the right to accept or reject the Bid for the supply of all or any one or more items of the drugs Bided for in a Bid without assigning any reason.
3. Bid Inviting Authority, or his authorized representative (s) has the right to inspect the factories of Bidders, before, accepting the rate quoted by them, or before releasing any purchase order(s), or at any point of time during the continuance of Bid and also has the right to reject the Bid or terminate/cancel the purchase

orders issued and or not to reorder, based on adverse reports brought out during such inspections.

4. The acceptance of the Bids will be communicated to the successful Bidders in writing by the Bid inviting authority. Immediately after receipt of acceptance letter, the successful Bidder will be required to deposit PERFORMANCE SECURITY and agreement but not later than 15 days.
5. **The approved rates of the successful Bidders would be valid upto 30.06.2024 (w.e.f date of letter of acceptance) and extendable upto 3 months, if required. Firm shall be bound to accept the extension period of Rate Contract.**
6. Moreover, purchase order can be placed after the issue of letter of acceptance, pending the execution of agreement and issuance of rate contract for an item.

11. **PERFORMANCE SECURITY**

The Successful Bidders shall be required to pay performance Security Deposit @ 2.5% of the Contract value. Performance security will not be taken from undertaking, corporation of GoI & GoR. The MSME Units of Rajasthan shall be required to pay Performance security @ 0.5% of the contract value.

The performance security shall have an upper limit of Rs 25 Lac to be deposited by a bidder at the time of signing of agreement (For one or many items). However, when the actual purchase orders cross a threshold for requiring additional security, the same will be required to be deposited by the supplier.

The performance guarantee should be paid upfront in respect of each contract on or before the due date fixed by Bid inviting authority in the form of Bank Guarantee (Performa given in Annexure XIV) in case the amount exceeds Rs. 5 Lakhs. For amount of upto 5 Lakhs it should be deposited in the form of demand draft/bankers cheque issued by a scheduled bank or may be deposited through challan annexure-1 (the validity of bank guarantee should be for a period of thirty six month from the date of issuance of Bank Guarantee) in favour of the Managing Director, Rajasthan Medical Services Corporation Ltd, Payable at Jaipur before releasing the purchase order by the ordering authority. In case Rate Matched Bidders who have agreed to supply at L-1 price, then the performance security Deposit of such bidders will be 5% of value of quantity fixed for them. (upper limit Rs 25 Lac). Performance Security shall remain valid and refunded 60 days beyond the date of completion of all contractual

obligations or after 36 months from the date of issuance of letter of acceptance, whichever is later.

12. AGREEMENT

a) The successful Bidder shall execute an agreement on a non-judicial stamp paper of value mentioned in the Acceptance Letter (stamp duty to be paid by the Bidder) within 15 days period from the date of Letter of acceptance / Letter of intent or within extended period by the Bid Inviting Authority, i.e. the Managing Director, Rajasthan Medical Services Corporation Ltd. The Specimen form of agreement is available in Annexure-IV. Failing to submission of performance security and execution of agreement within stipulated period as above, will result in forfeiture of Bid Security Deposit & other consequential action. **A bidder who is found successful in more than one product; he will be intimated through LOA / LOI to execute agreement for all the products / drugs / items. If such bidder will not execute agreement for one or more items, in such situation a penalty equal to minimum bid security e.i. Rs. 2.00 Lacs and in case of MSME Rs. 50000/- shall be imposed and the product for which agreement is not executed shall be debarred for a period of not less than 3 years.**

b) The Bidder shall not, at any time, assign, sub-let or make over the contract or the benefit therefore or any part thereof to any person or persons whatsoever.

c) All notices or communication relating to, or arising out of this agreement or any of the terms thereof shall be considered duly served on or given to the Bidder if delivered to him or left at the premises, places of business or abode.

13. SUPPLY CONDITIONS

1. Purchase orders along with the delivery destinations will be placed on the successful Bidder at the discretion of the Ordering Authority. Drugs and Medicines will be supplied at Jaipur MCDW/DDW Churu/DDW Bikaner Rajasthan.
2. The supplier shall supply the entire ordered quantity before the end of **60 days** from the date of issue of purchase order at the destinations mentioned in the purchase order, if the above day happened to be a holiday for RMSCL, the supply should be completed by 5.00 p.m. on the next working day. For drug items requiring sterility test and imported ones, the supply period will be **75 days** from the date of issue of purchase order.

3. All supplies will be scheduled for the period from the date of purchase order till the completion of the bid in installments, as may be stipulated in the purchase order.
4. **Shelf Life**: The labeled shelf life of drugs supplied should be not less than the period mentioned against each item in list of Drugs (Annexure-VIII). The remaining shelf life of the drugs at the time of delivery should not be less than ¾ of the labeled shelf life. Only those bidders shall quote who can manufacture and supply the product with the required shelf life. The product of labeled shelf life lesser than required shelf life will not be accepted. The product should not have such storage condition requiring it to be stored below 2°C.

   Quality Assurance: The supplier shall guarantee that the products as packed for shipment (a) comply with all provisions of specifications and related documents (b) meet the recognized standards for safety, efficacy and quality; (c) are fit for the purpose made; (d) are free from defects in workmanship and in materials and (e) the product has been manufactured as per WHO-GMP.

   In case of imported items the remaining shelf life of 60% or more may be accepted with an undertaking that the firm will replace the unused expired stores with fresh goods. However, firms supplying drugs with remaining shelf life of 75% or more need not submit such undertaking.
5. The protocol of the tests should include the requirements given in I.P for tablets and those required specifically for the product specifications. The Bidder must submit its Test/ Analysis Report for every batch of drug along with invoice. In case of failure on the part of the supplier to furnish such report, the batch of drugs will be returned back to the supplier and he is bound to replenish the same with approved laboratory test report. The supplier shall provide the validation data of the analytical procedure used for assaying the components and shall provide the protocols of the tests applied and the placebo material when demanded for the purpose of testing.
6. The Drugs and medicines supplied by the successful Bidder shall be of the best quality and shall comply with the specification, stipulations and conditions specified in the Bid documents. **Firm will also ensure that supply with same batch number should not be repeated in subsequent purchase orders.**

7. If supplies are not fully completed in **60 days** from the date of the Purchase Order (**75 days** for drugs of the category of serum, vaccine, enzymes, blood grouping reagents, biological products, powder for injections and imported drugs), the provisions of liquidated damages of Bid conditions will come into force. The Supplier should supply the drugs at the Warehouse specified in the Purchase Order and if the drugs supplied at a designated places other than those specified in the Purchase Order, transports charges will be recovered from the supplier.
8. **If the supplier fails to execute at least 50% of the quantity mentioned in a purchase order and such part supply is come into existence in three Purchase orders during the currency of contract period, then supplier shall be liable for debarment for the particular product for two years. Two years period will be reckoned from the date of issuance of such debarment order.**
9. If the Bidder fails to execute the supply within the stipulated time, the ordering authority is at liberty to make alternative purchase of the items of drugs and medicines for which the Purchase orders have been placed from any other sources (such as Public Sector undertakings at their rates, empanelled bidders, and bidders who have been technically qualified in the said bid) or in the open market or from any other Bidder who might have quoted higher rates at the risk and the cost of the supplier and in such cases the Ordering Authority/Bid inviting authority has every right to recover the cost and impose penalty as mentioned in Clause 19, apart from terminating the contract for the default.
10. The order stands cancelled after the expiration of delivery period, and if the extension is not granted with or without liquidated damages. Apart from risk/alternate purchase action, the Bidder shall also suffer forfeiture of the performance security and shall invite other penal action like blacklisting/Debarring disqualification from participating in present and future Bids of Bid Inviting Authority/ordering authority. **.** (As per guidelines for blacklisting/ debarring at annexure- IX including amendment)
11. It shall be the responsibility of the supplier for any shortage/damage at the time of receipt at the designated places.

12. If at any time the Bidder has, in the opinion of the ordering authority, delayed in making any supply by reasons of any riots, mutinies, wars, fire. storm, tempest or other exceptional cause, on a specific request made by the Bidder before expiring of supply period, the time for making supply may be extended by the ordering authority at its discretion for such period as may be considered reasonable. The exceptional causes do not include the scarcity of raw material, Power cut, labour disputes. Reasons must be beyond control of supplier.
13. The supplier shall not be in any way interested in or concerned directly or indirectly with, any of the officers, subordinates or servants of the Bid Inviting Authority in any trade or business or transactions nor shall the supplier give or pay promise to give or pay any such officers, subordinates or servants directly or indirectly any money or fee or other considerations under designation of "Customs" or otherwise, nor shall the supplier permit any person or persons whom so ever to interfere in the management or performance hereof under the power of attorney or otherwise without the prior consent in writing of the Bidder Inviting Authority.
14. If the supplier or any of its approved items gets debarred/banned/blacklisted in any state after entering into agreement with RMSCL, it shall be the responsibility of the supplier to inform RMSCL without any delay about the same.

i. In case the Firm is black listed/debarred/banned after submission of bid document, it should inform the RMSCL within 15 days of blacklisting/debarring/banning. If the blacklisted/debarred / banned firm does not inform the RMSCL within stipulated time, a penalty amounting to @ two per cent of purchase orders issued between the date of blacklisting /debarring/banning and the date of informing to RMSCL, both dates inclusive, shall be imposed, subject to a minimum penalty of Rs 20,000 and a maximum penalty up to Rs 2,00,000 only.

ii. If it is brought to the notice of RMSCL that the similar drug of the supplier firm has been found spurious / adulterated in any other state (whether the firm / product has been blacklisted/ debarred/ banned or not); then no further

purchase orders shall be issued for the product and the rate contract with the firm for the product shall be cancelled.

15. **If a supplier does not supply any quantity against two successive purchase orders then supplier shall be liable for debarment for the particular product for one year. One year period will be reckoned from the date of issuance of such debarment order.**
16. If a supplier fails to execute first order, without proper justification, a show cause notice may be given to him to respond within 7 days. If it does not respond or does not give reasonable justification, the corporation may order to L-2 and L-3, for entire failed supply on L-1 matched rate. If L-2 and L-3 matched rates are not available, then only purchase may be made on 'Risk and cost basis' as being done presently subject to other condition of Bid documents.
17. The supplier of sevoflurane anesthetic (Item code no. 491) shall install vaporizers on loan basis free of cost, in required numbers, as per the need of the Healthcare facilities/ institutions. The installation report of the vaporizers should be submitted along with the invoice.
18. **If the supplier fails to execute full supply of the quantity mentioned in a purchase order then a penalty of 15 % of Value of unsupplied quantity shall be charged. Cases of zero supply against a purchase order shall also be dealt with in same manner.**

14. LOGOGRAMS / Markings

Logogram means, wherever the context occurs, the design as specified below:-

DESIGNS FOR LOGORAMS

Logogram for item code except 448W	Logogram for item code 448W
RAJASTHAN MEDICAL SERVICES CORPORATION RMSC	NATIONAL HEALTH MISSION राष्ट्रीय स्वास्थ्य मिशन

-

INJECTIONS

Injection in ampoule form should be supplied either in Double constricted neck ampoules or snap off type ampoules with the label bearing the words "Rajasthan Govt. Supply- Not for sale निःशुल्क वितरण हेतु, QC – Passed" overprinted and the following logogram which will distinguish from the normal trade packing. Name of drug should be printed in English and Hindi languages and should be legible and be printed more prominently. Storage directions should be clear, legible, preferably with yellow highlighted background.

The vials should be supplied with aluminum seals containing the following logogram:

LIQUIDS

Liquid preparations should be in bottles with pilfer-proof caps bearing the following logogram:

Logogram for item code except 448W	Logogram for item code 448W and 489B

The top of the cap and the label to be affixed on the containers should bear a distint colour different from the colour of the label of the trade packs and they should be overprinted in red colour with the words **"Rajasthan Govt. Supply- Not for Sale**

निःशुल्क वितरण हेतु, **QC – Passed"** and the logogram. Name of drug should be printed in English and Hindi languages and should be legible and be printed more prominently. Storage directions should be clear, legible, preferably with yellow highlighted background.

OINTMENTS & CREAMS

Ointments & Creams should be supplied in tubes bearing the following logograms and the words **"Rajasthan Govt. supply- Not for sale** निःशुल्क वितरण हेतु, **QC – Passed"** overprinted. Name of drug should be printed in English and Hindi languages and should be legible and be printed more prominently. Storage directions should be clear, legible, preferably with yellow highlighted background.

TABLETS & CAPSULES

Tablets and Capsules should be supplied in Strips or Blisters or as mentioned in the list of items for bid. The strip, etc, should bear the following logograms and the words **"Rajasthan Govt. supply- Not for sale** निःशुल्क वितरण हेतु, **QC – Passed"** overprinted. Name of drug should be printed in English and Hindi languages and should be legible and be printed more prominently. Storage directions should be clear, legible, preferably with yellow highlighted background.

Logogram for item code except 448W	Logogram for item code 448W and 489B

-

SPECIMEN LABEL FOR OUTER CARTON

SHALL BE OF DIFFERENT COLOURS FOR DIFFERENT CLASS OF DRUGS

RAJASTHAN GOVT. SUPPLY
NOT FOR SALE

_____

(Name of Drugs etc.)_____

CONSTITUENTS OF……..
Name of the Drug, Manufactured by, Batch no
Mfg.Date, Exp. Date, Quantity/Kit

Net. Weight:……..Kg

Manufactured by/Assembled by

The name of the drug shall be mentioned in Hindi and English and should be legible and be printed more prominently. A uniform colour theme and artwork will be necessary. Apart from this "F**or Govt. of Rajasthan – Not for Sale** निःशुल्क वितरण हेतु, **QC – Passed"** along with logo of RMSCL will be printed on each strip/label of the bottle. The storage directions should be clear, legible and preferably with yellow highlighted background.

1. Bids for the supply for Drugs and medicines etc., shall be considered only if the Bidder gives undertaking in his Bid that the supply will be prepared and packed with the logogram printed on the strips of tablets and capsules and labels of bottles, ampoules and vials etc., as per the design mentioned above.
2. All tablets and capsules have to be supplied in standard packing in aluminum strip or blisters with aluminium foil back with printed logogram and shall also conform to schedule P1 of the Drugs & Cosmetics Act & Rules wherever it applies. Affixing of stickers and rubber stamps shall not be accepted.
3. Labels of Vials, Ampoules and Bottles containing the items Bided for should also carry the logogram.
4. Failure to supply Drugs etc., with the logogram will be treated as breach of the terms of agreement and liquidated damages will be deducted from bills payable as per conditions in Clause 18.2 Bidders who are not willing to agree to conditions above will be summarily rejected.

5. In case of imported drugs affixing rubber stamp on the original label is allowed with indelible ink on inner most and outer packing.

15. PACKING

1. The item shall be supplied in the package schedule given below and the package shall carry the logogram specified in clause -14. The labeling of different packages should be as specified below. The packing in each carton shall be strictly as per the specification mentioned. Failure to comply with this shall lead to non-acceptance of the goods besides imposition of penalties.
2. The pediatric drops should always be supplied with dropper. A measuring cap with suitable markings must be provided for other paediatric oral liquid preparations.
3. The labels in the case of injectables should clearly indicate whether the preparations are meant for IV, IM, SC, etc.
4. Injection vials should have flip off seals.
5. All plastic containers should be made of virgin grade plastic.
6. The name of the drug should be printed in clearly legible bold letters (It is advisable that the colour of font be different from other printed matter to make the name highly conspicuous.
7. It should be ensured that only first hand fresh packaging material of uniform size is used for packing. All packaging must be properly sealed and temper proof.
8. All packing containers should strictly conform to the specifications prescribed in the relevant pharmacopoeia/Act.
9. Packing should be able to prevent damages or deterioration during transit.
10. In the event of items supplied found to be not as per specifications in respect of their packing, the Ordering Authority is at liberty to make alternative purchase of the item for which the purchase orders have been placed from any other sources or from the open market or from any other Bidder who might have quoted higher rates at the risk and the cost of the supplier. In such cases the ordering authority has every right to recover the cost and impose penalty as mentioned in Clause 18.2 and 19.

I. SCHEDULE FOR PACKAGING OF DRUGS AND MEDICINES GENERAL SPECIFICATIONS

No corrugate package should weigh over 15 kgs (i.e. product + inner carton + corrugated box).

All items should be packed only in first hand strong boxes only.

Every corrugated box should preferably be of single joint and not more than two joints.

Every box should be stitched using pairs of metal pins with an interval of two inches between each pair.

The flaps should uniform meet but should not overlap each other. The flap when turned by 45-60 should not crack.

Every box should be sealed with gum tape running along the top and lower opening.

CARRY STRAP:

Every box should be strapped with two parallel nylon carry straps (they should intersect.)

LABEL:

Every corrugated box should carry a large outer label clearly indicating that the product is for "Rajasthan Govt. Supply-Not for Sale".

The Product label on the cartoon should be large, atleast 15 cms x 10 cms dimension. It should carry the correct technical name, strength or the product, date of manufacturing, date of expiry quantity packed and net weight of the box.

OTHERS:

NO box should contain mixed products or mixed batches of the same product.

II. SPECIFICATION FOR CORRUGATED BOXES HOLDING TABLETS/CAPSULES/PESSARIES

1. The total weight of the box should be approx of 7-8 Kgs.

III. SPECIFIATION FOR LARGE VOLUME BOTTLE i.e., ABOVE 100 ml AND BELOW 1 LIT.

1. All these bottles should be packed only in single row with partition between each and also with top and bottom pad of 3 ply.

IV. SPECIFICATION FOR IV FLUIDS

Each corrugated box may carry maximum of only 24 bottles of 500 ml in a single row or 50 bottles of 100 ml in 2 rows with individual sealed polythene cover and centre partition pad, top and bottom pads of 3 ply.

V. SPECIFICATION FOR LIQUID ORALS

100 bottles of 50 ml or 60 ml may be packed in a single corrugated in 2 rows with top, bottom and centre pad of 3 ply.

50 bottles of 100 ml – 120 ml may be packed in a similar manner in a single corrugated box.

If the bottles are not packed in individual carton, 3 ply partition should be provided between each bottle. The measuring device should be packed individually.

VI. SPECIFICATION FOR OINTMENT/CREAM/GELS PACKED IN TUBES:

No corrugated box should weigh more than 7-8 Kgs.

Every Ointment/Cream/Gel tube should be individually packed in carton and then packed in 20's in a grey board box, which may be packed in a corrugated box.

VII. SPECIFICATIONS FOR INJECTION (IN VIALS AND AMPOULES)

Vials may be packed in corrugated boxes weighing upto 15 Kgs. Ampoules should be packed in C.B weighing not more than 8 Kgs.

In the case of 10 ml Ampoules or 50 ampoules may be packed in a grey board box. Multiples of grey board boxes packed in CB. In case of ampoules larger than 10 ml only 25 ampoules may be packed in a grey board box with partition.

If the vial is packed in individual cartoon, there is no necessity for grey board box packing. The individual cartoon may be packed as such in the CB with centre pad.

In case of ampoules every grey board box should carry 5 amps alongwith Cutters placed in a polythene bag.

Vials of eye and ear drops should be packed in a individual cartoon with a dispensing device. If the vial is of FFS/BFS technology, they should be packed in 50's in a grey board box.

Cutters are not required with ampoules in the case of snap off type ampoules.

VIII. SPECIFICATION FOR ORS

Primary Packing:- The pouches/sachets of ORS should be three layered with following composition

Site	Material	Micron	MM	g/m^2
Inner	Polyethylene	50	0.040-0.050	36.9-46.1
Middle	Aluminium	09	0.009-0.015	24.3-40.5
Outside	Polyester	12	0.012-0.015	12.9-20.9

Secondary Packages and Tertiary package:-

50 sachets may be packed in grey board boxes and 10 grey board boxes in a C.B.

IX. LYSOL

Not more than four 5 liters cans may be packed in a single Box.

Government of India Guidelines

15(A) ITEM CODE ITEM CODE 448W- Ferrous Sulphate and Folic Acid Syrup

(For NCB)

A. SPECIFIC REQUIREMENTS

Item:

Iron and Folic acid Syrup shall conform to the requirements given IP 2014 under Iron & Folic Acid Syrup and the general requirements of Oral Liquids given in IP.

The drug shall be currently registered in India and shall meet all requirements of the licensing authorities of India.

Description:

Iron and Folic Acid Tablets (WIFS-JUNIOR) contain Ferrous Iron (derived from Ferrous Sulphate IP) and Folic Acid IP and a suitable anti-oxidant and antimicrobial agent in a suitable flavored vehicle . It is intended to be diluted well with water before use.

Each 1 ml of the syrup shall contain :

- Ferrous Iron (Derived from Ferrous sulphate IP) :20 mg
- Folic Acid IP 0.1 mg

The quality of each constituent should conform to the requirements of IP.

Protocol and Testing:

Complete Test Protocol and samples are taken and sent to the laboratory (identified by the purchaser) by the Inspecting Officer duly sealed and signed by him or his authorized representative.

Protocols of tests should include the requirements given in IP 2014 under Iron & Folic Acid Tablets and the general requirements for Oral Liquids.

The drug should be dispatched to the consignee only on clearance from the Testing Laboratory. The drug shall be released on the basis of Protocol scrutiny by the authorized representative of the Purchaser and testing of the drugs by authorized laboratory.

Each batch should be accompanied with a certificate from the manufacture that the drugs meet the specified requirements.

Random batches will be taken from the supplies of the State (post-delivery) and will be periodically tested (quarterly/six monthly) by DoHFW / MoHFW in identified labs separately for monitoring quality assurance.

-

Storage:

Iron and Folic Acid Syrup should be protected from light/moisture/rodents/damage to packaging. IFA Syrup should be stored in a cool and a dry place.

Shelf-life:

18 months, at least 3/4th of the shelf life of IFA must remain at the time of receiving the shipment. The supplier will provide manufacturer's stability test data substantiating the claimed shelf life in the offered package.

Labelling:

The label on each Bottle shall be map litho paper with minimum 300 gsm. The lable shall conform to the requirements of IP & Rule 96 of Drugs & Cosmetic Rules and shall appear in the language of English.

All labeling of IFA syrup should be in weatherproof ink and shall withstand immersion in water and remain intact. In addition to the requirements given in Rule 96 of Drug & Cosmetic Rules, all labels shall state the amount of ferrous sulphate and equivalent amount of Ferrous iron & Folic Acid, name of the anti-oxidant and antimicrobial agent, the name of the manufacturer, manufacturing license number, address of manufacturer, batch number, and expiry date.

If an artificial sweeteining is used, it should be highlighted on the label . Besides, having the flavouring agent used should be of food grade.

A Warning should be put on the label that 'Medication should be kept out of reach of children. '

The Bottle should have 6 fragmented marking at equal intervals as the entire content (50 ml) has to be consumed in 6 months and the consumption compliance can be verified. The marking can be either embossed on the bottle or printed on the labeling paper stuck on the bottle.

Labelling sticker should have a box space for writing the name of the child on the bottle.

Labelling should clearly indicate :

1. 'For children 6-59 months.'
2. Dosage 1 ml
3. Must be given orally after the meal – not to be given empty stomach
4. IFA syrup bottle should be stored in a cool and dry place and away from sunlight.

Labeling for secondary packaging:

A label of IFA SYRUP must be affixed either on the top and/or front surface of the secondary package. It should indicate the number of bottles, the amount of ferrous sulphate and equivalent amount of Ferrous iron & Folic Acid, the name of manufacturer, batch number, date of manufacture, date of expiry, and storage conditions. The label should in both English and Hindi / local language of the state.

Labeling for tertiary packaging (insulated packaging):

The external surface of insulated packages should be either white or in the natural color of corrugated carton.

The labels of IFA SYRUP on tertiary packaging must be attached to at least two sides. The label should include the name of the product "IFA SYRUP " the number of secondary packages (boxes)/strips/tablets, the name of the manufacturer, batch number, date of manufacture, and date of expiry.

Numbering of tertiary packaging:

All boxes should be numbered consecutively. Shipping documents should be included in the box labeled number l.

Additional Labeling:

All the containers and other outer containers shall be marked with the statement "GOVT SUPPLY-NOT FOR SALE" in English and Local language.

All labels on containers i.e. strips, cartoons etc. should be marked with the statement "GOVT SUPPLY-NOT FOR SALE" in bold letters in English and local language.

B. QUALITY ASSURANCE

Compliance:

The Supplier shall guarantee that the products as packed for shipment (a) comply with all provisions of the specification and related documents; (b) meet the recognized standards for safety, efficacy and quality; (c) are fit for the purposes made known to the Seller (d) are free from defects in workmanship and in materials and (e) the product has been manufactured as per cGMP included in Schedule M of Drugs & Cosmetic Rules.

Evidence:

The Supplier shall provide objective evidence, acceptable to the Purchaser, of the satisfaction of the requirements of this document for which no specific inspection has been mentioned.

The Supplier shall provide a copy of the Certificate of Analysis for each lot intended for shipment.

The Supplier shall provide the validation data of the analytical procedure used for assaying the components.

The test data for raw materials, in-process, finished product and packaging material testing must be on record for each lot shipped and must be made available to Purchaser's representatives when requested.

Inspection:

The Purchaser may inspect and sample, or cause to be sampled, the product at the Supplier's factory and/or warehouse at a mutually agreeable time prior to / after the shipment of the product.

Testing:

The Purchaser may cause independent laboratory testing of the samples picked randomly from pre and post-delivery shipment to be performed as deemed necessary to assure that the goods conform to the prescribed requirements. The said laboratory testing shall be of the Purchaser's choice if suitably equipped and qualified to conduct quality assurance tests on the product.

C. PACKING :

Primary Package:

Iron and Folic acid Syrup shall be packed in 50 ml capacity Pharmaceutical grade polyethylene terephthalate amber coloured bottles (AA8011 / AA 1200); and provided with temper evident ROPP cap (25/15mm or 25/17mm). The cap should be provided with inert liner. The bottle is to be provided with a auto dispenser 1 ml each time and packed in mono carton. The plastic cap – cum – orifice that release syrup must be firmly attached to the bottle so that it is impossible for the child to accidently swallow the entire content.

- The mono carton should also contain a 1 pager instruction leaflet in local language Hindi. *(Draft-annexed below as **Annexure : leaflet)***
- Toll free number must be indicated on every secondary package for contacting in case of product complaints.

Secondary Package:

The bottles should be packed in boxes for easy handling, transport and distriction from 3-ply corrugated cardboard having strength $(150)^3$ gsm.

- Toll free number must be indicated for contacting in case of product complaints.

Tertiary Package:

The boxes shall be packed in weather resistant triple walled insulated corrugated 7-ply cartons, usually containing 10 secondary packages having sufficient burst strength to hold weight of 100 bottles. The overall dimension of the carton should be such that the product does not get damaged during transportation and storage.

- Toll free number must be indicated for contacting in case of product complaints.

D. QUALIFICATION OF THE MANUFACTURER:

The Bidder shall furnish a certificate from the competent Regulatory Authority that the manufacturer of the pharmaceutical product is licensed to manufacture these products. The manufacturing facility must conform to cGMP Standards and Schedule M of Drugs & Cosmetic Rules.

E. RECALLS:

If products must be recalled because of problems with product quality or adverse reactions to the drug, the Supplier will be obliged to notify the purchaser providing full details about the reason leading to the recall and shall take steps to replace the product in question at its own cost with a fresh batch of acceptable quality, or withdraw and give a full refund if the product has been taken off the market due to safety problems.

In case the quality of the product is found to be sub-standard or unsatisfactory in quality checks, stringent action would be taken against them and the supplier can be black-listed for future supplies of the product.

F. COLOUR CODING:

The Labels on secondary packing, tertiary packing and shipper package shall be identified by background. (Standard RED Color).

G. BAR CODING:

Bar code shall be used to track down the product. It shall be printed on the label of Millboard/Grey board boxes and 5-Ply shipper containing

1. Product identification (GTIN 14) using application identifier (01)
2. Expiry date in YYMMDD format & using application identifier (17)
3. Master batch number using application identifier (10)

   Complete details on GSI standards along with technical guidelines can be downloaded from www.gs1india.org or www.gs1.org
4. Bar coding to be put on all Tertiary and Secondary Packing.

H. MARKINGS:

All containers and invoices must bear the IFA SYRUP name of the product, expiry dates of and appropriate storage conditions.

Inner boxes:

The inner boxes shall be marked with the following information in a clearly legible manner which is acceptable to the Purchaser:

- Name IFA SYRUP

-

- Generic name of the product
- Manufacturer's name and registered address
- Manufacturer's License number
- Lot or batch number
- Number of strips contained in box
- Date of manufacture (month and year)
- Expiration date (month and year)
- Instructions for storage and handling
- Place of manufacture
- Barcode

Exterior Shipping Cartons :

The following information shall be stenciled or labeled on the exterior shipping cartons on all four sides in bold letters at least **Ariel font size 14** with waterproof indelible ink in a clearly legible manner which is acceptable to the Purchaser:

- Name IFA SYRUP
- Generic name of the product
- Lot or batch number
- Date of manufacture (month and year)
- Expiration date (month and year)
- Manufacturer's name and registered address
  Consignee's address and emergency phone number including mobile number
- Contract number
- Number of tablets/strips/boxes contained in the carton
- Gross weight of each carton (in kg)
- Carton containing no. of …. Secondary packages
- Instructions for storage and handling
- Place of manufacture
- Barcode

I. <u>Documentation:</u>

Supplier shall provide to Purchaser a copy of the batch record, including all quality assurance documentation for the product being supplied.

Advance notice of arrival and advance shipping documentation:

Copies of the documentation for the goods to be supplied must be sent at least seven days in advance of arrival of the consignment. In the case of an individual contract for a

specific destination that requires a longer period of advance notice, a longer period should apply. The consignee(s) shall be intimated well in advance by registered letter/e-mail/telephone, so that the products are collected immediately after arrival.

The documentation must include the following:

- Pre-advice defined by the Purchaser
- Airway bill (AWB) if applicable;
- Supplier's invoice;
- Packing list;
- Lot release certificate (LRC) as per the requirements issued by the Regulatory authority for each lot and
- Any other document, certificate or instruction specified in the individual order.

The documents shall be sent by e-mail and fax by the freight forwarder or the manufacturer to the consignee, the Purchaser, and any other parties specified in the individual contract.

The pre-advice must contain the following information:

- Purchase order reference;
- Consignee requisition reference;
- Number of packages and gross weight(in Kilograms);
- Value of shipment(in Indian Rupees);
- A WB and Flight number(s) if applicable;
- Date and time for place of departure, transit (if applicable), and arrival;
- Instructions for collection;
- Any other information specified in the individual contract must also be included for the consignee.
- Invoice

The following information shall be stated on the invoice:

- Consignee's name, address, telephone number (including mobile no.) and e-mail ID.
- Purchase order reference;
- Consignee's requisition reference;
- Instructions to:"Telephone consignee upon arrival (repeat telephone number);

J. <u>DISPATCH</u>

Consignments should be scheduled to arrive outside weekends and/or public holidays.

Annexure: leaflet
[Ref. to Clause 15(A)(C)]

दवा (IFA Syrup) सम्बन्धी महत्वपूर्ण जानकारी

इस दवा (IFA Syrup) के कुछ सामान्य प्रश्नों के उत्तर इस पत्रक द्वारा प्राप्त होंगे। ये डॉक्टर, ANM या ASHA से बात करने की महत्ता की जगह नहीं लेता। इस दवा को बच्चे को देने से पहले कृपया इस पत्रक को ध्यान से पढें। यदि इस दवा के बारे में आपके मन में कोई भी सवाल हैं तो कृपया नजदीकी डॉक्टर, ANM या ASHA से पूछे। इस पत्रक को आप अपनी दवाई के साथ रखे, शायद इसे दुबारा पढ़ना पढ़े।

- **यह दवा (IFA Syrup) किसके लिए ?**

6–59 माह की उम्र के सभी बच्चों को यह दवा देनी चाहिए। एनीमिया की रोकथाम के लिए प्रत्येक बच्चे को यह दवा नियमित देनी चाहिए। एनीमिया से पीड़ित बच्चों के लिए डॉक्टर, ANM या ASHA की सलाह पर आवश्यकता से अधिक दवा देने की सलाह भी दी जा सकती हैं।

- **दवा : कितनी मात्रा में दी जानी हैं ?**

1 मि.ली. – सप्ताह में दो बार जैसे सोमवार एवं गुरूवार, मंगलवार एवं शुक्रवार आदि।

- **इस दवा (IFA Syrup) का उपभोग से क्या लाभ हो सकता हैं ? दवा को सप्ताह में दो बार लेने के लाभ :–**
  - ❖ यह दवा (IFA Syrup), लौह की कमी से होने वाले एनीमिया की रोकथाम और उसके इलाज के लिए iron और folic acid का एक साधन हैं। Iron और Folic acid बच्चे के शारीरिक, मानसिक, ज्ञानात्मक और प्रजनन स्वास्थ्य के लिए महत्वपूर्ण होता हैं।
  - ❖ लौह की कमी से होने पर एनीमिया पीड़ित बच्चों में थकावट, कम सक्रिय, कम ज्ञानात्मक विकास और विद्यालय में कार्यशीलता कम हो जाती हैं।
  - ❖ 1मि.ली. दवा सप्ताह में दो बार लेने से बच्चें के स्वास्थ्य में सुधार, सक्रियता एवं पढ़ाई में एकाग्रता और बच्चें की समझदारी बढती हैं।
  - ❖ बच्चें क्रियाशील, सतर्क बनते हैं एवं जल्दी थकते नहीं हैं।
- **इस दवा (IFA Syrup) को किस किसको पिलाना चाहिए ?**
  - ❖ 6–59 माह की उम्र के बच्चों को उनकी माताओं या उनके परिवार के वयस्कों के द्वारा पिलाना चाहिए।
  - ❖ 1मिली दवा (IFA Syrup) देने की तकनीक ASHA/ANM या डॉक्टर से सीखे।
- **इस दवा (IFA Syrup) को कब पिलावे ?**
  - ❖ दवा बच्चें को खाली पेट नहीं देनी चाहिए।

- ❖ दवा बच्चें को तब ही देवे जब कम से कम आधी कटोरी खाना खाया हो, सामान्यतः स्तनपान या रात के खाने के बाद ही दी जानी चाहिए।
- ❖ दवा देने के साथ–साथ खाने में बच्चों को लौह तत्व बढ़ाने वाले पदार्थ जो आसानी से पचाए जा सके वो देने चाहिए। लौह बढ़ाने वाले तत्व विटामिन सी से भरे खानें में होता हैं जैसे नींबू, अमरूद, आंवला, नारंगी, किण्वित या अंकुरित खाना आदि।

- **बच्चें को दवा देने से पहले डॉक्टर से सलाह लेवे, यदि :–**
  - ❖ बच्चा बीमार हैं (उदाहरणतः बुखार होना, डॉयरिया, निमोनिया, मलेरिया आदि।)
  - ❖ बच्चें को किसी दवा से रिएक्शन या एलर्जी (दुष्प्रभाव) है तो।
  - ❖ बच्चा गम्भीर कुपोषण से पीड़ित हैं तो। (इसके बारे में ASHA के द्वारा बताया जाएगा)। बच्चें को खून चढ़ाया (Blood Transfusion) जा रहा हो।
- **बच्चें को दवा नहीं पिलावे, यदि –**
  - ❖ दवा की शीशी को देने की अन्तिम तिथि (expiry date) निकल जाने पर या दवा में कुछ गड़बड़ी होने का अंदेशा हो।
- **कृपया घबराऐं नहीं यदि :–**
  - ❖ कुछ बच्चों में दवा के कारण जी मिचलाना, पेट की परेशानी, दस्त, कब्ज आदि हो सकते हैं। ये मंद नुकसान सामान्यतः अस्थाई होते हैं और बच्चें के शरीर में दवाईयों के प्रति अनुकूलन होने लगता हैं जिससे इनका प्रभाव गायब होने लगता हैं।
  - ❖ यदि ऐसा कोई प्रभाव निरन्तर रहता है, तो आप ASHA/ ANM या डॉक्टर को सम्पर्क कर।
  - ❖ सामान्यतः आयरन युक्त दवाईयों के कारण टट्टी का रंग काला होता है परन्तु यह नुकसानदायक नहीं होता, इसलिए अपने बच्चे की काली टट्टी को देखकर चिन्ता न करे।
  - ❖ इन संभावित दुष्प्रभावों की सूची देखकर चिंतित न हो।
- **इस दवा को कैसे सुरक्षित रखे। :–**
  - ❖ दवा की शीशी को अपने बच्चों से दूर रखें, उसकी आवश्यकता से अधिक खुराक बच्चें के लिए नुकसानदेह हो सकती हैं।
  - ❖ दवा की शीशी ठण्डी और सूखी जगह पर रखे और सूर्य की रोशनी से दूर रखे।
  - ❖ दवा की शीशी को गुसलखाने/स्नानघर में, सिंक के पास या खिड़की के पास न रखे।
  - ❖ दवा की शीशी के ढ़क्कन को दवा पिलाने के बाद कस के (tightly) बंद करे।

15(B). ITEM CODE 489B- IRON AND FOLIC ACID TABLETS (IFA-WIFS)

A. SPECIFIC REQUIREMENTS

Item:

Iron and Folic acid tablets (By brand name of IFA WIFS) shall conform to the requirements given in IP 2018 given under Iron & Folic Acid (IFA) Tablets and the general requirements of Tablets given in IP 2018. In addition it should comply with the requirements given in the Annexure IFA-WIFS.

The drug shall be currently registered in India and shall meet all requirements of the licensing authorities of India.

Description:

Iron and Folic Acid Tablets **(IFA-WIFS**) contain Ferrous Sulphate and Folic Acid. They are "sugar Coated" and "Blue" colored tablets (Indigo Carmine). Only Edible colors should be used.

Each sugar coated IFAWIFS tablet shall contain:

	Small
Dried Ferrous Sulphate IP equivalent to ferrous iron	60 mg
Folic Acid IP	0.5 mg

The quality of each constituent should conform to the requirements of IP.

Protocol and Testing:

Complete Test Protocol and samples are taken and sent to the laboratory (identified by the purchaser) by the Inspecting Officer duly sealed and signed by him or his authorized representative.

Protocols of tests should include the requirements given in IP 2018 under Iron & Folic Acid Tablets and the general requirements for Tablets including those specified in the Annexure.

The drug should be dispatched to the consignee only on clearance from the Testing Laboratory. The drug shall be released on the basis of Protocol scrutiny by the authorized representative of the Purchaser and testing of the drugs by authorized laboratory.

Each batch should be accompanied with a certificate from the manufacture that the drugs meet the specified requirements.

Random batches will be taken from the supplies of the State (post-delivery) and will be periodically tested (quarterly/six monthly) by DoHFW / MoHFW in identified labs separately for monitoring quality assurance.

Storage:

Iron and Folic Acid Tablets (IFA) should be protected from light/moisture/rodents/damage to packaging.

Shelf-life:

24 months, at least 5/6th of the shelf life of IFA must remain at the time of receiving the shipment. The supplier will provide manufacturer's stability test data substantiating the claimed shelf life in the offered package.

Labelling:

The label on each strip of **IFA-WIFS** shall conform to the requirements of Rule 96 of Drugs & Cosmetic Rules and shall appear in English.

All labeling of **IFA-WIFS** should be in weatherproof ink and shall withstand immersion in water and remain intact. In addition to the requirements given in Rule 96 of Drug & Cosmetic Rules, all labels shall state the amount of ferrous sulphate and equivalent amount of Ferrous iron & Folic Acid, the name of the manufacturer, manufacturing license number, address of manufacturer, batch number, and expiry date.

Labeling for secondary packaging:

A label of **IFA-WIFS** must be affixed either on the top and/or front surface of the secondary package. It should indicate the number of strips/tablets, the amount of ferrous sulphate and equivalent amount of Ferrous iron & Folic Acid, the name of **IFA-WIFS** drug manufacturer, batch number, date of manufacture, date of expiry, and storage conditions.

Labeling for tertiary packaging (insulated packaging):

The external surface of insulated packages should be either white or in the natural color of corrugated carton. The label should in both English and Hindi/local language of the State.

The labels of **IFA-WIFS** on tertiary packaging must be attached to at least two sides. The label should include the name of the product " **IFA-WIFS** " the number of secondary packages (boxes)/strips/tablets, the name of the manufacturer, batch number, date of manufacture, and date of expiry.

Numbering of tertiary packaging:

All boxes should be numbered consecutively. Shipping documents should be included in the box labeled number l.

Additional Labeling:

All the containers and other outer containers shall be marked with the statement "GOVT SUPPLY-NOT FOR SALE" in English and Local language.

All labels on containers i.e. strips, cartoons etc. should be marked with the statement "GOVT SUPPLY-NOT FOR SALE" in bold letters in English and local language.

B. QUALITY ASSURANCE

Compliance:

The Supplier shall guarantee that the products as packed for shipment (a) comply with all provisions of the specification and related documents; (b) meet the recognized standards for safety, efficacy and quality; (c) are fit for the purposes made known to the Seller (d) are free from defects in workmanship and in materials and (e) the product has been manufactured as per cGMP included in Schedule M of Drugs & Cosmetic Rules.

Evidence:

The Supplier shall provide objective evidence, acceptable to the Purchaser, of the satisfaction of the requirements of this document for which no specific inspection has been mentioned.

The Supplier shall provide a copy of the Certificate of Analysis for each lot intended for shipment.

The Supplier shall provide the validation data of the analytical procedure used for assaying the components.

The test data for raw materials, in-process, finished product and packaging material testing must be on record for each lot shipped and must be made available to Purchaser's representatives when requested.

Inspection:

The Purchaser may inspect and sample, or cause to be sampled, the product at the Supplier's factory and/or warehouse at a mutually agreeable time prior to / after the shipment of the product.

Testing:

The Purchaser may cause independent laboratory testing of the samples picked randomly from pre and post-delivery shipment to be performed as deemed necessary to assure that the goods conform to the prescribed requirements. The said laboratory testing shall be of the Purchaser's choice if suitably equipped and qualified to conduct quality assurance tests on the product.

C. PACKING :

Primary Package:

15 Tablets should be packed in an Aluminium -Aluminium strip with **IFA-WIFS** name displayed prominently.

Aluminium Strips: Thickness of Aluminium Foil: 40 microns with LDPE 25 micron coating /heat seal lacquer.

- Toll free number must be indicated on every secondary package for contacting in case of product complaints.

Secondary Package:

The strips should be packaged in boxes for easy handling, transport and distribution with WIFS name displayed prominently. The box may contain 10 strips. It shall be fabricated from Millboard/ grey board/ card board with a minimum of bursting strength of 400 gsm.

- Toll free number must be indicated for contacting in case of product complaints.

Tertiary Package:

The boxes shall be packed in weather resistant triple walled insulated corrugated 5-ply cartons, each ply having strength of minimum 150 gsm with WIFS name displayed prominently. It should be fabricated from virgin quality "A" grade material. The overall dimension of the carton should be such that the product does not get damaged during transportation and storage.

- Toll free number must be indicated for contacting in case of product complaints.

D. QUALIFICATION OF THE MANUFACTURER:

The Bidder shall furnish a certificate from the competent Regulatory Authority that the manufacturer of the pharmaceutical product is licensed to manufacture these products. The manufacturing facility must conform to cGMP Standards and Schedule M of Drugs & Cosmetic Rules.

E. RECALLS:

If products must be recalled because of problems with product quality or adverse reactions to the drug, the Supplier will be obliged to notify the purchaser providing full details about the reason leading to the recall and shall take steps to replace the product in question at its own cost with a fresh batch of acceptable quality, or withdraw and give a full refund if the product has been taken off the market due to safety problems.

In case the quality of the product is found to be sub-standard or unsatisfactory in quality checks, stringent action would be taken against them and the supplier can be black-listed for future supplies of the product.

F. COLOUR CODING:

The Labels on secondary packing, tertiary packing and shipper package shall be identified by background. (Standard Blue Color).

G. BAR CODING:

Bar code shall be used to track down the product. It shall be printed on the label of Millboard/Grey board boxes and 5-Ply shipper containing

5. Product identification (GTIN 14) using application identifier (01)
6. Expiry date in YYMMDD format & using application identifier (17)
7. Master batch number using application identifier (10)
8. Bar coding to be put on all Tertiary and Secondary Packing.

Complete details on GSI standards along with technical guidelines can be downloaded from www.gs1india.org or www.gs1.org

i. MARKINGS:

All containers and invoices must bear the **IFA-WIFS** name of the product, expiry dates of and appropriate storage conditions.

Inner boxes:

The inner boxes shall be marked with the following information in a clearly legible manner which is acceptable to the Purchaser:

- Name IFA-WIFS
- Generic name of the product
- Manufacturer's name and registered address
- Manufacturer's License number
- Lot or batch number
- Number of strips contained in box
- Date of manufacture (month and year)
- Expiration date (month and year)
- Instructions for storage and handling
- Place of manufacture
- Barcode

Exterior Shipping Cartons :

The following information shall be stenciled or labeled on the exterior shipping cartons on all four sides in bold letters at least **Ariel font size 14** with waterproof indelible ink in a clearly legible manner which is acceptable to the Purchaser:

- Name IFA – WIFS
- Generic name of the product
- Lot or batch number
- Date of manufacture (month and year)
- Expiration date (month and year)
- Manufacturer's name and registered address

Consignee's address and emergency phone number including mobile number

- Contract number
- Number of tablets/strips/boxes contained in the carton
- Gross weight of each carton (in kg)
- Carton containing no. of …. Secondary packages
- Instructions for storage and handling
- Place of manufacture
- Barcode

ii. <u>Documentation:</u>

Supplier shall provide to Purchaser a copy of the batch record, including all quality assurance documentation for the product being supplied.

Advance notice of arrival and advance shipping documentation:

Copies of the documentation for the goods to be supplied must be sent at least seven days in advance of arrival of the consignment. In the case of an individual contract for a specific destination that requires a longer period of advance notice, a longer period should apply. The consignee(s) shall be intimated well in advance by registered letter/e-mail/telephone, so that the products are collected immediately after arrival.

The documentation must include the following:

- Pre-advice defined by the Purchaser
- Airway bill (AWB) if applicable;
- Supplier's invoice;
- Packing list;
- Lot release certificate (LRC) as per the requirements issued by the Regulatory authority for each lot and
- Any other document, certificate or instruction specified in the individual order.

The documents shall be sent by e-mail and fax by the freight forwarder or the manufacturer to the consignee, the Purchaser, and any other parties specified in the individual contract.

The pre-advice must contain the following information:

- Purchase order reference;
- Consignee requisition reference;
- Number of packages and gross weight(in Kilograms);
- Value of shipment(in Indian Rupees);
- A WB and Flight number(s) if applicable;
- Date and time for place of departure, transit (if applicable), and arrival;
- Instructions for collection;

- Any other information specified in the individual contract must also be included for the consignee.
- Invoice

The following information shall be stated on the invoice:

- Consignee's name, address, telephone number (including mobile no.) and e-mail ID.
- Purchase order reference;
- Consignee's requisition reference;
- Instructions to:"Telephone consignee upon arrival (repeat telephone number);

iii. DISPATCH

Consignments should be scheduled to arrive outside weekends and/or public holidays.

Annexure IFA-WIFS

Additional tests: Ferrous Sulphate and Folic Acid Tablets

The method of analysis should be validated as per ICH guidelines

Seals Integrity Test:

Check 10strips. Bundle up the strips and submerge them under water in a vacuum desiccator or equivalent device. Draw a vacuum of about 18k Pa and hold for a minute. Examine for the air leakage indicated by a fine stream of bubbles. Re-establish normal pressure and open strips to examine for water penetration

Microbial Count:

When the test is conducted as per IP

-Total viable aerobic count-Not more than 10^3 bacteria and not more than 10^2 fungi per gram

-Absence of Escherichia coli.

16. QUALITY TESTING

1. Sampling of supplies from each batch will be done at the point of supply or distribution/storage points for testing. (The samples would be sent to different empanelled laboratories for testing by the ordering authority after coding). The RMSCL will deduct a sum of 1.5% from the amount of bill payable to supplier on account of handling and testing charges.
2. The Drugs shall have the active ingredients within the permissible level throughout the shelf life period of the drug. The samples may also be drawn periodically during the shelf life period. The supplies will be deemed to be completed only upon receipt of the quality certificates from the laboratories. Samples which do not meet quality requirements shall render the relevant batches liable to be rejected. If the sample is declared to be Not of Standard Quality or spurious or adulterated or misbranded, such batch/batches will be deemed to be rejected goods.
3. In the event of the samples of the Drugs and medicines supplied failing quality tests or found to be not as per specification the ordering authority is at liberty to make alternative purchase of items of drugs and medicines for which the Purchase orders have been placed from any other sources or from the open market or from any other Bidder who might have quoted higher rates at the risk and the cost of the supplier and in such cases the ordering authority has every right to recover the cost and impose penalty as mentioned in Clause 19.
4. The supplier shall furnish to the purchaser the evidence of bio-availability and/or bio-equivalence for certain critical drugs when asked for. If there is any problem in the field the B.M.R/B.P.R for the particular batch shall also be supplied when demanded.
5. The products should conform to the standards of IP/BP / USP as the case may be. In case the product is not included in the said compendium, the supplier, upon award of the contract, must provide the reference standards and testing protocols for quality control testing. For imported drugs respective countries pharmacopeia standards shall be acceptable (even if the product is official in IP)
6. The supply of any item shall be considered complete for the purpose of calculation of liquidated damages only when reference standards/ standard

testing procedure or test protocol/placebo materials are made available to the corporation along with the supply of items as per the purchase order. However these materials and documents shall be made available by supplier to Quality Cell of RMSCL Headquarter. Such requirement will however be indicated in the purchase order.

17. PAYMENT PROVISIONS

1. No advance payment towards costs of drugs, medicines etc., will be made to the Bidder.
2. On receipt of the prescribed consolidated invoice duly stamped and signed by authorized signatory and analytical laboratory report regarding quality, the payment would be made in 30 days positively. (Annexure- XII & XIII)
3. The in charge of district drug warehouse (DDW) will acknowledge the drugs received & ensure entry in e- Aushadhi software online. .
4. All bills/ Invoices should be raised in **triplicate** and in the case of excisable Drugs and Medicines; the bills should be drawn as per **GST Rules / other applicable Rules if any** in the name of the authority as may be designated. The supplier will deliver following document at the time of delivery at DDW/**MCDW**.
   a. In house test report of drug.
   b. The challan / invoice copy pertaining to DDW/ **MCDW**
5. **Payments for supplies will be considered after receipt of reports of standard quality on samples having been tested by approved laboratories of ordering authority.**

   (i) Payments can be initiated if 50 % supply has been made against a purchase order by a supplier before expiry of supply period/extended supply period.

   (ii) After expiry of supply period/extended supply period payments for actual supplies made against a purchase order will be made although supplies are less than 50 %.
6. If at any time during the period of contract, the price of Bided items is reduced or brought down by any law or Act of the Central or State Government or by the Bidder himself, the Bidder shall be bound to inform ordering authority immediately about it. Ordering authority empowered to unilaterally effect such

reduction as is necessary in rates in case the Bidder fails to notify or fails to agree for such reduction of rates.

In case the price of a drug fixed by NPPA (Govt of India) under applicable DPCO is less than the RMSCL contract price, the supplier shall be bound to make the supplies of such items at price fixed by the Govt.

7(a) In case of any enhancement in **GST as per** notification of the Government after the date of submission of Bids and during the Bid period, the quantum of additional **GST** so levied will be allowed to be charged extra as a separate item without any change in the basic of the price structure price of the Drugs approved under the Bid. For claiming the additional cost on account of the increase in **GST**, the Bidder should produce a letter from the concerned Excise authorities **/ GST authorities (Central and State)** for having paid additional **GST** on the goods supplied to ordering authority and also must claim the same in the invoice separately. **In case of reduction in rates of GST price will be reduced accordingly.**

Similarly if there is any reduction in the rate of essential drug, as notified by the Govt. **(Including NPPA)**, after the date of submission of Bid, the quantum of the price to the extent of reduction of essential drug will be deducted without any change in the basic price of the price structure of the drugs approved under the Bid.

7(b) In case of successful bidder has been enjoying **GST** exemption **or** any criteria of Turnover etc., such bidder will not be allowed to claim **GST** at later point of time, during the tenure of contract, when the **GST** is chargeable on goods manufactured/**Supplied**.

8. (i) If the supplier requires an extension in time for completion of contractual supply, on account of occurrence of any hindrance he shall apply in writing for extension on occurrence of hindrance but not after the stipulated date of completion of supply.

(ii) The purchase Officer may extend the delivery period with or without liquidated damages in case they are satisfied that the delay in the supply of goods is on account of hindrances. Reasons shall be recorded.

(iii) **Extension in delivery period:-** In case of extension in the delivery period with liquidated damages the recovery shall be made on the basis of following percentages of value of stores which the Bidder has failed to supply:-

a) Delay upto one fourth period of the prescribed delivery period; 2.5%
b) Delay exceeding one fourth but not exceeding half of the prescribed delivery period; 5%
c) Delay exceeding half but not exceeding three fourth of the prescribed delivery period; 7.5%
d) Delay exceeding three fourth of the prescribed delivery period; 10%

Note 1:- Fraction of a day in reckoning period of delay in supplies shall be eliminated if it is less than half a day. The maximum amount of liquidated damages shall be 10%.

Note 2:- In specific condition, permission for additional delay of 10 days may be granted for supply, in such a case an additional penalty of 5% shall be levied.

Note 3:- If a supplier seeks extension in supply period beyond two times the time indicated in purchase order, the supply period shall be extended with the condition that if the rate received in new bid(s) invited are lower than the rate contract in operation, then the supplier shall be entitled to the lower rates so received.

9. If, at any time during the continuance of this Agreement, the Supplier has, in the opinion of the Purchaser, delayed in making any supply ordered, by the reasons of any riots, mutinies, wars, fire, storm, tempest or other exceptional cause, on a specific request made by the Supplier before expiry of supply period indicated in P.O , the time for effecting delivery may be extended by the Purchaser surely at his discretion for such period as may be considered reasonable by the Purchaser. No further representation from the Supplier will be entertained on this account.

10. If the firm is Blacklisted/Debarred by State Govt. of Rajasthan during rate contract period/ after rate contract period, the firm has to follow below mentioned conditions:-

- Further Purchase orders should not be placed to firm.
- Purchase orders in process shall be cancelled.
- All unconsumed stock from DDWs should be lifted on the cost of firm.
- If payment is made for unconsumed stock it should be recovered from firm.

- All rate contracts should be cancelled.

18. DEDUCTION IN PAYMENTS:

1. If the supply is received in damaged conditions it shall not be accepted.
2. All the Bidder are required to supply the product with logogram and with prescribed packing specification. If there is any deviation in these Bid conditions a separate damages will be levied @ 2% irrespective of the ordering authority having actually suffered any damage/loss or not, without prejudice the rights of alternative purchase specified in Clause **No.15.10.**

19. QUALITY CONTROL DEDUCTION & OTHER PENALTIES:

1. If the successful Bidder fails to execute the agreement and/or to deposit the required performance security within the time specified or withdraws his Bid after the intimation of the acceptance of his Bid has been sent to him or owing to any other reasons, he is unable to undertake the contract, his contract will be cancelled and the Bid security Deposit deposited by him along with his Bid, shall stand forfeited by the Bid Inviting Authority and he will also be liable for all damages sustained by the Bid Inviting Authority apart from blacklisting/ debarring the supplier. (As per guidelines for blacklisting/ debarring at annexure IX)
2. (i) If the samples drawn from supplies do not conform to statutory standards, the supplier will be liable for relevant action under the existing laws and the entire stock in such batch should be taken back by the supplier within a period of 30 days from the issue of letter from ordering authority the information of which may be communicated by e- mail. The stock shall be taken back at the expense of the supplier. Ordering authority has the right to destroy such NOT OF STANDARD DRUGS IF THE SUPPLIER does not take back the goods within the stipulated time. Ordering authority will arrange to destroy the NOT OF STANDARD drugs within 90 days after the expiry of 30 days mentioned above, without further notice, and shall also collect demurrage charge calculated @ 2% per week on the value of the drugs rejected till such destruction.

   The Supplier shall replace the stock of NOSQ goods with fresh goods upon intimation to do so by the ordering authority.

(ii) **If RMSCL decides not to return the NOSQ drugs to supplier and decides to destroy NOSQ drugs at its level, then provision of demurrage charge will not apply. Means, if RMSCL writes to supplier to take back NOSQ drugs, then demurrage provision as per 19(2)(i) will be applied and if does not write to take back and decides to destroy drugs at its own level, then demurrage charge provision as per 19(2)(i) will not be applied.**

3. The supplier will not be entitled to any payment whatsoever for Items of drugs found to be of NOT OF STANDARD QUALITY whether consumed or not consumed and the ordering authority is entitled to deduct the cost of such batch of drugs from the any amount payable to the Bidder. On the basis of nature of failure, the product/supplier will be moved for Black Listing. (As per guidelines for blacklisting/ debarring at annexure IX including amendment)
4. For supply of drugs of NOT OF STANDARD QUALITY the respective Drugs Controller will be informed for initiating necessary action on the supplier and that the report of product shall be sent to the committee for appropriate action including blacklisting. (As per guidelines for blacklisting/ debarring at annexure IX)
5. The decision of the ordering authority or any Officer authorized by him as to the quality of the supplied drugs, medicines etc., shall be final and binding.
6. Ordering Authority will be at liberty to terminate without assigning any reasons thereof the contract either wholly or in part on 30 days notice. The Bidder will not be entitled for any compensation whatsoever in respect of such termination.
7. For infringement of the stipulations of the contract or for other justifiable reasons, the contract may be terminated by the ordering authority, and the supplier shall be liable for all losses sustained by the ordering authority, in consequence of the termination which may be recovered personally from the supplier or from his properties, as per rules.
8. Non performance of any contract provisions shall be examine and may disqualify the firm to participate in the future Bids.
9. **In the event of making ALTERNATIVE PURCHASE, as specified in Clause 13.10, Clause 15.10 and in Clause 16.3 the penalty will be imposed on supplier apart from forfeiture of Security Deposit. The excess expenditure**

over and above contracted process incurred by the ordering authority in making such purchases from any other sources or from the open market or from any other Bidder who has quoted higher rates and other losses sustained in the process, shall be recovered from the performance security or from any other money due and become due to the supplier and in the event of such amount being insufficient, the balance will be recovered personally from the supplier and provided further that such amount to be levied as per penalty from supplier on account of non-supply shall not be less than 15% of the value of non-supplied even when rates in alternative purchase method are lower / equivalent to rates in original tender.

10. In all the above conditions, the decision of the Bid Inviting Authority, viz Managing Director, Rajasthan Medical Services Corporation Ltd, would be final and binding; in case of any dispute regarding all cases under Bid procedure or in any other non-ordinary situation and would be acceptable to all.
11. All litigations related to the supplier for any defaults will be done by Bid Inviting Authority and his decision will be final and binding.
12. In the case of litigation as per court decision/award by arbitrator, if any amount of interest is payable/receivable etc. then RMSCL will charge interest@9% per annum simple interest and it will be payable @ 6% per annum simple interest only.

20. EMPANELMENT OF FIRMS

RMSCL invites Applications from eligible firms for Empanelment for supply of Drugs & Medicines mentioned in Annexure- VIII for one year. The empanelment would entitle a firm to participate in RMSCL for limited bids. Such situations may normally arise when the open bid for a Drugs & Medicines fails and there is an urgency to purchase it, or when the L-1 bidder has fail to supply, or the rate contract of an item ceases to exist for any reason. The Bidder has to submit an undertaking in the format given at Annexure-XI.

The empanelment can be renewed for the next one year term on payment of the empanelment fee as applicable at the time of renewal.

21. SAVING CLAUSE

No suit, prosecution or any legal proceedings shall lie against Bid Inviting Authority or any person for anything that is done in good faith or intended to be done in pursuance of Bid.

22. JURISDICTION

(1) In the event of any dispute arising out of the Bid or orders such dispute would be subject to the jurisdiction of the Courts of Jaipur or Honorable High Court (Jaipur Bench **only**).

(2) If approved bidder suffers by any decision or act or interpretation of procuring entity, he may request for appointment of a Sole Arbitrator to decide the issue. Fees and other charges shall be borne by both parties equally.

23. CORRECTION OF ARITHMETIC ERRORS:

Provided that a financial bid is substantially responsive, the procuring Entity will correct arithmetical errors during evaluation of Financial Bids on the following basis:

(i) If there is a discrepancy between the unit price and the total price that is obtained by multiplying the unit price and quantity, the unit price shall prevail and the total price shall be corrected, unless in the opinion of the Procuring Entity there is an obvious misplacement of the decimal point in the unit price, in which case the total price as quoted shall govern and the unit price shall be corrected;

(ii) If there is an error in a total corresponding to the addition or subtraction of subtotals, the subtotals shall prevail and the total shall be corrected; and.

(iii) If there is a discrepancy between words and figures, the amount in words shall prevail, unless the amount expressed in words is related to an arithmetic error, in which case the amount in figures shall prevail subject to clause (a) and (b) above.

If the Bidder that submitted the lowest evaluated bid does not accept the correction of errors, its Bid shall be disqualified and its Bid Security shall be forfeited or its Bid Securing Declaration shall be executed.

24. PROCURING ENTITY'S RIGHT TO VARY QUANTITY:

(i) At the time of award of contract, the quantity of Drugs, originally specified in the bidding documents may be increased or decreased. There will not be any minimum quantity guaranteed against bid quantity. The bid quantity is only indicative. Actual purchase can be more or less than the bid quantity based on actual consumption in the hospitals during Rate Contract period.

The supplier shall submit the supply commitment quantity'' in Annexure **VII at point no. 3** which will be used for the cases where the actual purchase quantity tends to increase substantially from the bid quantity.

(ii) If the procuring entity does not procure any subject matter of procurement or procures less than the quantity specified in the bidding documents due to change in circumstances, the bidder shall not be entitled for any claim or compensation except otherwise provided in the conditions of contract.

(iii) However a bidder is bound to supply up to quantity indicated in bid document, considering the total production capacity & capacity dedicated to RMSCL. Moreover, the actual purchases beyond Bid quantity may be made keeping in view the supply commitment of bidder to corporation.

25. <u>DIVIDING QUANTITIES AMONG MORE THAN ONE BIDDER AT (IN CASE OF PROCUREMENT OF GOODS):</u>

The bid quantity shall be fixed in following manner-
L-1(Single Bidder)100%
Between L-1 and Rate Matched Firm-1in the ratio of 60:40
Among L-1, Rate Matched Firm-1 and 2in the ratio of 50:25:25

The supply orders for quantity fixed as above may be issued as and when required. RMSCL has full rights to increase or decrease the bid quantity upto any limit during the contract period.

26. <u>GRIEVANCE REDRESSAL DURING PROCUREMENT PROCESS:</u>

The Designation and address of the First Appellate Authority is ***Special Secretary /*** Secretary, Medical, Health & Family Welfare, Govt. of Rajasthan.

The Designation and address of the Second Appellate Authority is Principal Secretary, Medical, Health & Family Welfare, Govt. of Rajasthan and Chairman, RMSCL.

i. Filling an appeal

If any Bidder or prospective bidder is aggrieved that any decision, action or omission of the Procuring Entity is in contravention to the provisions of the Act or the Rules of the Guidelines issued there under, he may file an appeal to First Appellate Authority, as specified in the Bidding Document within a period of ten days from the date of such decision or action, omission, as the case may be, clearly giving the specific ground or ground on which he feels aggrieved:

Provided that after the declaration of a Bidder as successful the appeal may be filed only by a Bidder who has participated in procurement proceedings:

Provided further that in case a Procuring Entity evaluates the Technical Bids before the opening of the Financial Bids, an appeal related to the matter of Financial Bids may be filed only by a Bidder whose Technical Bid is found to be acceptable.

ii. The Officer to whom an appeal is filed under Para (1) shall deal with the appeal as expeditiously as possible and shall Endeavour to dispose it of within thirty days from the date of the appeal.

iii. If the officer designated under Para (1) fails to dispose of the appeal filed within the period specified in Para (2), or if the Bidder or prospective bidder or the Procuring Entity is aggrieved by the order passed by the First Appellate Authority, the Bidder or prospective bidder or the Procuring Entity, as the case may be, may file a second appeal to second Appellate Authority specified in the Bidding Document in this behalf within fifteen days from the expiry of the period specified in Para (2) or of the date of receipt of the order passed by the First Appellate Authority, as the case may be.

iv. Appeal not to lie in certain cases

No appeal shall lie against any decision of the Procuring Entity relating to the following matters, namely:-

(a) Determination of need of procurement;

(b) Provision limiting participation of Bidders in the Bid process; (c) The decision of whether or not to enter into negotiations;

(d) Cancellation of a procurement process;

(e) Applicability of the provisions of confidentiality.

v. Form of Appeal

(a) An appeal under Para (1) or (3) above shall be in the annexed Form along with as many copies as there are respondents in the appeal.

(b) Every appeal shall be accompanied by an order appealed against, if any, affidavit verifying the facts stated in the appeal and proof of payment of fee.

(c) Every appeal may be presented to First Appellate Authority or Second Appellate Authority, as the case may be, in person or through registered post or authorised representative.

vi. Fee for filling appeal

(a) Fee for first appeal shall be rupees two thousand five hundred and for second appeal shall be rupees ten thousand, which shall be non-refundable.

(b) The fee shall be paid in the form of bank demand draft or banker's cheque of a Scheduled Bank in India payable in the name of Appellate Authority concerned.

vii. Procedure for disposal of appeal

(a) The First Appellate Authority or Second Appellate Authority, as the case may be, upon filling of appeal, shall issue notice accompanied by copy of appeal, affidavit and documents, if any, to the respondents and fix date of hearing.

(b) On the date fixed for hearing, the First Appellate Authority or Second Appellate

Authority, as the case may be, shall,-

(i) Hear all the parties to appeal present before him; and

(ii) Peruse or inspect documents, relevant records or copies thereof relating to the matter.

(c) After hearing the parties, perusal or inspection of documents and relevant records or copies thereof relating to the matter, the Appellate Authority concerned shall pass an order in writing and provide the copy of order to the parties free of cost.

(d) The order passed under sub-clause (c) above shall be placed on the State Public procurement Portal.

27. COMPLIANCE WITH THE CODE OF INTEGRITY AND NO CONFLICT OF INTEREST:

Any person participating in a procurement process shall-

a) Not offer any bribe, reward or gift or any material benefit either directly or indirectly in exchange for an unfair advantage in procurement process or to otherwise influence the procurement process;

b) Not misrepresent or omit misleads or attempts to mislead so as to obtain a financial or other benefit or avoid an obligation;

c) Not indulge in any collusion, Bid rigging or any-competitive behaviour to impair the transparency, fairness and progress of the procurement process;

d) Not misuse any information shared between the procuring Entity and the Bidders with an intent to gain unfair advantage in the procurement process;

e) Not indulge in any coercion including impairing or harming or threatening to do the same, directly or indirectly, to any part or to its property to influence the procurement process;

f) Not obstruct any investigation or audit of a procurement process;

g) Disclose conflict of interest, if any; and

h) Disclose any previous transgressions with any Entity in India or any other country during the last three years or any debarment by any other procuring entity.

Conflict of interest:-

The Bidder participating in a bidding process must not have a Conflict of Interest.

A Conflict of interest is considered to be a situation in which a party has interests that could improperly influence that party's performance of official

duties or responsibilities, contractual obligations, or compliance with applicable laws and regulations.

I. A Bidder may be considered to be in Conflict of interest with one or more parties in bidding process if, including but not limited to:

a. Have controlling partners/shareholders in common; or

b. Receive or have received any direct or indirect subsidy from any of them; or

c. Have the same legal representative for purposes of the Bid; or

d. Have a relationship with each other, directly or through common third parties, that puts them in a position to have access to information about or influence on the Bid of another Bidder, or influence the decisions of the Procuring Entity regarding the bidding process; or

e. The Bidder participates in more than one Bid in a bidding process. Participation by a Bidder in more than one Bid will result in the disqualification of all Bids in which the Bidder is involved. However, this does not limit the inclusion of the same subcontractor, not otherwise participating as a Bidder, in more than one Bid; or

f. The Bidder or any of its affiliates participated as a consultant in the preparation of the design or technical specification of the Goods, Works or Services that are the subject of the Bid; or

g. Bidder or any of its affiliates has been hired (or is proposed to be hired0 by the Procuring Entity as engineer-in0chage/ consultant for the contract.

28. FALL CLAUSE

The prices under a rate contract shall be subject to price fall clause. If the rate contract holder quotes / reduces its price to render similar goods, works or services at a price lower than the rate contract price to anyone in the State at any time during the currency of the rate contract, the rate contract price shall be

automatically reduced with effect from the date of reducing or quoting lower price, for all delivery of the subject matter of procurement under that rate contract and the rate contract shall be amended accordingly. The firms holding parallel rate contracts shall also be given opportunity to reduce their price by notifying them the reduced price giving them fifteen days time to intimate their acceptance to the revised price. Similarly, if a parallel rate contract holding firm reduces its price during currency of the rate contract, its reduced price shall be conveyed to other parallel rate contract holding firms and the original rate contract holding firm for corresponding reduction in their prices. If any rate contract holding firm does not agree to the reduced price, further transaction with it, shall not be conducted.

29. APPLICABILITY OF RULES

Besides above conditions the provisions of RTPP Act 2012 & RTPP Rules 2013 will be applicable.

Managing Director
Rajasthan Medical Services Corporation Ltd

ANNEXURE-I

Annexure - 1

CAUTION : USE "FCMBR" MENU OPTION IN FINACLE INSTEAD OF "TM"

Bank Copy

punjab national bank

DIST. NO.

Branch

Institute Name: Rajasthan Medical Services Corporation, Jaipur

Institute ID: RMSCJ - A/c No. 2246002100024414

Date of Deposit: DD MM YY

DETAILS OF THE SUPPLIER

Supplier Name

Tender Ref. No.

Type of Deposit: Select any one out of - Tender Fees/EMD/SD/Tender Processing fees/Others

Mobile No.

Cash Deposit:

Denomination	₹	Ps
1000 *		
500 *		
100 *		
50 *		
20 *		
10 *		
5 *		
Coins *		
Total		

Cheque Deposit:

Chq No	Date of Chq	Name of Bank	₹	Ps

Total fee payable ₹

Commission ₹ 0 0 0 0 0 - 0 0

Total amount ₹ -

Amount (in words): ₹ _____

Name of the Depositor

Signature

Address for communication

For Bank use only

Acknowledgement

Cashier/Officer

Customer Copy

punjab national bank

DIST. NO.

Branch

Institute Name: Rajasthan Medical Services Corporation, Jaipur

Institute ID: RMSCJ - A/c No. 2246002100024414

Date of Deposit: DD MM YY

DETAILS OF THE SUPPLIER

Supplier Name

Tender Ref. No.

Type of Deposit: Select any one out of - Tender Fees/EMD/SD/ Tender Processing fees/Others

Mobile No.

Cash Deposit:

Denomination	₹	Ps
1000 *		
500 *		
100 *		
50 *		
20 *		
10 *		
5 *		
Coins *		
Total		

Cheque Deposit:

Chq No	Date of Chq	Name of Bank	₹	Ps

Total fee payable ₹

Commission ₹ 0 0 0 0 0 - 0 0

Total amount ₹ -

Amount (in words): ₹ _____

Name of the Depositor

Signature

Address for communication

For Bank use only

Acknowledgement

Cashier/Officer

-

ANNEXURE-II (A)
(Ref. Caluse no .3 (i))

Form A

Application by MSME for price preference or Purchase Preference or both in Procurement of Goods

To,
The General Manager
DIC, District…….

1. Name of Applicant with Post
2. Permanent Address
3. Contact Details
    a) Telephone No.:
    b) Mobile no. :
    c) Fax no.:
    d) Email Address:
4. Name of micro & small enterprise:
5. Office Address:
6. Address of Work Place:
7. No. & Date of Entrepreneurs Memorandum-II/Udyog Aadhaar Memorandam (enclose photo copy)
8. Products for which Entrepreneurs Memorandum-II/ Udyog Aadhaar Memorandum availed:
9. Products for which are at present being produced by the enterprise:
10. Products for which price preference or Purchase preference or both has been applied for:
11. Production capacity as per Capacity Assessment Certificate
    (enclose photocopy of Capacity Assessment Certificate)

Serial No	**Product**	**Production Capacity**	
		Quantity	**Value**
1			
2			
3			
4			

12. List of Plant & Machinery installed

Serial No	**Name of Plant & Machinery**	**Quantity**	**Value**
1			
2			
3			

13. List of Testing Equipments installed

-

Serial No	Name of Plant & Machinery	Quantity	Value
1			
2			
3			
4			

14. Benefits availed as per price preference certificate in last financial year and current financial year

a. Benefits depositing Bid Security and Performance Security:

Last financial year			Current financial year	
Departments	**Bid Security**	**Performance Security**	**Bid Security**	**Performance Security**

b. Details of Supply orders received:

Last financial year				Current financial year		
Departments	**No. & Date of purchase order**	**Amount for which purchase order received**	**Amount of goods supplied**	**No. & Date of purchase order**	**Amount for which purchase order received**	**Amount of goods supplied**

I declare that the above all facts given in the application are correct and my enterprise is producing the items mentioned in column No. 10

Date **Signature**

(Name of the applicant along with seal of post)

-

CERTIFICATE

(See clause 10)

File no. _____

Date_____

It is certified that M/s _____ was inspected by _____on dated _____ and the facts mentioned by the enterprise are correct as per the record shown by the applicant. The enterprise is eligible for Price Preference or Purchase Preference or both under this notification. The certificate is valid for one year from the date of its issue .

Office Seal

Signature
(Full Name of the Officer)
General Manager
District Industries Centre
Rubber Seal/Stamp

Enclosure- (1) Application
(2)
(3)

-

ANNEXURE-II (B)
Ref. Clause No.8 & 3(i)

Form-'B'
Format of Affidavit
(On Non Judicial Stamp Paper of Rs. 10/-)

I……S/o……Age……..Yrs……. residing at……Proprietor/Partner/Director of M/s……do hereby solemnly affirm and declare that:

(a) My/Our above noted enterprises M/s…… has been issued acknowledgement of Entrepreneurial Memorandum Part-II by the Districts Industries Center……The acknowledgement No. is…….dated…….and has issued for Manufacture of following items.

(i)
(ii)
(iii)
(iv)
(v)

(b) My/Our above noted acknowledgement of Entrepreneurial Memorandum Part-II has not been cancelled or withdrawn by the Industries Department and that the enterprise is regularly manufacturing the above items.

(c) My/Our enterprise is having all the requisite plant and machinery and is fully equipped to manufacture the above noted items.

Place…….

Signature of Proprietor/Director
Authorized Signatory with Rubber Stamp and date

VERIFICATION

I……S/o…….Aged……Yrs …….residing at……Proprietor/Partner/Director of M/s……verify and confirm that the contents at (a), (b) & (c) above are true and correct to the best of my knowledge and nothing has been concealed therein. So help me God.

DEPONENT

-

ANNEXURE-III
Ref. Clause No. 5 (m)

ANNUAL TURN OVER STATEMENT

The Annual Turnover ***(for drugs and medicines including Surgical and sutures Business)*** of M/s._____for the past three years are given below and certified that the statement is true and correct.

S.No.	**Years**	**Turnover in Crore (INR.)**
1	2017-18	
2	2018-19	
3	2019-20	
Total		**Rs.** **Crore**
Average turnover per annual		**Rs.** **Crore**

OR

S.No.	**Years**	**Turnover in Crore (INR.)**
1	2018-19	
2	2019-20	
3	2020-21	
Total		**Rs.** **Crore**
Average turnover per annual		**Rs.** **Crore**

Date:

Seal:

Signature of Auditor/
Chartered Accountant
(Name in Capital)

-

ANNEXURE-IV
Ref. Clause No.12(a)

AGREEMENT

This Deed of Agreement is made on this _____day of _____2022 by M/s._____ represented by its Proprietor/Managing partner/Managing Director having its Registered Office at _____and its Factory Premises at _____

(hereinafter referred to as "Supplier" which term shall include its successors, representatives, heirs, executors and administrators unless excluded by the Contract) on one part and Rajasthan Medical Services Corporation Ltd, represented by its Executive Director (P) having is office at Swasthya Bhawan, Tilak Marg, C-Scheme, Jaipur (hereinafter referred to as "The Purchaser" which term shall include its successors, representatives, executors assigns and administrator unless excluded by the Contract) on the other part.

Where as the Supplier has agreed to supply to the Purchaser, the Drugs and Medicines with specifications mentioned in the Schedule attached here to at the prices noted there in and in the manner and under the terms and conditions here in after mentioned and where as the Supplier has deposited with the Purchaser a sum of Rs_____(Rupees only) as Performance Security for the due and faithful performance of this Agreement, to be forfeited in the event of the Supplier failing duly and faithfully to perform it. Now these presents witness that for carrying duly and faithfully to perform it. Now these presents witness that for carrying out the said Agreement in this behalf into execution the Supplier and the Purchaser do hereby mutually covenant, declare, contract and agree each of them with the other of them in the manner following, that is to say,

1. The term "Agreement", wherever used in this connection, shall mean and include the terms and conditions contained in the invitation to E-

Bid floated for the rate contract cum supply for Drug & Medicines For Rajasthan Medical Services Corporation Ltd, (Rate Contract for the period ending on 30.06.2024) (F.02(353)/RMSCL/PROCUREMENT/DRUG/NIB-10/2022/ 1236 Dated:-30.04.2022) and technical bid opened on 31.05.2022 the instruction to Bidders, the conditions of Bid, acceptance of Bid, particulars hereinafter defined and those general and special conditions that may be added from time to time.

2. (a) The Agreement is for the supply by the Supplier to the Purchaser of the Drug and Medicines specified in the agreement on the terms and conditions set forth in the Agreement.

7. (b) This Agreement shall be deemed to have come into force with effect from the date of issuance of letter of acceptance _____ and it shall remain in force up to **30.06.2024** and extendable upto 3 months, if required. Firm shall be bound to accept the extension period of Rate Contract.

(c) The Bid quantity noted against each item in the schedule attached hereto indicates only the probable total requirements of the Purchaser in respect of each item for the Agreement Period indicated in Clause (b) above. This quantity may increase or decrease at the discretion of the Purchaser. The Supplier shall make supplies of the Drugs and Medicines on the basis of the Purchaser Orders placed on him from time to time by the ordering Authorities of the purchaser specifying the quantities required to be supplied required to be supplied at the specific location in the state of Rajasthan.

TERMINATION OF CONTRACT ON BREACH OF CONDITION

1 (a) In case the Supplier fails or neglects or refuse to faithfully perform any of the Covenants on his part herein contained, it shall be lawful for the Purchaser to forfeit the amount deposited by the Supplier as PERFORMANCE SECURITY and cancel the Contract.

(b) In case the Supplier fails, neglects, or refuse to observe, perform, fulfill and keep, all or any one or more or any part of any one of the Covenants, stipulation and provisions herein contained, it shall be lawful for the Purchaser

on any such failure, neglect or refusal, to put an end to this Agreement and thereupon every article, cause and thing herein contained on the part of the Purchaser shall cease and be void, and in case of any damage, loss, expenses, difference in cost or other moneys from out of any moneys for the time being payable to the Supplier under this and/or any other Contract and in case such last mentioned moneys are insufficient to cover all such damages, losses, expenses, difference in cost and other moneys as aforesaid, it shall be lawful for the Purchaser to appropriate the Performance Security made by the Supplier as herein before mentioned to reimburse all such damages, losses, expenses, difference in cost and other money as the Purchaser shall have sustained, incurred or been put to by reason of the Supplier having been guilty of any such failure, negligence or refusal as aforesaid or other breach in the performance of this Contract.

(c) If at any time during the course of the Contract, it is found that any information furnished by the Supplier to the Purchaser, either in his Bid or otherwise, is false, the Purchaser may put an end to the Contract/Agreement wholly or in part and thereupon the provisions of Clause (a) above shall apply.

2 The Purchaser reserves the right to terminate without assigning any reasons therefore the Contract/Agreement either wholly or in part without any notice to the Supplier. The Supplier will not be entitled for any compensation whatsoever in respect of such termination of the Contract/Agreement by the Purchaser.

NOTICE ETC, IN WRITING

3 All Certificates or Notice or orders for time or for extra, varied or altered supplies which are to be the subject of extra or varied charges whether so described in the Agreement or not, shall be in writing, and unless in writing, shall not be valid, biding or be of any effect whatsoever.

SUPPLIERS NOT HAVE ANY INTEREST IN THE OFFICERS CONCERNED AND SUBORDINATES

4 The Supplier shall not be in any way interested in or concerned directly or indirectly with, any of the Officers, Subordinate or Servants of the Purchaser. In any trade, business or transactions nor shall the Supplier give or pay or promise to give or pay any such Officer, Subordinate or Servant directly or

indirectly any money or fee or other consideration under designation of "Custom" or otherwise; nor shall the Supplier permit any person or persons whomsoever to interfere in the management or performance hereof under power of attorney or otherwise without the consent in writing the consent in writing of the Purchaser obtained in first hand.

BANKRUPTCY OF THE SUPPLIER

5 In case the Supplier at any time during the continuance of the Contract becomes bankrupt or insolvent or commits any act of bankruptcy or insolvency under the provisions of any law in that behalf for the time being in force, or should compound with his creditors, it shall be lawful for the Purchaser to put an end to the Agreement, and thereupon every article, clause and thing herein contained to be operative on the part of the Purchaser, shall cease and be void and the Purchaser shall have all the rights and remedies given to him under the preceding clauses.

SERVING OF NOTICE ON SUPPLIER

6 All notice or communication relating to or arising out of this Agreement or any of the terms thereof shall be considered duly served on or given to the Supplier if delivered to him or left at his premises, place of business or abode.

7 And it is hereby agreed and declared between the parties hereto that in case any question of dispute arises touching the construction or wording of any of clause herein contained on the rights, duties, liabilities of the parties hereto or any other way, touching or arising out of the presents, the decision of the Managing Director, Rajasthan Medical Services Corporation Ltd in the matter shall be final and binding.

8 All disputes arising out of this agreement and all questions relating to the interpretation of this agreement shall be decide by the Govt. and the decision of the Govt. shall be final.

SUPPLIER (Signature, Name & Address With Stamp)

EXECUTIVE DIRECTOR (P),
RAJASTHAN MEDICAL SERVICES CORPORATION LTD.

Witness (Signature, Name & Address)

1.

2.

Witness

1.

2.

-

ANNEXURE – V
Ref. Clause No. 5 (u)

Check List

Section	Details of requirement	Document Type	Yes/No If Yes Page No.
A	**BID SECURITY DEPOSIT, RISL Fess, Bid Processing Fees, Empanelment Fees.**	Challan/DD/ e–deposit generated receipt of Bid Security Deposit, bid fee and RISL fee and SSI certificate for exemption with Annexure-II	
B	**Technical documents**	Manufacturing Licence/loan licence	
		Manufacturing Licence renewal /validity certificate	
		Non Conviction Certificate issued by the Drugs Controller	
		WHO-GMP Certificate	
		Import License, if imported.	
		Sale License, in the case of imported drugs	
		Copy of record of import to establish 3 years market standing, if imported.	
		Product Permissions by the Licensing Authority for each and every product quoted	
		Market Standing Certificate issued by the licensing Authority	
		Annexure-VI Check List Of Details Regarding Products Quoted	
C	**Other Documents**	Documentary evidence for the constitution of the company / concern	
		The instruments such as power of attorney resolution of board etc	
		Copies of balance sheet & profit loss account for three years	
		GST Registration & Proof of GST Return	
		Copy of PAN	
		Annual Turnover Statement	
		Annexure-VII Declaration and Undertaking	
		Annexure-XI Undertaking For Empanelment	

-

Annexure – VI
Ref. Clause No. 5 (u)

Check list of details regarding products quoted

Product permission as per condition no. 5 (c) and Market Standing as per condition 5 (g)

S. No.	Quoted Item /Code no.	Product permission enclosed on page no.	Date of product permission / Approval	Product permission of formulation Generic / Branded	Specification as per Code no. Yes/ No	As per MSC product Mfg & Mkt since last 3 years		
						Page No.	Yes/ No	Date of Issue
1								
2								
3								
4								
5								

-

Annexure – VII

Ref. Clause No. 5 (o),(q),(r),(t),(v),(w)

Declaration & Undertaking

(For F.02(353)/RMSCL/PROCUREMENT/DRUG/NIB-10/2022/ 1236 Dated:-30.04.2022

(On Non-Judicial Stamp Paper of Rs 500/-)

I Name……S/o…….Age……..Prop./Partner/Director/Power of attorney holder of firm M/s……situated at (Complete address of Mfg. unit)……bearing drug license on Form 25, 28, 10 etc bearing Number……. &……..respectively, issued on dated……..valid/Renewed up to……..do here by declare on oath as follows:-

1. That none of the quoted Drug and Medicines manufactured / imported by us since grant of above drug license have been found as of spurious or adulterated quality and no case in this regard is pending in any court.
2. That the quoted product is manufactured/imported by us, and none has been declared as "Not of standard quality" during last two years.
3. That we have following Commitment of quantity in our plant at above address:-[Ref. Clause No. 24]

S. No.	**Quoted item Code No. & Name of Drugs**	**Monthly Capacity in all shifts in nos.**	**Annual Production Capacity**	**Monthly supply Commitment to RMSCL in nos.(Not Less than 5% off estimated bid quantity)**	**Supply Commitment quantity during rate contract period (not be less than estimated bid quantity)**	**Estimated Bid Quantity as per Annexure VIII**	**GSTIN Number & Name of State where GSTIN registered**
1.							
2.							

4. That concern/company/firm does not stand blacklisted/banned/debarred on any ground by Bid Inviting Authority or Govt. of Rajasthan or its departments on the date of bid submission. The concern/company/firm does not stand blacklisted/banned/debarred on the ground of conviction by court of law or the products being found spurious or adulterated by any other State /Central Government or it's any agencies (central Drugs procurement agencies). **But my firm is blacklisted/banned/debarred on a different ground by a**

-

procurement agency, the details of which are given below----------
----------(Write 'NIL' if no such matter exists)

5. That our Firm/Company and its Proprietor/Partner/Directors/ Power of attorney holders have not been convicted for contravention of any provisions of Drugs & Cosmetic Act 1940 and rules made there under since grant of license.
6. That we have been granted product permission by the State Licensing Authority for manufacture of quoted products as per the details given below:-

S. No.	Code No.	Name of the Product	Date of product permission obtained from the Licensing Authority	Whether Endorsement is in Generic or Trade Name	Issuing Licensing Authority	Own manufacturing / Loan Licensee (Please mention)	Drug manufacturing/Import License Number for quoted items
1.							
2.							

7. That we have over three years' experience in the manufacture of the quoted product, or the quoted imported product has over 3 years market standing.
8. That we have approved qualified staff, machines & equipments along with capacity to manufacture above category of drugs and our unit have been issued **WHO-GMP*** by Licensing Authority vide letter No…….dated…….valid upto……..
9. That we hereby confirm that we have deposited all the VAT/Sale Tax/ **GST & filling returns as applicable** as on……..With the department. **central excise / State commercial department** is due on M/s……as on……..
10. That I will supply the Drug and Medicines per the designs given in Bid clause no 14 and as per the instructions given in this regard.
11. That I/We have carefully read all the conditions of e- Bid in Ref. no. F.02(353)/RMSCL/PROCUREMENT/DRUG/NIB-10/2022/ 1236 Dated:-30.04.2022 for Rate Contract cum Supply, of Drugs and Medicines (**Rate Contract for the period ending on 30.06.2024**) for Rajasthan Medical Services Corporation Ltd and accept all conditions of Bid, including amendments

if any. If case of typographical error found in submitted documents / affidavits, in this case we accept all the Terms and conditions of bid documents.

12. I/We agree that the Bid Inviting Authority forfeiting the Bid security Deposit and or Performance Security and blacklisting /Debarring/Banning me/ us for a period of 5 years or as deemed fit if, any information furnished by us proved to be false/fabricated at the time of inspection and not complying the conditions as per Schedule M of the said Act or at any time during the Bid process.

13. I/ we hereby declare under Section 7 of Rajasthan Transparency in Public Procurement Act, 2012. that:

    b. I/we possess the necessary professional, technical, financial and managerial resources and competence required by the Bidding Document issued by the Procuring Entity;

    c. I/we have fulfilled my/our obligation to pay such of the taxes payable to the Union and the **State Government or any local authority** as specified in the Bidding Document;

    d. I/we are not insolvent, in receivership, bankrupt or being wound up. not have my/our affairs administered by a court or a judicial officer, not have my/our business activities suspended and not the subject of legal proceedings for any of the foregoing reasons;

    e. I/we do not have, and our directors and officers not have, been convicted of any criminal offence related to my/our professional conduct or the making of false statements or misrepresentations as to my/our qualifications to enter into a procurement contract within a period of three years preceding the commencement of this procurement process, or not have been otherwise disqualified pursuant to debarment proceedings;

    f. l/we do not have a conflict of interest as specified in the Act, Rules and the Bidding Document, which materially affects fair competition.

14. The quoted rates of any items is not more than the price fixed by the govt. under the current drugs (Price control) order.

15. Our complete address for communication……

    ……

    ……

-

……Pin…….

Pan No.----------

E-mail address : - ……...

Phone No. /Mobile No……

16. Bank detail for e banking :-

Name of account holder ……..

Full name of Bank with Branch ……..

Address of Bank ……Pin……

A/c no. with full digits…….

IFSC code ……

17. Authorized/nominating person

Name: ……

Designation:-……

Aadhar Number:-…….

E-mail address:-…….

Phone No./Mobile No…….

Photograph of Authorized/ nominating person

Signature of Authorized / nominating person

(Name of Deponent & Signature)
Designation

Verification

I……..S/o……(Designation)……
Affirm on oath that the contents/information from para 1 to 17 as mentioned above, are true & correct to the best of my knowledge and nothing is hidden. I also declare on oath, that if any information furnished by me as above is found wrong, false, forged or fabricated; the Corporation will be at liberty to cancel the Bid for which I shall be solely responsible and the firm may be Debarred/Banned/ blacklisted / prosecuted for the same.

(Name of Deponent & Signature)

Witness :- (Name, Address & Signature)

1

2

*The GMP/WHO-GMP certificate must not be older than one year from the last date of Bid submission in case validity is not mentioned in the certificate.

-

Annexure – VIII
Ref. Clause No. 9 (2, 3)

List of Drugs with Specifications

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
1	NRD-1	solution	Artificial saliva		24	10000	
2	NRD-2	Solution	Balanced Salt Calcium free 1000 ml [solution], Non PVC Polyolefin Sterile free flex bag		24	20000	
3	NRD-3	Cap.	Alpha+Lipoic Acid + Leycopen +Multivitamin and Miltiminerals	10x10	24	11418566	
4	NRD-4	Cap.	Glucosamine + Hydrochloride +Methylsulfonylmethane	10x10	24	1461182	
5	NRD-5	Cap.	Racecadotril 100mg	10x10	24	1298260	
6	NRD-6	Cap.	Rabeprazole +Levosulpiride	10x10	24	10339960	
7	NRD-7	Cap.	Acitretin 10 mg	10x10	24	20000	
8	NRD-8	Cap.	Acitretin 25 mg	10x10	24	20000	
9	NRD-9	Cap.	Alectinib 150 mg	10x10	24	4000	
10	NRD-10	Cap.	All Trans Retinoic Acid 10 mg	10x10	24	26000	
11	NRD-11	Cap.	Anti-Oxidants (Beta Carotene-10 mg,Vit-E 25mg,Vit-C 100 mg,Copper 1.5 mg,Managanese 1.5 mg,Zinc 7.5 mg,Selenium 150 microgram)	10x10	24	15395700	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
12	NRD-12	Cap.	Aprepitant 125 mg	10x10	24	270364	
13	NRD-13	Cap.	Budesonide 9 mg	10x10	24	20000	
14	NRD-14	Cap.	Calcium Dobesilate 500MG	10x10	24	20000	
15	NRD-15	Cap.	Ceritinib 50 mg	10x10	24	4000	
16	NRD-16	Cap.	Ceritinib 100 mg	10x10	24	4000	
17	NRD-17	Cap.	Ceritinib 200 mg	10x10	24	4000	
18	NRD-18	Cap.	Ceritinib 250mg	10x10	24	3000	
19	NRD-19	Cap.	Clomipramine IP 25 mg	10x10	24	10000	
20	NRD-20	Cap.	Cyclosporine 100 mg	10x10	24	100000	
21	NRD-21	Inj.	Dacarbazine 200 mg	vial / Amp	24	5000	
22	NRD-22	Cap.	Danazol 100mg	10x10	24	20000	
23	NRD-23	Cap.	Evening Primosa 1000 Mg	10x10	24	30000	
24	NRD-24	Respule	Formetrol 12mcg + Budesonide 400 mcg.		24	20000	
25	NRD-25	Cap.	Indacaterol and Glycopyronium inhalation powder 110/50 mcg	10x10	24	10000	
26	NRD-26	Cap.	Isotretinoin 10mg	10x10	24	154000	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
27	NRD-27	Cap.	Isotretinoin 20 mg	10x10	24	40000	
28	NRD-28	Cap.	Lomustine 40 mg	10x10	24	4000	
29	NRD-29	Cap.	Minocycline 100mg.	10x10	24	10000	
30	NRD-30	Cap.	Mycophenolate Mofetil 500MG	10x10	24	62000	
31	NRD-31	Cap.	Netupitant + Palonosetron 300 mg + 0.5 mg	10x10	24	10000	
32	NRD-32	Cap.	Ramipril IP 5 mg	10x10	24	100000	
33	NRD-33	Cap.	Rucaparib 200 mg	10x10	24	10000	
34	NRD-34	Cap.	Rucaparib 300 mg	10x10	24	10000	
35	NRD-35	Cap.	Silodosin 4 mg	10x10	24	873760	
36	NRD-36	Cap.	Silodosin 8 mg	10x10	24	864680	
37	NRD-37	Cap.	Temozolamide 250 mg	10x10	24	20000	
38	NRD-38	Cap.	Vitamin A 25000 IU	10x10	24	100000	
39	NRD-39	solution	Carbolic Acid 50% in 500 ml		24	10000	
40	NRD-40	solution	Carbolic Acid 100% in 500 ml		24	20000	
41	NRD-41		Continuous Ambulatory Peritoneal Dialysis Fluid 2 ltr		24	40000	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
42	NRD-42	Cream	Lidocaine 25 mg + Prilocaine 25mg	15 gm	24	11000	
43	NRD-43	Cream	/Ointment (Modified Lanolin)	15 gm	24	5000	
44	NRD-44	Cream	Aloe Vera Moisturizing	50 gm	24	40000	
45	NRD-45	Cream	Amophous Hydrogel with Colloid Silver Wound Dressing	100 gm	24	4000	
46	NRD-46	Cream	Amorolfine 0.25%	15 gm	24	20000	
47	NRD-47	Cream	Azelaic acid 20%	15 gm	24	60400	
48	NRD-48	Cream	Benzoyl Peroxide 2.5 %	20 gm	24	12800	
49	NRD-49	Cream	Desonide 0.05%	15 gm	24	68000	
50	NRD-50	Cream	Fenticonazole 2%	15 gm	24	5000	
51	NRD-51	Cream	Glycolic Acid 6%	30 gm	24	60400	
52	NRD-52	Cream	Hydrocortisone 1%	15 gm	24	12000	
53	NRD-53	Cream	Hydroquinone 2%	20 gm	24	65000	
54	NRD-54	Cream	Kojic acid 2%, Arbutin,Niacinamide	30 gm	24	76400	
55	NRD-55	Cream	Luliconazole 1%	30 gm	24	1188544	
56	NRD-56	Cream	Mometasone 0.1 %	30 gm	24	82000	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
57	NRD-57	Cream	Mometasone 2%		24	20000	
58	NRD-58	Cream	Neomycin Sulphate Cream	20 gm	24	20000	
59	NRD-59	Cream	Permethrin 1% rinse	60 gm	24	12000	
60	NRD-60	Gel	Adaplene (0.1% W/W)		24	67800	
61	NRD-61	solution	Desflurane USP 240 ml bottle		24	420	
62	NRD-62	Inj.	Dextrose with Sod.Chloride polypack 5% 500ml	500 ml	24	32000	
63	NRD-63	Inj.	Distilled Water 10ml	10 ml	24	13000	
64	NRD-64	Inj.	Sodium Chloride and Dextrose 0.45% infusion 500ml	500 ml	24	10000	
65	NRD-65	DPI	Salmetrol 50mcg+Fluticasone 500 mcg		24	9600	
66	NRD-66	DPI	Budesonide 400 mcg		24	5000	
67	NRD-67	DPI	Glycopyrronium 25 + Formoterol 6 mcg		24	5000	
68	NRD-68	DPI	Glycopyrronium 25		24	20000	
69	NRD-69	DPI	Glycopyrronium 50		24	10000	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
70	NRD-70	DPI	Levosalbutamol 100mcg+ Ipratropium Bromide 40mcg		24	32000	
71	NRD-71	Drop	Diastase Pepsin with simethicone 15 ml		24	1779480	
72	NRD-72	Drop	Furosemide 10mg/ml	30 ml	24	2000	
73	NRD-73	Drop	Ondansetron Oral Solution 30 ml		24	1106630	
74	NRD-74	Eye Drop	Prednisolone Acetate Opthalmic Suspension 10 ml		24	474280	
75	NRD-75	Drop	Terbutalin	15 ml	24	462580	
76	NRD-76	Drop	Hydroxyzine Oral Solution 15 ml		24	624490	
77	NRD-77	Drop	Ambroxol	15 ml	24	50000	
78	NRD-78	Drop	Anticold	15 ml	24	1786700	
79	NRD-79	Drop	Astymine C (Vitamin C+ Essential amino acid)	15 ml	24	40000	
80	NRD-80	Drop	Enzyme	30 ml	24	1143370	
81	NRD-81	Drop	Iron (Ferrous Ascorbate)	30 ml	24	100000	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
82	NRD-82	Drop	Simethicon 40mg+Dill oil 0.005ml + fennel oil 0.0007ml30 ml		24	10000	
83	NRD-83	Drop	Vitamin – E 50mg/ml, 400 IU	30 ml	24	19000	
84	NRD-84	Drop	Vitamin D3 400IU/ml		24	1079170	
85	NRD-85	Drop	Vitamin D3 800IU/ml		24	931370	
86	NRD-86	Drops	Cefpodoxime Oral Suspension 20mg/ml	15 ml	24	10000	
87	NRD-87	Enema	Lactulose	100 ml	24	20000	
88	NRD-88	Drops	Docosahexaenoic 30ml		24	10000	
89	NRD-89	Ear Drop	Acetic Acid otic solution 2%	5 ml	24	20000	
90	NRD-90	Ear Drop	Gentamycin	60 ml	24	10000	
91	NRD-91	Elixir	Digoxin 0.25%		24	42000	
92	NRD-92	Eye Drop	Carboxymethylcellulose + Glycerin	5 ml	24	500710	
93	NRD-93	Eye Drop	Moxifloxacin+ Difluoprednate	5 ml	24	71014	
94	NRD-94	Eye Drop	Natamycin Opthalmic Suspension 5%	5 ml	24	59184	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
95	NRD-95	Eye Drop	Olaptadine & Ketorolac	5 ml	24	153520	
96	NRD-96	Eye Drop	Polymyxin B 10000IU/gm + Neomycin 3400IU/gm	5 ml	24	320792	
97	NRD-97	Eye Drop	Betadin 5%	5 ml	24	4000	
98	NRD-98	Eye Drop	Brinozolamide+Brimonidine	5 ml	24	10000	
99	NRD-99	Eye Drop	CPM+CMC+Nephazoline	5 ml	24	6400	
100	NRD-100	Eye Drop	Cyclopentolate 1%	5 ml	24	21000	
101	NRD-101	Eye Drop	Dorzolamide 2%	5 ml	24	36556	
102	NRD-102	Eye Drop	Flurometholone 0.1%	5 ml	24	10000	
103	NRD-103	Eye Drop	Gatifloxacin+Prednisolone	5 ml	24	143690	
104	NRD-104	Eye Drop	HPMC 0.3%	5 ml	24	10200	
105	NRD-105	Eye Drop	Itraconazole 1%	5 ml	24	10000	
106	NRD-106	Eye Drop	Loteprednol 0.25%	5 ml	24	34000	
107	NRD-107	Eye Drop	Moxifloxacin 0.5%+Ketorolac Tromethamine 0.5%	5 ml	24	20000	

-

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
108	NRD-108	Eye Drop	Moxifloxacin and Dexamethasone	5 ml	24	24000	
109	NRD-109	Eye Drop	Moxifloxacin and Prednisolone	5 ml	24	117440	
110	NRD-110	Eye Drop	Nepafenac 0.1%	5 ml	24	116000	
111	NRD-111	Eye Drop	Oloptadine opthalmic solution 0.1%	5 ml	24	20000	
112	NRD-112	Eye Drop	Pilocarpine	5 ml	24	102000	
113	NRD-113	Eye/Ear Drop	Prednisolone Sodium Phosphate 1%	5 ml	24	130000	
114	NRD-114	Eye Drop	Proparacaine 0.5% W/v	5 ml	24	84000	
115	NRD-115	Eye Drop	Sodium Chloride 5 %	5 ml	24	170560	
116	NRD-116	Eye Drop	Sulfacetamide 20%	5 ml	24	50000	
117	NRD-117	Eye Drop	Travapost+Timolol	5 ml	24	20000	
118	NRD-118	Eye Drop	Tropicamide+Phenylepherine	5 ml	24	113132	
119	NRD-119	Eye Drop	Voriconazole	5 ml	24	10000	
120	NRD-120	Eye Ointment	Azithromycin 1%	5 gm	24	50000	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
121	NRD-121	Eye Ointment	Chloramphenicol 0.5%	5 gm	24	30000	
122	NRD-122	Eye Ointment	Chloramphenicol +Polymycin	5 gm	24	201300	
123	NRD-123	Eye Ointment	Chloramphenicol +Polymycine + Dexamethasone	5 gm	24	213360	
124	NRD-124	Eye Ointment	Ganciclovir 0.15%	5 gm	24	10000	
125	NRD-125	Eye Ointment	Itraconazole 1%	5 gm	24	101000	
126	NRD-126	Eye Ointment	Moxifloxacin 0.5%	5 gm	24	23000	
127	NRD-127	Eye Ointment	Sodium Chloride 6%	5 gm	24	9000	
128	NRD-128	Gargle	Povidone iodine	50 ml bottle	24	22000	
129	NRD-129	Eye Drop	Gatifloxacin 0.3%	5 ml	24	20000	
130	NRD-130	Gel	Diltiazem 2% P/R	20 gm	24	40000	
131	NRD-131	Gel	Nifedipine + Lidocaine P/R	20 gm	24	40000	
132	NRD-132	solution	Glycine Irrigation Solution 1.5% 3LTR		24	10000	
133	NRD-133	Granules	Esmoprazole 10mg	per sachet	24	200000	
134	NRD-134		Hormonal Intra Uterine Device		24	50000	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
135	NRD-135	Tab.	HP Kit (Pantoprazole 40 mg +Metronidazole 400 mg +Clarithromycin 500 mg	10x10	24	22000	
136	NRD-136	Tab.	Hydrocortisone Oromucosal 5 Mg	10x10	24	50000	
137	NRD-137	Tab.	Hydrocortisone Oromucosal 10 Mg	10x10	24	50000	
138	NRD-138	Tab.	Hydrocortisone Oromucosal 20 Mg	10x10	24	50000	
139	NRD-139	solution	Hydrogen 11% + Silver Nitrate .01%	5 litre can	24	100000	
140	NRD-140	Inhaler	Tiotropium + Glycopyrolate 25mg		24	2000	
141	NRD-141	Inj	Metoprolol 5ml vial	vial	24	30000	
142	NRD-142	Inj.	Docetaxel 20mg	vial / Amp	24	41640	
143	NRD-143	Inj.	Docetaxel 80 mg	vial / Amp	24	10000	
144	NRD-144	Inj.	Folinic Acid 200mg/vial	vial / Amp	24	20000	
145	NRD-145	Inj.	Sodium Chloride 3% 100ml	100 ml	24	50000	
146	NRD-146	Inj.	ACTH Synacthen 250 Mcg	vial / Amp	24	4000	
147	NRD-147	Inj.	Adalimumab - 40 mg	vial / Amp	24	1000	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
148	NRD-148	Inj.	Ado- Trastuzumab 100 mg	vial / Amp	24	600	
149	NRD-149	Inj.	Ado- Trastuzumab 160 mg	vial / Amp	24	600	
150	NRD-150	Inj.	Alpha Beta Arteether 2 ml	vial / Amp	24	202894	
151	NRD-151	Inj.	Prostaglandin 500MCG/ml	vial / Amp	24	5000	
152	NRD-152	Inj.	Aminocaproic Acid 20ML	vial / Amp	24	10000	
153	NRD-153	Inj.	Amoxycillin & Clavulanic acid 300 MG	vial / Amp	24	20000	
154	NRD-154	Inj.	Ampicillin + Salbactum 1.5g	vial / Amp	24	101000	
155	NRD-155	Inj.	Progesterone Injection 50	vial / Amp	24	50000	
156	NRD-156	Inj.	Artesunate 120 mg	vial / Amp	24	40000	
157	NRD-157	Inj.	Atezolizumab 1200 mg	vial / Amp	24	1000	
158	NRD-158	Inj.	Avelumab 200 mg	vial / Amp	24	1000	
159	NRD-159	Inj.	Azacitidine 50mg	vial / Amp	24	30000	
160	NRD-160	Inj.	Azacitidine 100mg	vial / Amp	24	20000	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
161	NRD-161	Inj.	Azithromycin 10 ml vial equaivelent to 500 mg	vial / Amp	24	399924	
162	NRD-162	Inj.	Bacitracin for Injection 25,000 IU	vial / Amp	24	10000	
163	NRD-163	Inj.	Bortezomib 2.5	vial / Amp	24	30100	
164	NRD-164	Inj.	Botulinum Toxin Type A for injection/Botulinum Toxin Type B for injection 100 IU	vial / Amp	24	4000	
165	NRD-165	Inj.	Botulinum Toxin Type A for injection/Botulinum Toxin Type B for injection 50 IU	vial / Amp	24	200	
166	NRD-166	Inj.	Busulfan 60mg/1ml	vial / Amp	24	600	
167	NRD-167	Inj.	Cabazitaxel 20 Mg	vial / Amp	24	6100	
168	NRD-168	Inj.	Cabazitaxel 40 Mg	vial / Amp	24	600	
169	NRD-169	Inj.	Caffeine Cirate 20mg/ml	vial / Amp	24	40000	
170	NRD-170	Inj.	Calcium Chloride 5mL vial	vial / Amp	24	10000	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
171	NRD-171	Inj.	Calcium Gluconate/folinate	vial / Amp	24	350400	
172	NRD-172	Inj.	Carbetocin 1ml/100micro.	vial / Amp	24	14000	
173	NRD-173	Inj.	Carfilzomib 20 mg	vial / Amp	24	11000	
174	NRD-174	Inj.	Carfilzomib 60 mg	vial / Amp	24	4000	
175	NRD-175	Inj.	Carmustine 100 mg	vial / Amp	24	10000	
176	NRD-176	Inj.	Caspofungin 50 mg	vial / Amp	24	13000	
177	NRD-177	Inj.	Caspofungin 70 mg	vial / Amp	24	20000	
178	NRD-178	Inj.	Cefipime 1000MG + Tazobactum 125MG	vial / Amp	24	20000	
179	NRD-179	Inj.	Cefoperazone 1gm+Tazobactum 125mg	vial / Amp	24	14000	
180	NRD-180	Inj.	Cefoperazone 500mg	vial / Amp	24	20000	
181	NRD-181	Inj.	Ceftazidime 1gm+Sulbactam500 mg	vial / Amp	24	9800	
182	NRD-182	Inj.	Ceftazidime+ Avibactum 2gm+500mg	vial / Amp	24	4000	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
183	NRD-183	Inj.	Ceftizoxime 1 Gm	vial / Amp	24	4000	
184	NRD-184	Inj.	Ceftriaxone IP 125 mg	vial / Amp	24	4000	
185	NRD-185	Inj.	Ceftriaxone +Salbactum+ disodium EDTA	vial / Amp	24	4000	
186	NRD-186	Inj.	Ceftriaxone and Sulbactam 1.5g	vial / Amp	24	51000	
187	NRD-187	Inj.	Ceftriaxone1000mg+ Tazobactom125mg	vial / Amp	24	5000	
188	NRD-188	Inj.	Cefuroxime 1Gm	vial / Amp	24	4580	
189	NRD-189	Inj.	Cetrorelix Acetate 0.25 mg	vial / Amp	24	5000	
190	NRD-190	Inj.	Cetuximab 100 mg	vial / Amp	24	10000	
191	NRD-191	Inj.	Cetuximab 500mg	vial / Amp	24	8000	
192	NRD-192	Inj.	Chloramphenicol 1gm/vial	vial / Amp	24	22000	
193	NRD-193	Inj.	Cladrabine 10 mg	vial / Amp	24	10000	
194	NRD-194	Inj.	Clarithromycin 500mg	vial / Amp	24	20000	
195	NRD-195	Inj.	Clindamycin 600mg/4ml	vial / Amp	24	150000	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
196	NRD-196	Inj.	Clonidine 150mcg/ml	vial / Amp	24	30000	
197	NRD-197	Inj.	Compound Sodium Lactate (Ringer Lactate) in Glass Bottle 500ml	500 ml Glass Bottle	24	444806	
198	NRD-198	Inj.	Crystilline Penicillin 2 Lakh	vial / Amp	24	10000	
199	NRD-199	Inj.	Cytarabine 1000 mg	vial / Amp	24	5000	
200	NRD-200	Cap.	D Penicillamine 250mg	10x10	24	5000	
201	NRD-201	Inj.	Dextrose 5% 500 ml Glass Bottle	500 ml Glass Bottle	24	5000	
202	NRD-202	Inj.	Daratumumab 100 mg	vial / Amp	24	2000	
203	NRD-203	Inj.	Daratumumab400 mg	vial / Amp	24	2000	
204	NRD-204	Inj.	Darbepoietin Alfa 100mcg	vial / Amp	24	3000	
205	NRD-205	Inj.	Darbepoietin Alfa 200 mcg	vial / Amp	24	3000	
206	NRD-206	Inj.	Darbepoietin Alfa 500mcg	vial / Amp	24	3000	
207	NRD-207	Inj.	Decitabine 50 mg	vial / Amp	24	3000	
208	NRD-208	Inj.	Decitabine 100 mg	vial / Amp	24	300	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
209	NRD-209	Inj.	Degarelix 80 mg	vial / Amp	24	2000	
210	NRD-210	Inj.	Degarelix 120 mg	vial / Amp	24	2000	
211	NRD-211	Inj.	Degludec insulin 300IU/3ml	vial / Amp	24	10000	
212	NRD-212	Inj.	Denosumab 120 mg	vial / Amp	24	2000	
213	NRD-213	Inj.	Deriphylline 1 ampul	vial / Amp	24	30000	
214	NRD-214	Inj.	Detemir Insuline	vial / Amp	24	10000	
215	NRD-215	Inj.	Dexmedetomidine 100mcg/ml	vial / Amp	24	42470	
216	NRD-216	Inj.	Dextran 40	vial / Amp	24	10000	
217	NRD-217	Inj.	Diazoxide 300 mg/20ml	vial / Amp	24	2000	
218	NRD-218	Inj.	Digoxin 2Mg	vial / Amp	24	20000	
219	NRD-219	Inj.	Diltiazem 25 mg	vial / Amp	24	5000	
220	NRD-220	Inj.	Docetaxel 120 mg	vial / Amp	24	22460	
221	NRD-221	Inj.	Doxycycline for Injection 100 mg	vial / Amp	24	524120	
222	NRD-222	Inj.	Durvalumab 120 mg	vial / Amp	24	2000	
223	NRD-223	Inj.	Durvalumab 500mg	vial / Amp	24	2000	
224	NRD-224	Inj.	Enalapril 1.25 mg 1 ml	vial / Amp	24	10000	
225	NRD-225	Inj.	Ephedrine 30 mg/ml	vial / Amp	24	46000	
226	NRD-226	Inj.	Epirubicin 50mg/ml	vial / Amp	24	0	
227	NRD-227	Inj.	Epirubicin 150mg/ml	vial / Amp	24	4000	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
228	NRD-228	Inj.	Eribulin 0.5mg	vial / Amp	24	4000	
229	NRD-229	Inj.	Eribulin 1 mg	vial / Amp	24	2000	
230	NRD-230	Inj.	Ertapenem sodium 1gm = Ertapenem 1.046 gm	vial / Amp	24	2000	
231	NRD-231	Inj.	Etomidate 20 mg	vial / Amp	24	10708	
232	NRD-232	Inj.	Etomidate MCT/LCT 10ml vial	vial / Amp	24	4000	
233	NRD-233	Patch	Fentanyl 25IU Patch		24	5000	
234	NRD-234	Patch	Fentanyl 50IU Patch		24	4200	
235	NRD-235	Inj.	Fluconazole 100Mg	vial / Amp	24	20000	
236	NRD-236	Inj.	Fluconazole 200 mg	vial / Amp	24	359096	
237	NRD-237	Inj.	Fludarabine Phosphate Injection 100mg	vial / Amp	24	20000	
238	NRD-238	Inj.	Fludarabine Phosphate Injection 50mg	vial / Amp	24	3000	
239	NRD-239	Inj.	Fluorescien sodium IP 20% vail 3 ml for diagnostic fundus fluorescien angiography	vial / Amp	24	4000	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
240	NRD-240	Inj.	Fluphenazine Deconate Injection (Long Acting) 25mg/ml Ampule	vial / Amp	24	4000	
241	NRD-241	Inj.	Folic acid +Methylcobalamine 10 ml pack	vial / Amp	24	8000	
242	NRD-242	Inj.	Fondaparinux 2.5mg	vial / Amp	24	1000	
243	NRD-243	Inj.	Fosphenytoin Sodium 150mg/ml	vial / Amp	24	2100	
244	NRD-244	Inj.	FSH 75 IU	vial / Amp	24	5000	
245	NRD-245	Inj.	FSH 150 IU	vial / Amp	24	5000	
246	NRD-246	Inj.	Fulvestrant 250mg	vial / Amp	24	22506	
247	NRD-247	Inj.	GDW 5% Glass Bottle/500ml	500 ml	24	261594	
248	NRD-248	Inj.	Glyceryl Trinitrate injection, diluted 5mg/ml	vial / Amp	24	100000	
249	NRD-249	Inj.	Goserelin Acetate implant 3.6 mg	vial / Amp	24	2000	
250	NRD-250	Inj.	Haemocoagulase 1 ML	vial / Amp	24	141076	
251	NRD-251	Inj.	Haloperidol (Long Acting) 50mg/ml Ampoule	vial / Amp	24	5000	

-

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
252	NRD-252	Inj.	Horse -ATG(Anti Thymocyte Globulin) 250 mg	vial / Amp	24	20000	
253	NRD-253	Inj.	HP-HMG (Highly Human Menopausal parodied Gonadotropin) 150 IU	vial / Amp	24	4000	
254	NRD-254	Inj.	HP-HMG (Highly Human Menopausal parodied Gonadotropin) 75 IU	vial / Amp	24	2000	
255	NRD-255	Inj.	Hydralazine 20mg/ml	vial / Amp	24	12000	
256	NRD-256	Inj.	Indomethacin Lyophilized Powder 1mg	vial / Amp	24	24000	
257	NRD-257	Inj.	Inotuzumab1 mg	vial / Amp	24	2000	
258	NRD-258	Inj.	Insulin Aspart	vial / Amp	24	20000	
259	NRD-259	Inj.	Insulin Glulisine (Monocomponent Insulin Glulisine) 100 IU/ml/3 ml Cartridges	vial / Amp	24	50000	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
260	NRD-260	Inj.	Insulin Glulisine (Monocomponent Insulin Glulisine) 100 IU/ml/3 ml prefilled Pen	3 ml prefilled Pen	24	50000	
261	NRD-261	Inj.	Insulin Lispro	vial / Amp	24	400	
262	NRD-262	Inj.	Interferon Beta 1-a 30mg	vial / Amp	24	200	
263	NRD-263	Inj.	Intralipds	vial / Amp	24	5000	
264	NRD-264	Inj.	Invert Sugar 10% (Fructodex 10%) 500 CC	500 ml	24	2010	
265	NRD-265	Inj.	Iohexol USP (solution for Injection) non Ionic contrast medium in sterile aqueous solution, 300 mg lodine/ml non ionic 50 ml	vial	24	20000	
266	NRD-266	Inj.	Ipilimumab 50 mg	vial / Amp	24	400	
267	NRD-267	Inj.	Irinotecan 40mg/5ml	vial / Amp	24	101800	
268	NRD-268	Inj.	Irinotecan 100 mg/5ml	vial / Amp	24	10000	
269	NRD-269	Inj.	Isolyte G	vial / Amp	24	50000	
270	NRD-270	Inj.	Isolyte P 10% 500 ML	500 ml	24	10300	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
271	NRD-271	Inj.	Lacosamide Infusion	vial / Amp	24	3040	
272	NRD-272	Inj.	Levobupivacaine 0.5% (20mg/4ml) Ampule	vial / Amp	24	600	
273	NRD-273	Inj.	Levofloxacine 500mg/100 ml	vial / Amp	24	295642	
274	NRD-274	Inj.	Levosulpride 12.5 MG/ML	vial / Amp	24	10500	
275	NRD-275	Inj.	Lignocaine (preservative free) 2%	vial / Amp	24	110000	
276	NRD-276	Inj.	Lignocaine + Adrenaline (1:10000, 2:10000)	vial / Amp	24	100000	
277	NRD-277	Inj.	Lignocaine 10% spray	vial / Amp	24	5000	
278	NRD-278	Inj.	Lignocaine Hydrochloride 2% 50ml vial	vial / Amp	24	10000	
279	NRD-279	Inj.	Liposomal Doxorubicin 20mg	vial / Amp	24	10524	
280	NRD-280	Inj.	Liposomal Doxorubicin 50 mg	vial / Amp	24	4000	
281	NRD-281	Inj.	Lorazepam 1.0 mg	vial / Amp	24	100000	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
282	NRD-282	Inj.	Lorazepam 5 mg	vial / Amp	24	100000	
283	NRD-283	Inj.	L-orinithine L- aspartate 10 ml	vial / Amp	24	97882	
284	NRD-284	Inj.	Low Molecular Wt. Heparin 0.4mg	vial / Amp	24	40000	
285	NRD-285	Inj.	Mephentermine 50mg/ml	vial / Amp	24	51996	
286	NRD-286	Inj.	Meropenem 2gm	vial / Amp	24	100000	
287	NRD-287	Inj.	Mesna 200 mg/2ml (Sod. Mercaptoethane Sulphate)	vial / Amp	24	50000	
288	NRD-288	Inj.	Methotrexate 250 mg	vial / Amp	24	21400	
289	NRD-289	Inj.	Methotrexate 1000 mg	vial / Amp	24	10000	
290	NRD-290	Inj.	Methylene Blue	vial / Amp	24	11600	
291	NRD-291	Inj.	Methylprednisolon Acetate 40mg	vial / Amp	24	159836	
292	NRD-292	Inj.	Methylprednisolon Acetate 125mg	vial / Amp	24	22100	
293	NRD-293	Inj.	Metotrexate 15mg (Preservative Free)	vial / Amp	24	4000	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
294	NRD-294	Inj.	Midazolam 5mg/ml 1 ml	vial / Amp	24	10000	
295	NRD-295	Inj.	Milrinone 10 MG	vial / Amp	24	3400	
296	NRD-296	Inj.	Mitomycin 2 mg	vial / Amp	24	20350	
297	NRD-297	Inj.	Mitomycin 40 mg	vial / Amp	24	8000	
298	NRD-298	Inj.	Mitoxanthrone Infusion 10 mg	vial / Amp	24	20160	
299	NRD-299	Inj.	Mitoxanthrone Infusion 20mg	vial / Amp	24	5000	
300	NRD-300	Inj.	Moxifloxacin intra cameral 0.5%	vial / Amp	24	15000	
301	NRD-301	Inj.	Moxifloxin 400mg/100ml	vial / Amp	24	179278	
302	NRD-302	Inj.	Multivitamin 10 ml	vial / Amp	24	850500	
303	NRD-303	Inj.	Nabpaclitaxel (Paclitaxel Nano Particle)100 mg	vial / Amp	24	1000	
304	NRD-304	Inj.	Nandrolone Decanoate 100mg	vial / Amp	24	10000	
305	NRD-305	Inj.	Nandrolone Decanoate 50 mg	vial / Amp	24	368296	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
306	NRD-306	Inj.	Natalizumab 300 mg	vial / Amp	24	600	
307	NRD-307	Inj.	Neostigmine+ Glycopyrrolate 2.5 mg/ 0.5 mg	vial / Amp	24	3400	
308	NRD-308	Inj.	Netilmycin 300mg/3ml	vial / Amp	24	200	
309	NRD-309	Inj.	Nicardipin 10mg	vial / Amp	24	1000	
310	NRD-310	Inj.	Nicorandil 48 mg	vial / Amp	24	141690	
311	NRD-311	Inj.	Nimodipine Infusion 10mg/50 ml	vial / Amp	24	5000	
312	NRD-312	Inj.	Nimotuzumab 50 mg	vial / Amp	24	1200	
313	NRD-313	Inj.	Nivolumab 40 mg	vial / Amp	24	600	
314	NRD-314	Inj.	Nivolumab 100 mg	vial / Amp	24	600	
315	NRD-315	Inj.	Normal Saline 500 ml Glass Bottle	500 ml	24	681748	
316	NRD-316	Inj.	Normal Saline 1000 ml Glass Bottle	1000 ml	24	30000	
317	NRD-317	Inj.	Octreotide 100mg	vial / Amp	24	20000	
318	NRD-318	Inj.	Octreotide-LAR (long Acting Release) 20 mg	vial / Amp	24	2100	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
319	NRD-319	Inj.	Octreotide-LAR (long Acting Release) 30 mg	vial / Amp	24	1000	
320	NRD-320	Inj.	Lidocaine1% intra cameral	vial / Amp	24	400	
321	NRD-321	Inj.	Omalizumab 150 mg vial	vial / Amp	24	80000	
322	NRD-322	Inj.	Ornidazole 500mg	vial / Amp	24	550	
323	NRD-323	Inj.	Palonosetron 0.25mg	vial / Amp	24	10100	
324	NRD-324	Inj.	Paracetamol infusion 500 mg with both Temper evident caps spray 10%	vial / Amp	24	50000	
325	NRD-325	Inj.	Paracetamol infusion 1000 mg with both Temper evident caps spray 10%	vial / Amp	24	50000	
326	NRD-326	Inj.	Peg Asparaginase 3750 IU 5 ml	vial / Amp	24	10000	
327	NRD-327	Inj.	PEG filgrastim injection 6mg	vial / Amp	24	2200	
328	NRD-328	Inj.	Pembrolizumab 50 mg	vial / Amp	24	400	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
329	NRD-329	Inj.	Pembrolizumab100 mg	vial / Amp	24	600	
330	NRD-330	Inj.	Pemetrexed 100mg	vial / Amp	24	42380	
331	NRD-331	Inj.	Pemetrexed 500 mg	vial / Amp	24	2400	
332	NRD-332	Inj.	Pertuzumab 100 mg	vial / Amp	24	400	
333	NRD-333	Inj.	Phenylephrine Hydrochloride 10 mg/ml	vial / Amp	24	2320	
334	NRD-334	Inj.	Pilocarpine 0.5% W/v	vial / Amp	24	39774	
335	NRD-335	Inj.	Piperacillin 1 gm + Tazobactum 125 mg	vial / Amp	24	90000	
336	NRD-336	Inj.	Piracetam 200mg	vial / Amp	24	173734	
337	NRD-337	Inj.	Placental Extract 2ml	vial / Amp	24	1980	
338	NRD-338	Inj.	Plerixafor 24 mg	vial / Amp	24	400	
339	NRD-339	Inj.	Polymyxin B for Injection 1 million	vial / Amp	24	1000	
340	NRD-340	Inj.	Potassium Chloride for Injection	vial / Amp	24	10000	
341	NRD-341	Inj.	Procaine Penicillin fortified 2 lack	vial / Amp	24	2000	
342	NRD-342	Inj.	Protamine Sulphate 5ML	vial / Amp	24	2040	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
343	NRD-343	Inj.	Rabbit-ATG (Anti Thymocyte Globulin)100 mg	vial / Amp	24	600	
344	NRD-344	Inj.	Ramucirumab 100 mg	vial / Amp	24	200	
345	NRD-345	Inj.	Ramucirumab 500 mg	vial / Amp	24	400	
346	NRD-346	Inj.	Ranizumab 10mg/ml	vial / Amp	24	200	
347	NRD-347	Inj.	Rasburicase 1.5 mg	vial / Amp	24	1100	
348	NRD-348	Inj.	Recombinant FSH 150 IU	vial / Amp	24	10000	
349	NRD-349	Inj.	Recombinant FSH 300IU	vial / Amp	24	10000	
350	NRD-350	Inj.	Recombinant HCG 250 IU	vial / Amp	24	10000	
351	NRD-351	Inj.	Recombinant LH 75IU	vial / Amp	24	10000	
352	NRD-352	Inj.	Reteplase 18 mg	vial / Amp	24	10046	
353	NRD-353	Inj.	Risperidone prolonged released Depot 25 mg	vial / Amp	24	50000	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
354	NRD-354	Inj.	Risperidone prolonged released Depot 50mg	vial / Amp	24	50000	
355	NRD-355	Inj.	Rituximab 100 mg	vial / Amp	24	117604	
356	NRD-356	Inj.	Rituximab 500 mg	vial / Amp	24	10000	
357	NRD-357	Inj.	Rocuronium 100mg/10ml	vial / Amp	24	2680	
358	NRD-358	Inj.	Romiplostim 125 mcg	vial / Amp	24	4000	
359	NRD-359	Inj.	Romiplostim 250 mcg	vial / Amp	24	5000	
360	NRD-360	Inj.	Romiplostim 500 mcg	vial / Amp	24	5000	
361	NRD-361	Inj.	Ropivacaine 0.75% 20ml vial	vial / Amp	24	5100	
362	NRD-362	Inj.	Ropivacaine 0.75% 3 ml Ampule (Heavy)	vial / Amp	24	3080	
363	NRD-363	Inj.	Secukinumab 150 mg	vial / Amp	24	60032	
364	NRD-364	Inj.	Sildenafil 0.8mg	vial / Amp	24	300	
365	NRD-365	Inj.	Sodium Bicarbonate Injection	vial / Amp	24	1000	
366	NRD-366	Inj.	Sodium Fluroresceine Dye 20%	vial / Amp	24	200	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
367	NRD-367	Inj.	Sodium Hyaluronate 1.4mg	vial / Amp	24	2000	
368	NRD-368	Inj.	Streptomycin 1gm	vial / Amp	24	2010	
369	NRD-369	Inj.	Streptomycin 500mg	vial / Amp	24	24000	
370	NRD-370	Inj.	Sugmadex	vial / Amp	24	40	
371	NRD-371	Inj.	Teicoplanin 200 mg	vial / Amp	24	8600	
372	NRD-372	Inj.	Teicoplanin 400 mg	vial / Amp	24	10000	
373	NRD-373	Inj.	Tenecteplase 20mg	vial / Amp	24	640	
374	NRD-374	Inj.	Tenecteplase 40 mg	vial / Amp	24	200	
375	NRD-375	Inj.	Testosteron Propionate 50mg	vial / Amp	24	10000	
376	NRD-376	Inj.	Testosteron Propionate 250Mg	vial / Amp	24	10000	
377	NRD-377	Inj.	Thiamine 100ml	vial / Amp	24	22000	
378	NRD-378	Inj.	Ticarcillin and Clavulanic acid	vial / Amp	24	10000	
379	NRD-379	Inj.	Tigecycline for injection 50mg	vial / Amp	24	8000	
380	NRD-380	Inj.	Tigecycline for injection 100mg	vial / Amp	24	10000	
381	NRD-381	Inj.	Tobaramycin 80mg	vial / Amp	24	2000	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
382	NRD-382	Inj.	Topotecan 1 mg	vial / Amp	24	10400	
383	NRD-383	Inj.	Topotecan 2.5 mg	vial / Amp	24	10000	
384	NRD-384	Inj.	Topotecan 4 mg	vial / Amp	24	3000	
385	NRD-385	Inj.	t-PA 20mg Alteplase for Injection	vial / Amp	24	200	
386	NRD-386	Inj.	t-PA 50mg Alteplase for Injection	vial / Amp	24	300	
387	NRD-387	Inj.	Trabectedin 1 mg	vial / Amp	24	600	
388	NRD-388	Inj.	Tranexamic Acid 500mg/5ml	vial / Amp	24	40000	
389	NRD-389	Inj.	Trastuzumab 440 mg	vial / Amp	24	37100	
390	NRD-390	Inj.	Trastuzumab150Mg	vial / Amp	24	4000	
391	NRD-391	Inj.	Triamcinolone Acetonide 10 mg per ml	vial / Amp	24	62900	
392	NRD-392	Inj.	Triamcinolone Acetonide 40 mg per ml	vial / Amp	24	69100	
393	NRD-393	Inj.	Trypan Blue 0.6%	vial / Amp	24	2800	
394	NRD-394	Inj.	Triptorelin 0.1 mg	vial / Amp	24	10000	

-

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
395	NRD-395	Inj.	Triptorelin 3.75 mg	vial / Amp	24	10000	
396	NRD-396	Inj.	Triptorelin 11.25 mg	vial / Amp	24	10000	
397	NRD-397	Inj.	Varicella immunoglobulin for IV use	vial / Amp	24	20400	
398	NRD-398	Inj.	Vasopressin 3ml	vial / Amp	24	5200	
399	NRD-399	Inj.	Verapamil 2.5 mg/ml	vial / Amp	24	1200	
400	NRD-400	Inj.	Vinorelbine 10mg	vial / Amp	24	10100	
401	NRD-401	Inj.	Vinorelbine 50mg	vial / Amp	24	4000	
402	NRD-402	Inj.	Vitamin D (600000 IU)	vial / Amp	24	530288	
403	NRD-403	Inj.	Insulin Glargine 300 IU per ml/prefilled Pen	vial / Amp	24	50000	
404	NRD-404	Inj.	Insuline 50/50	vial / Amp	24	20000	
405	NRD-405	Jelly	Xylocaine Lubricating 30gm		24	24000	
406	NRD-406		Lignocaine 4% 30Ml		24	100004	
407	NRD-407		Lignocaine Viscous		24	8000	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
408	NRD-408	Inj.	Liver specific MRI contrast agent (Gadobenate disodium (Gd-BOPTA), Gadoxetate disodium (Gd-EOB-DTPA), Mangafodipirtri sodium (Mn-DPDP), Ferumoxide, Ferucarbotran)	vial / Amp	24	10000	
409	NRD-409	Cap.	L-Ornithine L-Aspartate (150mg) + Pancreatin (100mg)	10x10	24	110000	
410	NRD-410	Lotion	Asceptic (chlorhexadine gluconate 7.5% +=15%cetrimide solu + Isopropyl 17%	50 ml	24	2000	
411	NRD-411	Lotion	Clotrimazole 1%+Beclomethasone 0.25%	50 ml	24	61000	
412	NRD-412	Lotion	Ketaconazole 2%	50 ml	24	70400	
413	NRD-413	Lotion	Minoxidil 2%	50 ml	24	769800	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
414	NRD-414	Lotion	Minoxidil 5%	50 ml	24	20000	
415	NRD-415	Lotion	Minoxidil 10 %	50 ml	24	20000	
416	NRD-416	Lotion	Podophyliin Toxin	50 ml	24	4180	
417	NRD-417	Lotion	Sulphur + Calamine	50 ml	24	1000	
418	NRD-418	Lotion	sunscreen (octinoxate,avobenzone , oxybenzone) spf 30	50 ml	24	266000	
419	NRD-419	Lozenses	Clotrimazole 10Mg	10x10	24	20000	
420	NRD-420	Oil	(Medium Chain Triglyceride)	50 ml	24	6000	
421	NRD-421	MDI	Budesonide 200 mcg.		24	94000	
422	NRD-422	MDI	Formeterol 6mcg.+ Fluticasone 250 mcg. Inhalation		24	28000	
423	NRD-423	MDI	Formoterol 6 mcg. + Budesonide 200 mcg.		24	6000	
424	NRD-424	MDI	Formoterol 6 mcg. + Budesonide 400 mcg.		24	10000	
425	NRD-425	MDI	Leosalbutamol 50mcg.+ Ipratopium 40mcg.		24	30000	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
426	NRD-426	MDI	Levosalbutamol inhalation Solution 50ml/gm		24	50000	
427	NRD-427	Mouth Paint	Lignocaine 1%	50 ml	24	266830	
428	NRD-428	Mouthwash	1.5% Hydrogen Peroxide	50ml	24	200	
429	NRD-429	Nasal Spray	Fluticasone FT	each	24	17300	
430	NRD-430	Nasal Spray	Midazolam 0.5mg/5ml		24	5000	
431	NRD-431	Ointment	Neomycin sulphate and Bacitracin Zinc ointment USP 5 mg + 500 IU/gm	20 gm	24	44000	
432	NRD-432	Inj.	Sodium Chloride 0.9% 3000ML(N.S)	vial / Amp	24	20520	
433	NRD-433	Inj.	Sodium Chloride bottel 100ML	vial / Amp	24	16000	
434	NRD-434	Ointment	Magnesium sulphate, Sulphacetamide, Urea 75 gm	75 gm	24	4410	
435	NRD-435	Ointment	Clobetasol+Salicylic acid 0.5%+6%	20 gm	24	62500	
436	NRD-436	Ointment	Heparin 50 IU Benzyl Nicotinate 2 mg		24	10000	
437	NRD-437	Ointment	Fluticasone	20 gm	24	10000	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
438	NRD-438	Ointment	Neomycin, Polmyxin and Bacitracin zinc ophthalmic 15 gm IP		24	30000	
439	NRD-439	Ointment	Tacrolimus 0 .03% 15 gm		24	66900	
440	NRD-440	Ointment	Tacrolimus 0 .1% 15 gm		24	72900	
441	NRD-441	Ointment	Zinc Oxide +Alo Vera +Semethicone	20 gm	24	2000	
442	NRD-442		Omega 3Fatty Acid 50ML		24	10002	
443	NRD-443	Oral Drop	Caffiene Citrate Oral Solution	3 ml	24	2200	
444	NRD-444	Paint	Mercunium Chloride	100 gm	24	1000	
445	NRD-445	Paint	salicylic acid 16.7% + lactic acid 16.7%	10 ml	24	1000	
446	NRD-446	Paste	Coloplast 60 Gm		24	4000	
447	NRD-447	Paste	EEG 400GM		24	10000	
448	NRD-448	Patch	Diclofenac Each Transdermal patch contain 200 mg Diclofenac		24	10000	
449	NRD-449	Pessary	povidone iodine	1x10x10	24	20400	
450	NRD-450	Powder	Milk Low Birth Formula	200 gm	24	20000	

-

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
451	NRD-451	Inj.	Recombinant Human Growth Hormone 4IU vial With Syringe	vial / Amp	24	500	
452	NRD-452	Resp.	Enterogermina 2billion spores 5ml		24	7000	
453	NRD-453	Resp.	Formeterol 20mcg +Budesonide 0.5mg		24	5000	
454	NRD-454	Resp.	Levosalbutamol 2.5 mg + Ipratropium 500 mcg 2.5 ml		24	20000	
455	NRD-455	Respule	N-acetylcysteine (NAC) 200mg/ml		24	2088	
456	NRD-456	Respules	Budesonide 0.5mg/ml		24	20210	
457	NRD-457	Respules	Budesonide 1ml		24	24000	
458	NRD-458	Respules	Glycopyrronium 25mcg. Inhalation 2ml.		24	20000	
459	NRD-459	Respules	Sodium Chloride 3 %		24	20000	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
460	NRD-460	Respules	Tiotropium Bromide dry powder 30/pack		24	16000	
461	NRD-461		Revolizer/ rotahaler Device		24	10000	
462	NRD-462		Root Canal Sealer (Calcium Carbonate)		24	2000	
463	NRD-463	Sachet	Fosfomycin 3gm		24	1000	
464	NRD-464	Sachet	HMF for Pretem	1 gm sachet each	24	23306	
465	NRD-465	Sachet	L-Arginine+proanthocynadine granules 3mg	3 mg each sachet	24	6000	
466	NRD-466	Sachet	Polyethyene glycol + Sodium Chloride+Sodium Bi Carbonate+Potassium Chloride	2 gm sachet	24	20000	
467	NRD-467	Sachet	Racecadotril Sachet 30 mg	each sachet	24	50000	
468	NRD-468	Inj.	Etanercept 25MG/0.5ML	vial / Amp	24	3000	
469	NRD-469	solution	Polyethyene glycol with Elctrolyte approx 130gm		24	400	
470	NRD-470	Spray	Lidocaine 10% 20Ml		24	2400	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
471	NRD-471	Spray	Superoxidized	100 ml	24	3000	
472	NRD-472	Suppository	Mesalazine	1 gm sachet each	24	4000	
473	NRD-473	Suppsitory	Glycerin 2 gm/ml	2x5	24	21000	
474	NRD-474	Suppsitory	Paracetamol 170 mg Each Suppsitory contain paracetamol 170 Mg	2x5	24	40000	
475	NRD-475	Syp.	Cefaclor Each 5 ml contain Cefaclor 125 Mg	30 ml	24	50000	
476	NRD-476	Syrup	Codiene Phosphate	60 ml	24	20000	
477	NRD-477	Syrup	Amlodipine oral solution 1 MG/ ML	100 ml	24	400000	
478	NRD-478	Syrup	Artemether 40mg + Lumefantrine 240 mg 30ml		24	4000	
479	NRD-479	Syrup	B. complex	200 ml	24	200000	
480	NRD-480	Syrup	Baclofen Oral Solution 5 MG /ML	100 ml	24	20000	
481	NRD-481	Syrup	Calcium Phosphate 200 ml		24	10000	
482	NRD-482	Syrup	Cefixime Oral Suspension 50MG	30 ml	24	32000	
483	NRD-483	Syrup	Cefixime Oral Suspension 100MG	30 ml	24	116000	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
484	NRD-484	Syrup	Cefpodoxime Proxetil Oral suspension 50MG	30 ml	24	66000	
485	NRD-485	Syrup	Cefpodoxime Proxetil Oral suspension 100MG	30 ml	24	200000	
486	NRD-486	Syrup	Cefuroxime Axetil oral suspension 125mg/5ml	30 ml	24	2200	
487	NRD-487	Syrup	Clarithromycin for oral suspension 125mg/5ml	30 ml	24	24000	
488	NRD-488	Inj.	Cefoperazone 1mg Inj.	vial / Amp	24	30000	
489	NRD-489	Syrup	Cyclosporine Oral solution 100mg/ml	50 ml	24	1600	
490	NRD-490	Inj.	Rabbit-ATG (Anti Thymocyte Globulin) 250 mg	vial / Amp	24	200000	
491	NRD-491	Syrup	Cyproheptadine 200ML		24	2956220	
492	NRD-492	Syrup	Dextromethorphan Hcl + Chlorpheniramine	100 ml	24	30000	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
493	NRD-493	Syrup	Diatrizoic Acid Salts & Meglumine 66% & Sodium 10% & Iodine content 370 mg/ml 30 ml		24	50000	
494	NRD-494	Syrup	Drotavarine	60 ml	24	1955580	
495	NRD-495	Syrup	Each 15 ml contains: Milk of Magnesia 11.25 ml+ Liquid Paraffin 3.75 ml 170 ml		24	100000	
496	NRD-496	Syrup	each 5 ml Containing : Paracetamol 125 mg + Ibuprofen 100 mg 60 ml		24	300000	
497	NRD-497	Syrup	Enzyme 100 ML		24	24000	
498	NRD-498	Syrup	Esomperazole	60 ml	24	20000	
499	NRD-499	Syrup	Fluconazole oral suspension	60 ml	24	12000	
500	NRD-500	Syrup	Furosemide Oral Solution 10mg/30ml	30 ml	24	10000	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
501	NRD-501	Syrup	L-Carnitine 500mg/5ml in 30 ml		24	20000	
502	NRD-502	Syrup	L-Carnosine 100mg/5ml in 200ml		24	50000	
503	NRD-503	Syrup	Levofloxacin Oral Solution	60 ml	24	3050350	
504	NRD-504	Syrup	Linezolid 100mg/5ml in 30ml		24	37000	
505	NRD-505	Syrup	Mefenamice Acid 100mg/5ml	60 ml	24	3518320	
506	NRD-506	Syrup	Mefenemic Acid 50 mg + Paracetamol 250 mg /60 ml		24	400000	
507	NRD-507	Syrup	Melatonin 60 ml		24	50000	
508	NRD-508	Syrup	Montelucast+Levocetrizine	60 ml	24	3980840	
509	NRD-509	Syrup	Nitrofurantoin oral suspension 25mg/5ml in 100		24	5000	
510	NRD-510	Syrup	Ondansetron oral suspension	30 ml	24	2011920	
511	NRD-511	Syrup	Oxybutynin oral suspension5 ml	30 ml	24	4000	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
512	NRD-512	Syrup	Phenobarbitone 20mg/5ml in 100ml		24	339800	
513	NRD-513	Tab.	Prednisolone IP 50mg	10x10	24	500000	
514	NRD-514	Syrup	Piracetam 500mg/5ml in 100ml		24	20000	
515	NRD-515	Syrup	Potassium Magnesium citrate	200 ml	24	21000	
516	NRD-516	Syrup	Ranitidine oral suspension	100 ml	24	40000	
517	NRD-517	Syrup	Rifaximin	60 ml	24	20000	
518	NRD-518	Syrup	Sodium Bicarbonate oral suspension	200 ml	24	10000	
519	NRD-519	Syrup	Sodium Picosulphate oral suspension	100 ml	24	10200	
520	NRD-520	Syrup	Sorbitol + Tricholine Citrate	200 ml	24	24000	
521	NRD-521	Syrup	Sucralphate	200 ml	24	11200	
522	NRD-522	Syrup	Triclofos oral suspension500 mg/ 5ml in 30ml		24	20000	
523	NRD-523	Syrup	Ursodeoxycholic oral suspension 125mg/5ml in 100ml		24	28000	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
524	NRD-524	Syrup	Zinc oral suspension 20 mg/100 Ml		24	981570	
525	NRD-525	Syrup	/Susp. Azithromycin oral suspension 100mg/5ml	15 ml	24	2038382	
526	NRD-526	Syrup	/Susp. Azithromycin oral suspension 200mg/5ml	30 ml	24	1942340	
527	NRD-527	Tab.	Midodrine 5mg	10x10	24	10000	
528	NRD-528	Tab./Cap.	Hydroxyurea 500mg	10x10	24	40000	
529	NRD-529	Tab.	CoQ 300mg(Capsule of Co-enzyme Q10 with Lycopene,Selenium & omega 3 fatty acid)	10x10	24	30000	
530	NRD-530	Tab./Cap.	Everolimus 5mg	10x10	24	103200	
531	NRD-531	Tab./Cap.	Everolimus 10mg	10x10	24	20000	
532	NRD-532	Tab./Cap.	Tacrolimus 0.25	10x10	24	129000	
533	NRD-533	Tab./Cap.	Nintedanib 150MG	10x10	24	3000	
534	NRD-534	Tab.	6-Mercaptopurine 20 mg	10x10	24	10000	
535	NRD-535	Tab.	Acebrophylline SR 200 Mg	10x10	24	116000	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
536	NRD-536	Tab.	Aceclofenac + Thiocolchicoside	10x10	24	20000	
537	NRD-537	Tab.	Aceclofenac SR 200 mg	10x10	24	40000	
538	NRD-538	Tab.	Aceclofenac+Paracetamol+ Serratiopeptidase (100+325+15 mg)	10x10	24	620000	
539	NRD-539	Tab.	Afatinib 20 mg	10x10	24	6000	
540	NRD-540	Tab.	Afatinib 30 mg	10x10	24	6000	
541	NRD-541	Tab.	Afatinib 40 mg	10x10	24	1000	
542	NRD-542	Tab.	Alendronate Sodium 70 mg	10x10	24	50000	
543	NRD-543	Tab.	Alfuzosin 10 mg	10x10	24	27000	
544	NRD-544	Tab.	Alpelisib 150 mg	10x10	24	2000	
545	NRD-545	Tab.	Alpelisib 200 mg	10x10	24	1000	
546	NRD-546	Tab.	Alpelisib 250 mg	10x10	24	1000	
547	NRD-547	Tab.	Amantidine 100mg	10x10	24	70000	
548	NRD-548	Tab.	Amisulpride 50 mg	10x10	24	42000	
549	NRD-549	Tab.	Apixaban 2.5 mg	10x10	24	24400	
550	NRD-550	Tab.	Apixaban 5mg	10x10	24	96000	
551	NRD-551	Tab.	Aripiprazole 10 mg	10x10	24	52000	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
552	NRD-552	Tab.	Aripiprazole 5 mg	10x10	24	20000	
553	NRD-553	Tab.	Aspirin IP 300 mg	10x10	24	10000	
554	NRD-554	Tab.	Aspirin Dispresible 325mg	10x10	24	2000	
555	NRD-555	Tab.	Atomoxetin 10 mg	10x10	24	10000	
556	NRD-556	Tab.	Atomoxetin 18 mg	10x10	24	10000	
557	NRD-557	Tab.	Atomoxetin 25 mg	10x10	24	10000	
558	NRD-558	Tab.	Atroxentine 250mg (Trientine HCL)	10x10	24	10000	
559	NRD-559	Tab.	Axitinib 5 Mg	10x10	24	8000	
560	NRD-560	Tab.	Bilastin 20 MG	10x10	24	62600	
561	NRD-561	Tab.	Biotin 5 MG	10x10	24	107000	
562	NRD-562	Tab.	Bosentan 62.5 mg	10x10	24	3600	
563	NRD-563	Tab.	Bosutinib 500 mg	10x10	24	4000	
564	NRD-564	Tab.	Brivaracetam 50mg	10x10	24	65000	
565	NRD-565	Tab.	Buprinorphine 2 mg	10x10	24	5000	
566	NRD-566	Tab.	Calcium Acetate 667	10x10	24	36000	
567	NRD-567	Tab.	Calcium Folinate 15 mg	10x10	24	30000	
568	NRD-568	Tab.	Capmatinib 200 mg	10x10	24	1000	
569	NRD-569	Tab.	Carbimazole 10 mg	10x10	24	4000	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
570	NRD-570	Tab.	Cefixime + Potassium Clavulanate 200+125mg	10x10	24	110000	
571	NRD-571	Tab.	Cefpodoxime proxetil 100mg	10x10	24	2788020	
572	NRD-572	Tab.	Cefpodoxime 200mg	10x10	24	810000	
573	NRD-573	Tab.	Cefpodoxime CV 375	10x10	24	808000	
574	NRD-574	Tab.	Chlordiazepoxide 25 mg	10x10	24	30000	
575	NRD-575	Tab.	Chlordiazsepoxide 10 Mg + Clidinium 25 mg	10x10	24	36000	
576	NRD-576	Tab.	Chlorthalidone 6.25 mg	10x10	24	8000	
577	NRD-577	Tab.	Cholchicine 0.5mg	10x10	24	200	
578	NRD-578	Tab.	Cilostazol 50mg	10x10	24	8800	
579	NRD-579	Tab.	Cilostazol 100mg	10x10	24	10000	
580	NRD-580	Tab.	Clarithromycin 250 MG	10x10	24	10000	
581	NRD-581	Tab.	Clarithromycin 500mg	10x10	24	2111220	
582	NRD-582	Tab.	Cilnidipine 5 mg	10x10	24	200000	
583	NRD-583	Tab.	Cilnidipine10 mg	10x10	24	963720	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
584	NRD-584	Tab.	Cilnidipine 20 mg	10x10	24	100000	
585	NRD-585	Tab.	Clonazepam 0.25	10x10	24	100000	
586	NRD-586	Tab.	Clonazepam 1Mg	10x10	24	20000	
587	NRD-587	Tab.	Clozapine 25 mg	10x10	24	92000	
588	NRD-588	Tab.	Clozapine 50 mg	10x10	24	200000	
589	NRD-589	Tab.	Clozapine 100 mg	10x10	24	100000	
590	NRD-590	Tab.	Cotriamazole 480MGs	10x10	24	2000	
591	NRD-591	Tab.	Cefuroxime Axetil 500 mg.	10x10	24	4000	
592	NRD-592	Tab.	Cyproheptadine 4Mg	10x10	24	36000	
593	NRD-593	Tab.	Cyproterone Acetate 2 mg +Ethynil Estradiol. 035mg	10x10	24	5700	
594	NRD-594	Tab.	Dabigatran 150 mg	10x10	24	3000	
595	NRD-595	Tab.	Dabigatran 110 mg	10x10	24	10200	
596	NRD-596	Tab.	Dabrafenib 50 mg	10x10	24	1000	
597	NRD-597	Tab.	Dacomitinib 15 mg	10x10	24	2000	
598	NRD-598	Tab.	Dacomitinib 30 mg	10x10	24	1000	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
599	NRD-599	Tab.	Dapagliflozin 10 MG	10x10	24	1641320	
600	NRD-600	Tab.	Dapoxetine 30 mg	10x10	24	1000	
601	NRD-601	Tab.	Dapsone 100 mg	10x10	24	68000	
602	NRD-602	Tab.	Deflazacort 6mg	10x10	24	3452220	
603	NRD-603	Tab.	Deflazacort 12 MG	10x10	24	5000	
604	NRD-604	Tab.	Desvenlafaxine 50mg	10x10	24	4000	
605	NRD-605	Tab.	Diclo & Sera& Para.	10x10	24	406000	
606	NRD-606	Tab.	Diclofenac + Thiocolchicoside	10x10	24	400000	
607	NRD-607	Tab.	Dienogest 2mg	10x10	24	50960	
608	NRD-608	Tab.	Diltiazem prolonged released 90mg	10x10	24	12000	
609	NRD-609	Tab.	Dimethyl Fumarate120 mg	10x10	24	40000	
610	NRD-610	Tab.	Dimethyl Fumarate 240mg	10x10	24	30000	
611	NRD-611	Tab.	Disulfiram 125 mg	10x10	24	4000	
612	NRD-612	Tab.	Disulfiram 250mg	10x10	24	5000	
613	NRD-613	Tab.	Donepezil 5 mg	10x10	24	44000	
614	NRD-614	Tab.	Duloxetine gastro resistant 20 mg	10x10	24	546782	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
615	NRD-615	Tab.	Duloxitine gastro resistant30 mg	10x10	24	646822	
616	NRD-616	Tab.	Dydrogesterone 10mg	10x10	24	21200	
617	NRD-617	Tab.	Eltrombopag 25MG	10x10	24	20000	
618	NRD-618	Tab.	Eltrombopag 50MG	10x10	24	20000	
619	NRD-619	Tab.	Empagliflazone 10mg	10x10	24	20000	
620	NRD-620	Tab.	Empagliflazone 25mg	10x10	24	20000	
621	NRD-621	Tab.	Entacapone 200 mg	10x10	24	3000	
622	NRD-622	Tab.	Erlotinib 150 mg	10x10	24	30280	
623	NRD-623	Tab.	Erlotinib 100mg	10x10	24	10000	
624	NRD-624	Tab.	Esomeprazole 40 Mg	10x10	24	7399500	
625	NRD-625	Tab.	Estradiol Valerate 2 mg	10x10	24	11000	
626	NRD-626	Cream	Estradiol Valerate		24	1000	
627	NRD-627	Tab.	Enzalupamide 40mg	10x10	24	21000	
628	NRD-628	Tab.	Ethynil Estradiol 0.02mg+ Tab Desogestral 0.15mg	10x10	24	4600	
629	NRD-629	Tab.	Etizolam 0.5 mg	10x10	24	60000	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
630	NRD-630	Tab.	Etoricoxib+thiocolchicoside(60+8 mg)	10x10	24	232000	
631	NRD-631	Tab.	Exemestane 25 mg	10x10	24	22000	
632	NRD-632	Tab.	Febuxostat 40 mg	10x10	24	970540	
633	NRD-633	Tab.	Febuxostat 80 mg	10x10	24	805540	
634	NRD-634	Tab.	Fexofenadine 120 MG	10x10	24	26000	
635	NRD-635	Tab.	Fexofenadine 180 MG	10x10	24	90000	
636	NRD-636	Tab.	Fingolimod 0.5 mg	10x10	24	20000	
637	NRD-637	Tab.	Fludrocortisone 100Mcg	10x10	24	200	
638	NRD-638	Tab.	Flunarizine 10mg	10x10	24	60000	
639	NRD-639	Tab.	Fluvoxamine 100 mg	10x10	24	20000	
640	NRD-640	Tab.	Fluvoxamine 50 mg	10x10	24	24000	
641	NRD-641	Tab.	Folinic Acid 15mg	10x10	24	50000	
642	NRD-642	Tab.	Formaline	10x10	24	2200	
643	NRD-643	Tab.	Furosemide 20mg + Spironolactone 50mg	10x10	24	220000	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
644	NRD-644	Tab.	Glucosamine hydrocloride + Diacerin 50 mg	10x10	24	5257680	
645	NRD-645	Tab.	Ibrutinib 140mg	10x10	24	10200	
646	NRD-646	Tab.	Indomethacin 75 mg SR	10x10	24	100000	
647	NRD-647	Tab.	Inositol + Myoinositol 1000mg	10x10	24	40000	
648	NRD-648	Tab.	Ivabradine 5mg	10x10	24	205000	
649	NRD-649	Tab.	Ivermectin 6 mg + Albendazole 400 mg	10x10	24	40000	
650	NRD-650	Tab.	Ivermectin 6mg	10x10	24	40000	
651	NRD-651	Tab.	Ivermectin 12mg	10x10	24	100000	
652	NRD-652	Tab.	Ketoconazole 200 MG	10x10	24	10000	
653	NRD-653	Tab.	Lacosamide 50 mg	10x10	24	10000	
654	NRD-654	Tab.	Lamotrigine Dispersible 100MG	10x10	24	10000	
655	NRD-655	Tab.	Lapatinib 500mg	10x10	24	10200	
656	NRD-656	Tab.	Lenalidomide 25MG	10x10	24	30000	
657	NRD-657	Tab.	Lenalidomide 10 mg	10x10	24	20000	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
658	NRD-658	Tab.	Lenvatinib 4 mg	10x10	24	20000	
659	NRD-659	Tab.	Lenvatinib 10 mg	10x10	24	20000	
660	NRD-660	Tab.	Levetiracetam IP 250 mg	10x10	24	20000	
661	NRD-661	Tab.	Levodopa+Carbidopa 125	10x10	24	28000	
662	NRD-662	Tab.	Levodopa+Carbidopa+Entacapone 100mg/25mg/200mg	10x10	24	4000	
663	NRD-663	Tab.	Levofloxacin 750 mg	10x10	24	100000	
664	NRD-664	Tab.	Levosulpride 75mg	10x10	24	12000	
665	NRD-665	Tab.	Levothyroxine Sodium 25 mcg	10x10	24	2961590	
666	NRD-666	Tab.	Levothyroxine Sodium 75 mcg	10x10	24	200000	
667	NRD-667	Tab.	Linaglipitin 2.5mg	10x10	24	21000	
668	NRD-668	Tab.	Linaglipitin 5mg	10x10	24	20000	
669	NRD-669	Tab.	Lopinavir 200Mg+Ritonavir 50 mg	10x10	24	10000	
670	NRD-670	Tab.	Loratadine 10 mg	10x10	24	6000	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
671	NRD-671	Tab.	Lorlatinib 25 mg	10x10	24	2000	
672	NRD-672	Tab.	Lorlatinib 100 mg	10x10	24	20000	
673	NRD-673	Tab.	Megestrol Acetate 160 mg	10x10	24	10000	
674	NRD-674	Tab.	Melatonin 3 mg	10x10	24	9000	
675	NRD-675	Tab.	Melphalan 2mg	10x10	24	11500	
676	NRD-676	Tab.	Metolazone 5mg	10x10	24	7200	
677	NRD-677	Tab.	Methimazole 5 mg	10x10	24	4000	
678	NRD-678	Tab.	Methimazole 10mg	10x10	24	50000	
679	NRD-679	Tab.	Methotrexate 7.5MG	10x10	24	70000	
680	NRD-680	Tab.	Methotrexate 15mg	10x10	24	30000	
681	NRD-681	Tab.	Methylphenidate 10 mg	10x10	24	100000	
682	NRD-682	Tab.	Methylprednisolone 4mg	10x10	24	67000	
683	NRD-683	Tab.	Methylprednisolone 16mg	10x10	24	2006100	
684	NRD-684	Tab.	Methylprednisolone 8mg	10x10	24	2286740	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
685	NRD-685	Tab.	Meverberine 135 mg + Chlordiazepoxide 10 mg	10x10	24	10000	
686	NRD-686	Tab.	Midostaurin 25 mg	10x10	24	8000	
687	NRD-687	Tab.	Mirabegeron 25 mg	10x10	24	10000	
688	NRD-688	Tab.	Mirabegeron 50 mg	10x10	24	5000	
689	NRD-689	Tab.	Mirtazapine 7.5mg	10x10	24	5000	
690	NRD-690	Tab.	Mirtazapine 15mg	10x10	24	10000	
691	NRD-691	Tab.	Mifepristone 25mg	10x10	24	10000	
692	NRD-692	Tab.	Montelukast 4 mg	10x10	24	100000	
693	NRD-693	Tab.	Montelukast 5 mg	10x10	24	100000	
694	NRD-694	Tab.	Montelukast 10 mg	10x10	24	200000	
695	NRD-695	Tab.	Morphine 10MG	10x10	24	19800	
696	NRD-696	Tab.	Morphine 30MG	10x10	24	10000	
697	NRD-697	Tab.	Moxifloxacin 400 Mg	10x10	24	4171680	
698	NRD-698	Tab.	Moxonidine 0.2 mg	10x10	24	22200	
699	NRD-699	Tab.	Moxonidine 0.3 mg	10x10	24	121200	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
700	NRD-700	Tab.	N-Acetylecystine effervescent form, orange flavour, 600 mg	10x10	24	54160	
701	NRD-701	Tab.	Naltrexone 50 mg	10x10	24	4000	
702	NRD-702	Tab.	Nebivolol 5mg	10x10	24	200	
703	NRD-703	Tab.	Nebivolol 10mg	10x10	24	20000	
704	NRD-704	Tab.	Nicorandil 5mg	10x10	24	203200	
705	NRD-705	Tab.	Nicoumalone 1 Mg	10x10	24	321660	
706	NRD-706	Tab.	Nicoumalone 3 Mg	10x10	24	10000	
707	NRD-707	Tab.	Nicoumalone 4 Mg	10x10	24	290780	
708	NRD-708	Tab.	Nifidipine 20MG	10x10	24	1000	
709	NRD-709	Tab.	Nifidipine 20MG SR	10x10	24	50000	
710	NRD-710	Tab.	Nilotinib 150 mg	10x10	24	53588	
711	NRD-711	Tab.	Nilotinib 200 mg	10x10	24	10000	
712	NRD-712	Tab.	Nilotinib 300mg	10x10	24	10000	
713	NRD-713	Tab.	Nitazoxanide 500mg	10x10	24	2000	
714	NRD-714	Tab.	Nitrazepam 5mg	10x10	24	2515800	
715	NRD-715	Tab.	Nitrazepam 10 mg	10x10	24	50000	
716	NRD-716	Tab.	Olaparib 50 mg	10x10	24	6000	
717	NRD-717	Tab.	Olaparib 150 mg	10x10	24	10000	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
718	NRD-718	Tab.	Olmesartan medoxomil 20 MG	10x10	24	100000	
719	NRD-719	Tab.	Orciprenaline 10 Mg	10x10	24	6200	
720	NRD-720	Tab.	Osimertinib 80 mg	10x10	24	10000	
721	NRD-721	Tab.	Oxcarbazepine 300MG	10x10	24	24000	
722	NRD-722	Tab.	Oxcarbazepine 450MG	10x10	24	3000	
723	NRD-723	Tab.	Oxazepam 15mg	10x10	24	24000	
724	NRD-724	Tab.	Pancreatin Gastroresistant 10,000MG(with proteiase & amylase)	10x10	24	10000	
725	NRD-725	Tab.	Pantoprazole 20MG	10x10	24	90000	
726	NRD-726	Tab.	Paracetomol 650 mg	10x10	24	31915900	
727	NRD-727	Tab.	Paroxetine 12.5mg	10x10	24	2000	
728	NRD-728	Tab.	Paroxetine 25mg	10x10	24	10000	
729	NRD-729	Tab.	Pazopanib 200mg	10x10	24	6000	
730	NRD-730	Tab.	Pazopanib 400mg	10x10	24	6000	
731	NRD-731	Tab.	Penicillin V 400MG	10x10	24	2000	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
732	NRD-732	Tab.	Pentoxifylline Extended Release/SR 400mg	10x10	24	21000	
733	NRD-733	Tab.	Perampanel 2 mg	10x10	24	35000	
734	NRD-734	Tab.	Perampanel 4mg	10x10	24	20000	
735	NRD-735	Tab.	Pheniramine 25 MG	10x10	24	10000	
736	NRD-736	Tab.	Phenozopyridine 200Mg	10x10	24	30000	
737	NRD-737	Tab.	Pirfenidone 200 mg	10x10	24	4400	
738	NRD-738	Tab.	Pirfenidone 400 mg	10x10	24	5000	
739	NRD-739	Tab.	Piroxicam DT 20mg	10x10	24	50000	
740	NRD-740	Tab.	Pomalidomide 2 mg	10x10	24	20000	
741	NRD-741	Tab.	Pomalidomide 4 mg	10x10	24	10000	
742	NRD-742	Tab.	Posacozazole 100mg	10x10	24	10000	
743	NRD-743	Syp.	Posacozazole 40mg/ml	105 ml	24	10000	
744	NRD-744	Tab.	Prasugrel 10MG TAB	10x10	24	241000	
745	NRD-745	Tab.	Prazosin 5MG	10x10	24	153200	
746	NRD-746	Tab.	Prednisolone IP 40mg	10x10	24	100000	
747	NRD-747	Tab.	Primidone 50 mg	10x10	24	22000	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
748	NRD-748	Tab.	Primidone 250 mg	10x10	24	30000	
749	NRD-749	Tab.	Prochlorperazine 5mg	10x10	24	10000	
750	NRD-750	Tab.	Progesterone only Pills	10x10	24	1100	
751	NRD-751	Tab.	Propranolol 10mg	10x10	24	200000	
752	NRD-752	Tab.	Propranolol 40 mg SR	10x10	24	200000	
753	NRD-753	Tab.	Propylthiouracil 100 mg	10x10	24	520440	
754	NRD-754	Tab.	Pyridoxine 100 mg	10x10	24	13200	
755	NRD-755	Tab.	Ranolazine 500MG	10x10	24	607600	
756	NRD-756	Tab.	Rasagiline1MG	10x10	24	3000	
757	NRD-757	Tab.	Regorafenib 40 mg	10x10	24	6000	
758	NRD-758	Tab.	Repaglinamide 0.5mg	10x10	24	10000	
759	NRD-759	Tab.	Repaglinamide 1mg	10x10	24	1000	
760	NRD-760	Tab.	Ribociclib 200 mg	10x10	24	6000	
761	NRD-761	Tab.	Rifampicin 150 mg	10x10	24	10000	
762	NRD-762	Tab.	Rifampicin 450 mg	10x10	24	10000	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
763	NRD-763	Tab.	Rifampicin 600 mg	10x10	24	10000	
764	NRD-764	Tab.	Rifaximin 200	10x10	24	22000	
765	NRD-765	Tab.	Rifaximin 550mg	10x10	24	6000	
766	NRD-766	Tab.	Rivaroxaban 10mg	10x10	24	405000	
767	NRD-767	Tab.	Rivaroxaban 15mg	10x10	24	20000	
768	NRD-768	Tab.	Rivaroxaban 20mg	10x10	24	20000	
769	NRD-769	Tab.	Rizatriptan 10mg	10x10	24	6000	
770	NRD-770	Tab.	Ropinirole 0.25mg	10x10	24	45000	
771	NRD-771	Tab.	Rosuvastatin 10mg + Fenofibrate 160mg	10x10	24	2021800	
772	NRD-772	Tab.	Ruxolitinib 5 mg	10x10	24	8000	
773	NRD-773	Tab.	Ruxolitinib 10 mg	10x10	24	5000	
774	NRD-774	Tab.	Ruxolitinib 15 mg	10x10	24	3000	
775	NRD-775	Tab.	Ruxolitinib 20 mg	10x10	24	3000	
776	NRD-776	Tab.	Selegiline 5mg	10x10	24	10000	
777	NRD-777	Tab.	Serratiopeptidase 10mg	10x10	24	6013000	
778	NRD-778	Tab.	Serratiopeptidase 20 mg	10x10	24	200000	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
779	NRD-779	Tab.	Sevelamer Carbonate 800 mg	10x10	24	410000	
780	NRD-780	Tab.	Sildosin + Dutasteride	10x10	24	20000	
781	NRD-781	Tab.	Silymarin 70mg.	10x10	24	20000	
782	NRD-782	Tab.	Sitagliptine + Metformin (50/500)	10x10	24	220000	
783	NRD-783	Tab.	Sildenafil 20 mg	10x10	24	4100	
784	NRD-784	Tab.	Sofosbuvir 400 mg+ Velpatasvir 100 mg	10x10	24	10000	
785	NRD-785	Tab.	Solifenacin succinate 10 mg	10x10	24	12000	
786	NRD-786	Tab.	Sorafenib 200 mg	10x10	24	28200	
787	NRD-787	Tab.	Sultamicin 375 MG	10x10	24	2000	
788	NRD-788	Tab.	Sunitinib 12.5 mg	10x10	24	14200	
789	NRD-789	Tab.	Sunitinib 25 mg	10x10	24	20000	
790	NRD-790	Tab.	Sunitinib 50 mg	10x10	24	10000	
791	NRD-791	Tab.	Tacrolimus 1MG	10x10	24	58000	
792	NRD-792	Tab.	Tamsulosin + Dutasteride	10x10	24	600000	
793	NRD-793	Tab.	Tapentadol 50mg	10x10	24	10000	
794	NRD-794	Tab.	Tegafur + Uracil 100 mg	10x10	24	6000	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
795	NRD-795	Tab.	Tenofovir 300MG	10x10	24	8000	
796	NRD-796	Tab.	Tetrabenazine 25mg	10x10	24	26000	
797	NRD-797	Tab.	Ticagrelor 90mg	10x10	24	402000	
798	NRD-798	Tab.	Tofacitinib 5 mg	10x10	24	5200	
799	NRD-799	Tab.	Tolvapatan 15mg	10x10	24	10000	
800	NRD-800	Tab.	Topiramate 50MG	10x10	24	70000	
801	NRD-801	Tab.	Torsemide 20mg	10x10	24	20000	
802	NRD-802	Tab.	Tramadol 37.5mg + Paracetamol 325mg	10x10	24	3000	
803	NRD-803	Cap.	Trametinib 0.5mg + Davarafenide 150mg	10x10	24	2000	
804	NRD-804	Tab.	Trimetazidine 35mg	10x10	24	201800	
805	NRD-805	Tab.	Trimetazidine 60mg	10x10	24	10000	
806	NRD-806	Tab.	Trypsin + Rutoside+Bromelain	10x10	24	100000	
807	NRD-807	Tab.	Trypsin Chymotripsin	10x10	24	3366002	
808	NRD-808	Tab.	Ulipristal 5mg	10x10	24	30000	
809	NRD-809	Tab.	Voriconazole 200 mg	10x10	24	10400	
810	NRD-810	Tab.	Verapamil Hydrochloride Sustained Release 40	10x10	24	50000	

S.No	Drug Code	Formulation	Name of Medicine	Packing unit	Minimum labelled Shelf Life (In Months)	Quantity	Remarks
811	NRD-811	Tab.	Verapamil Hydrochloride Sustained Release 120	10x10	24	54000	
812	NRD-812	Tab.	Vildagliptin 50mg	10x10	24	2533020	
813	NRD-813	Tab.	Voglibose 0.2 mg Tab	10x10	24	2654020	
814	NRD-814	Tab.	Voglibose 0.3 mg Tab	10x10	24	2550700	
815	NRD-815	Tab.	Warfarin 1MG	10x10	24	2000	
816	NRD-816	Tab.	Warfarin 2MG	10x10	24	1000	
817	NRD-817	Tab.	Warfarin 3MG	10x10	24	1000	
818	NRD-818	Tab.	Zinc 50MG	10x10	24	7061720	
819	NRD-819	Tab.	Zolpidem 10mg	10x10	24	20000	
820	NRD-820	Tab.	Zonisamide 50mg	10x10	24	6000	
821	NRD-821	Tab.	Zonisamide 100 mg	10x10	24	7200	
822	NRD-822	Inhaler	Tiotropium 9mcg Inhaler		24	263650	
823	NRD-823	Inj.	Human Albumin 20% in 50 ml Vial	vial / Amp	24	45340	
824	NRD-824	Inj.	Tetanus Vaccine (Adsorbed) IP in 0.5 ml	vial / Amp	24	666222	

Note:-

It may be noted that if any further amendments in packing unit, shelf life etc. is issued then a corrigendum will be published and informed.

The above quantity mentioned for this supply cum rate contract is indicative and may vary as per the actual requirement of hospitals.
The bidder should quote rate for the above mentioned packing unit only.

General Requirement:-

1. The manufacturer should ensure Stability of the formulations and its ingredients in the packing supplied.
2. The blister packing of tablets/Capsules should have Aluminium foil back.
3. Strip packing should be of Aluminium / Alu- Alu foils.
4. Aluminium foil strips refer to thickness not less than 40 microns.
5. The rigid PVC used in blister packing should be of not less than 250 microns.
6. Small tablets packed in blister should be packed to facilitate easy removal of a tablet without breaking/ crushing.
7. Containers for 400 ml (or 400 gm) or more, should have an inner lid also.
8. Syrup and Suspension should be palatable enough.
9. The measuring cap / dropper supplied with oral liquid formulation should have suitable marking.
10. The minimum size (length x breadth) of a blister strip shall be 6.5cm X 3cm.
11. Generic name of a drug should be printed in clearly legible bold letters. The font size of the name of drug on any tablet strip/ blister shall not be less than '9' in bold capital letters of Times New Roman or Arial font, e.g., LOSARTAN TABLETS IP even on small strips/ blisters. The font size shall be correspondingly bigger on bigger strips / blisters. Besides this, other contents on the label should also be legible.
12. The stereo printing of batch no. , Mfg date, Exp date on the reverse side of strip/blister should run atleast two times.
13. Quote rate in BOQ for the packing exactly given in annexure VIII. For example
    - If the packing unit is given for 10x10 tablets / capsule, the rate should be quoted for 10x10 tablets / capsule, and not for 1 tablet / capsule or 10 tablets/ capsule.
    - If the packing unit is given for 10x10x1 tablets / capsule, the rate should be quoted for 10x10 tablets / capsule, and not for 1 tablet / capsule or 10 tablets/ capsule.
    - If the packing unit is given for 10x14 tablets / capsule, the rate should be quoted for 10x14 tablets / capsule, and not for 1 tablet / capsule or 10 tablets/ capsule.
    - If the packing unit is given for 2 ml ampoule (25 ampoules), the rate should be for 25 ampoules and not for 1 ampoule or 10 ampoules etc.
    - If the packing unit is given for 2 ml ampoule (10 ampoules), the rate should be for 10 ampoules and not for 1 ampoule etc.

-

Annexure -IX
Ref. Clause No. 13, 16 & 19

RAJASTHAN MEDICAL SERVICES CORPORATION LTD

GUIDELINES FOR BLACK LISTING / DEBARRING OF PRODUCT OR COMPANY

1. ON SUBMISSION OF FALSE, FORGED OR FABRICATED DOCUMENTS OR CONCEALING OF FACTS:

1.1 The tenderer who submits false, forged or fabricated documents or conceals facts with intent to win over the tender or procure purchase order; EMD of such tenderer firm will be forfeited and firm will be liable for debarring for a period of not Less than 2 years. The firm will also be liable for Legal action depending on the facts & circumstances of the case.

2. ON ACCOUNT OF FAILURE TO ENTER INTO AGREEMENT OR WITHDRAWL AFTER AGREEMENT OR REFUSAL / FAILURE TO SUPPLY:

2.1 **The successful Bidder fails to execute the agreement after being declared as L-1, L-2 or L-3 etc. to perform the obligations under the Bid conditions, Bid Security Deposit of such Bidder firm shall be forfeited.**

If an LoA for more than one products is issued to a successful bidder and he/she/it fails to execute agreement for few items, in such case, a penalty of Rs. 2.00 lac and in case of MSME of the State of Rajasthan Rs. 50,000 shall be imposed on successful bidder and the product for which agreement is not executed shall be debarred for a period of not less than 3 years.

2.2 The successful tenderer after entering into an agreement withdraw or fail to honour commitments as per tender conditions, Security Deposit of such tenderer firm will be forfeited and firm will be liable for debarring for a period of not Less than 2 years.

3. ON ACCOUNT OF NON-SUPPLY:

3.1 The supplier shall start to supply according to tender condition from the date of purchase order and shall complete the supplies within 60/75 days as mentioned in Purchase Order or as stated in tender condition.

3.2 RMSC will be at liberty to accept or reject the supply made belatedly as per the terms and conditions of the tender documents. In the event of acceptance of delayed supply the liquidated damages shall be imposed at the rate stipulated in conditions of the tender document.

3.3 If the supplier fails to execute the purchase order and informs RMSC about its inability to execute the order and non-compliance of the purchase order due to act of vis-majeure, then the Managing Director, RMSC will issue appropriate order on merits of case.

3.4 If the supplier fails to execute atleast 50% of the quantity mentioned in single purchase order and such failure in supply continues for three purchase orders, then supplier firm will be liable for debarring for a period of 2 years. As a result such supplier will be ineligible to participate in any of the tenders for particular item(s) of drugs / medicines for a period of 2 years.

4. ON ACCOUNT OF QUALITY FAILURE OF DRUGS & MEDICINES:

4.1 The drugs supplied by the suppliers to the District Drug Warehouses are quarantined and samples of each and every batch of drugs /medicines are drawn on random basis and forwarded to Quality Control Wing of RMSC at the headquarter. The samples are then sorted; common batches pooled, coded and are sent to the empanelled laboratories for quality control test as per the QC Policy of RMSC.

4.2 Samples of all sterile surgicals & sutures items falling in the categories of drugs will also be drawn as per above policy and all of them will be subjected essentially for sterility testing.

4.3 If such samples **pass** quality test in all respects, RMSC will instruct its Warehouses to issue items of drugs to various hospitals / institutions

4.4 If the sample fails in quality test and report is received certifying that sample is **not of standard quality**, the drugs of the batch will not qualified for issue and supplier shall be informed to take back stocks of such batch, which failed the quality test and other consequences would follow as per the conditions in the tender documents.

-

Minor defects

4.5 (1) If one batch of a particular item supplied during contract period fails in any of the quality test conducted by the tender inviting authority and/or by the Drugs Control Department, then Penalty of not less than 5.0% of Purchase Order value of that particular item shall be levied."

4.5 (2) If two batches of a particular item supplied during contract period fail in any of the quality tests conducted by the tender inviting authority and/or by the Drugs Control Department, then that particular product of that firm will be blacklisted for a period up to 3 years but not less than 06 months in any case.

(*Tablets/Capsules failing in dissolution test and active contents found 70% and above for thermo labile products and upto 5% less than the prescribed limits for thermo stable products.)

Grossly substandard

4.6 (1) If **any batch of a particular item** supplied under a tender tenure by the supplier is declared as **Not of Standard Quality** by an empanelled lab or Govt. Lab which falls in **grossly substandard** category and such failure is further confirmed by another empanelled lab / Govt. Lab, then the product shall be liable for debarring for a period of not Less than one (1) years.

(2) If **two or more batches** supplied under a tender tenure by the supplier is declared as **Not of Standard Quality** by an empanelled lab or Govt. Lab, which falls in **grossly substandard** and such failure is further confirmed by Govt. Lab, then the **Product** shall be liable for debarring for a period of not less than two (2) years.

4.7 If the supplier supplied **more than one drug** (subject to a minimum of 6 drugs) during a tender duration and 50% of such drugs are blacklisted, the **firm** is liable to be blacklisted for a period of **2 years** from the date of intimation after observing the procedure.

Spurious or Adulterated

4.8 In case, any sample (even one batch) is declared as **Not of Standard Quality** by an empanelled lab or Govt. Lab which falls in **Spurious or Adulterated** category and if such failure is further confirmed by Govt. Lab

during its entire shelf life, the **Company** shall be liable for debarring for a period of **not less than 5 years.**

4.9 If any statutory sample of RMSC supply drug is drawn by Drugs Control Officer on suo-moto basis or on complaint and if it fails in quality parameters, the report is conclusive till it is challenged by supplier / company. If it is challenged then the report of Director, C.D.L., Kolkata shall be conclusive and action as contemplated in foregoing paragraphs will be initiated in the matter of debarring of product or company. However if failure is of such nature wherein Drugs Controller of State grants prosecution sanction under Drugs & Cosmetics Act, 1940, then even failure of such one batch shall be considered adequate for debarring the product for not less than 2 years and in case of involvement of three different products the **Supplier / Company** as a whole shall be liable for debarring for a period of not Less than 3years.

5 PROCEDURE IN THE EVENT OF QUALITY FAILURE WILL INVOLVE THE FOLLOWING STEPS:

5.1 On receipt of adverse quality test report from empanelled lab or Govt. Lab of a quarantined stock, instructions will be issued immediately through e-mail to the concerned District Drug Warehouses to not to release such stock and entries be made by QC Cell at headquarter in e-aushadhi software for batch rejection i.e. not to be released for distribution to institutions / DDC's.

5.2 Warehouse In-charge will take appropriate measures immediately to segregate such stock and label all cartons as "NOSQ Drugs-Not for release" and shift it from quarantine area to Non-Release / Rejected Drugs Area (which is under lock & key) till its lifting by the supplier.

5.3 Immediately on receipt of NOSQ report, the second sample should be sent to another empanelled lab / Govt. Lab by the by QC Cell.

5.4 The supplier shall be informed immediately about the test results and instructions be issued to lift the entire stock at supplier's expenses of such batch no. drug which is declared as "NOSQ" by the empanelled lab / Govt. Lab. However, in case of serious quality failure i.e. if drug is declared or adjudged spurious, adulterated or grossly substandard, one of drug warehouse In-charge will be directed to contact the District Drugs Control

officer for drawing statutory sample of such batch as per Act. The DDW In-charge has to keep adequate quantity of such drug for statutory sampling by Drugs Control officer.

5.5 In case of drug declared as **Not of Standard Quality** on subsequent sampling after the batch was released the procedure given in sub-Para 5.2 will be followed in respect of stock available with the warehouse. In respect of stock already issued and drug warehouse In-charge will take immediate steps to RETRIEVE the unused stock of such drugs from all such institutions and D.D.C.s by all possible mode and means and he/she will ensure that no such NOSQ drug is further distributed to the patients and ensure effective recall.

5.6 On receipt of test report from empanelled lab / Govt. Lab, show cause notice will be issued immediately to the concerned supplier calling for explanation within 3 days from the date of receipt of notice in respect of quality failure of concerned batches of drug. The supplier will be required to submit the batch manufacturing record, batch analysis report, raw material purchase record & raw material test reports etc. Opportunity for personal hearing, if desired by supplier, may also be accorded.

5.7 On confirmation of the test result by the second laboratory, the case will be referred to the disciplinary committee of RMSC for further action.

5.8 In case when the second report is contradictory to the first report, the statutory sample will be sent to Govt. Lab, whose report will be final and if the sample has been tested by the Govt. Lab at any stage, its report will be conclusive & final unless challenged as per provisions of Drugs & Cosmetics Act, 1940.

6. EXAMINATIONS OF ISSUES BY DISCIPLINARY COMMITTEE OF RMSC

6.1 Each & every case of submission of false documents, failure to execute agreement, non-supply or quality failure, etc. will be referred to disciplinary committee of RMSC for examination on a case to case basis for making appropriate technical recommendation to Managing Director for further appropriate action.

6.2 The recommendations of disciplinary committee will be placed before the Managing Director, RMSC who shall take appropriate action which may deem fit in the light of facts & circumstances of the case by way imposing penalty or debarring or Debarring of the particular product or supplier/ company.

6.3 If, the quality failure is of such nature that a particular product has been blacklisted according to the procedure stated above, the supplier will not be eligible for participating in any of the tenders for the particular item floated by RMSC for the specified period. For such purpose period of debarring will be counted from date of issue of order and it will deemed to be over on completion of the period and as such no fresh orders will normally be required for re-eligibility purpose. Similarly if the supplier /company is blacklisted the supplier will not be eligible for participating in any of the tenders for any of the items during blacklisted period.

7. POWER OF REVIEW:

Subsequent to the action taken on the basis of available facts if some new facts & evidences such as reversal of test results findings by Appellate Laboratories etc. are brought to the notice of the corporation, the Managing Director of RMSC will have the right to review the earlier action. He may seek advice from the disciplinary committee in such matters.

8. RIGHT TO APPEAL:

Any supplier / company against whom the above action is taken may prefer an appeal within 30 days of date of debarring order to the Principal Health Secretary, Medical & Health Department, Govt. of Rajasthan who shall decide the same.

9. SAVINGS :

The debarring of particular product or supplier / firm will be done without prejudice to other penalty which may be imposed as per the conditions of tender documents and also to other actions which may be initiated under Drugs and Cosmetics Act 1940 or any other law of land. RMSC will display names of such blacklisted products and companies on its website and also circulate the same among all stakeholders viz. PSME, DM&HS, DC

including respective State Drug Controllers where the supplier / company is located.

10. JURISDICTION:

In the event of any dispute arising out of the orders and implementation thereof, such dispute shall be subject to the jurisdiction of the Courts of Jaipur City only or Hon'ble Rajasthan High Court, Bench at Jaipur.

11. EXPLANATIONS:

(i) Increase in the cost of raw materials, power cut, Labour strike, insolvency, closure of the factory would not be considered as act of vis-majeure.

(ii) The Spurious, Adulterated, Grossly sub-standard drug shall have the explanation as per guidelines issued by Govt. of India for taking action on "Not of Standard quality drugs."

On the basis of quantitative analysis (Assay), the NOSQ drug shall be distinguished in the following manner :-

Category of NOSQ drugs	**Active ingredient content (Assay)**	
	Thermo stable	**Thermolabile**
Minor	Upto 5% less than the prescribed lower limit	Above 70% to the prescribed lower limit
Grossly Substandard	Below 5% of the prescribed lower limit to 50%	70% to 40%
Spurious	Below 50%	Below 40%

(iii) Purchase Orders, if any, already issued before taking any debarring action or replacement orders given in past will not be affected in view of action taken as per above guidelines but all strict quality checks shall be observed for each supply of products.

(iv) The action proposed as above is not in conflict to any express conditions laid down in corresponding tender and in case of any overlapping, the tender condition will prevail.

-

ANNEXURE-X

FORM NO. 1 [See rule 83 of RTPP]

Memorandum of Appeal under the Rajasthan Transparency in Public Procurement Act, 2012

Appeal No..... of.....
Before the..... (First/Second Appellate Authority)

1. Particulars of appellant:
   (i) Name of the appellant:
   (ii) Official Address, if any:
   (iii) Residential address:

2. Name and address of the respondent (S):
   (i)
   (ii)
   (iii)

3. Number and date of the order appealed against and name and designation of the officer/ authority who passed the order (enclose copy), or a statement of a decision, action or omission of the Procuring Entity in contravention to the provisions of the Act by which the appellant is aggrieved:

4. If the Appellant proposes to be represented by a representative, the name and postal address of the representative:

5. Number of affidavits and documents enclosed with the appeal:

6. Ground of appeal:
.....
.....
..... (Supported by an affidavit)

7.
Prayer:
.....
.....
Place.....
Date.....

Appellant's Signature

-

ANNEXURE-XI
Ref. Clause No. 1(d), 5(y), 20

UNDERTAKING FOR EMPANELMENT

I Name…….S/o…….Age……..Prop./Partner/Director/ Power of attorney holder of firm M/s……..situated at (Complete address of Mfg. unit)…….bearing drug license on Form 25 & 28 or form 10 bearing Number……. &……..respectively, issued on dated……..valid/Renewed up to……..do here by declare on oath as follows:-

1. That I have applied for empanelment for supply of Drugs & Medicines for the items I have quoted in the bid as enlisted in Annexure –VII
2. That I/We have carefully read all the conditions of E- Bid in Ref. no. F.02(353)/RMSCL/PROCUREMENT/DRUG/NIB-10/2022/ 1236 Dated:- 30.04.2022 for supply Cum rate contract and empanelment for supply of Drug and Medicines For Rajasthan Medical Services Corporation Ltd and accept all conditions of Bid, including amendments if any.
3. That I will be considered empanelled for the items which are declared technically responsive.
4. That I have deposited the required fees for empanelment or previous bid ref no……

Date

Name & Signature with Seal

-

Annexure-XII
Ref. Clause No.17.2

Supplier Consolidated Invoice

Name of Supplier: …….
Complete Address: ……..
E-mail ID: ……..

DL NO.:	**GST No.:**	**HSN Code**	Invoice No.: Date:

Purchaser: Managing Director **Address:** Rajasthan Medical Services Corporation Ltd, Gandhi-Block, Swasthaya Bhawan, Tilak Marg, C-Scheme, Jaipur Phone No. 0141- 2228066 **RMSCL GSTIN.08AAFCR2824M1Z3**	Purchase Order No.: …….. Date: ……..

Name of Item/Description : …….. **Drug Code (RMSCL) : ……**

S.No	Name of DDW	Odered Qty.	Invoice/ Challan no.	Date	Packing Size	Batch No.	Mfg. Date	Exp. Date	Quantity Supplied in No. (Batch wise)	Basic Rate (without GST)	Basic Amount (without GST)
1	2	3	4	5	6	7	8	9	10	11	12

Remarks:	Total Basic Amount	
	Rate of (%) GST(CGST)	
	Rate of (%) GST(SGST)	
	Rate of (%) GST(IGST)	
	Total GST Amount(CGST+SGST+IGST)	
	Grand Total (Basic Amount+ GST Amount)	

Authorised Signatory

-

Annexure-XIII
Ref. Clause No. 17.2

Analytical Report Regarding Quality

Name of Supplier:-						
Address:-						
PO No:-		**Date:-**				
Drug Name:-						
Details of in house test report:-						
S. No.	**Name of Lab.**	**Test report No.**	**Date**	**Batch No.**	**Qty. Supplied**	**Result**
1.						
2.						
3.						
4.						
5.						
6.						
7.						
8.						
9.						
10.						
11.						
12.						

Authorised Signatory

-

Annexure-XIV
Ref. Clause No. 11

Security form (Bank guarantee)

To,

Managing Director Rajasthan Medical Services Corporation Ltd
WHEREAS…….(Name of Supplier)

Hereinafter called "the Supplier" has undertaken, in pursuance of Contract (Letter of Acceptance) No…….dated……2022 to supply……(Description of Goods) hereinafter called "the Contract".

AND WHEREAS it has been stipulated by you in the said Contract that the Supplier shall furnish you a bank Guarantee from a Scheduled Bank for the sum specified therein as security for compliance with the Supplier's performance obligations in accordance with the Contract.

AND WHEREAS we have agreed to give the supplier a Guarantee:

THEREFORE WE hereby affirm that we are Guarantors and responsible to you, on behalf of the Supplier, up to a total of ……..(Amount of the Guarantee in Words and Figures) and we undertake to pay you, upon your first written demand declaring the Supplier to be in default under the said Contract and/or any other contract or for set off any other dues pending against the supplier, without cavil or argument, any sum or sums within the limit of ……(Amount of Guarantee) as aforesaid, without your needing to prove or to show grounds or reasons for your demand or the sum specified therein.

This Bank guarantee is payable at Jaipur Branch ……

This guarantee is valid until the……day of……2025……...

Signatures and Seal of Guarantors

Date……..……

Address:……
……

Note:- The validity of bank guarantee should be for 36 months from the date of issuance of Bank Guarantee.